WO1991002814A1 - Nucleic acid amplification process - Google Patents

Nucleic acid amplification process Download PDF

Info

Publication number
WO1991002814A1
WO1991002814A1 PCT/EP1989/000981 EP8900981W WO9102814A1 WO 1991002814 A1 WO1991002814 A1 WO 1991002814A1 EP 8900981 W EP8900981 W EP 8900981W WO 9102814 A1 WO9102814 A1 WO 9102814A1
Authority
WO
WIPO (PCT)
Prior art keywords
dna
sequence
rna
primer
polymerase
Prior art date
Application number
PCT/EP1989/000981
Other languages
French (fr)
Inventor
Lawrence T. Malek
Cheryl Davey
Original Assignee
Akzo N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4137506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1991002814(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo N.V. filed Critical Akzo N.V.
Priority to KR1019910700397A priority Critical patent/KR920702866A/en
Priority to JP50909789A priority patent/JPH04501057A/en
Publication of WO1991002814A1 publication Critical patent/WO1991002814A1/en
Priority to DK068591A priority patent/DK68591A/en
Priority to FI911877A priority patent/FI911877A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/702Specific hybridization probes for retroviruses
    • C12Q1/703Viruses associated with AIDS
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6865Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Definitions

  • This invention relates to a process for amplifying a specific nucleic acid sequence.
  • nucleic acids are highly specific in binding to complementary nucleic acids and are thus useful to determine whether a specific nucleic acid is present in a sample.
  • sample means a mixture containing nucleic acids
  • sufficiently complementary means that two nucleic acids, a primer and a template, are capable of specific interaction which allows efficient, primer-dependent and template-directed synthesis of DNA, under given conditions of ionic strength and temperature.
  • nucleic acid probes are highly specific, it is preferable in some situations to probe the nucleic acid sequence itself rather than the protein produced by the nucleic acid sequence.
  • a diagnostic method based solely on protein detection would be unreliable for determining the presence of infectious particles of hepatitis B virus, due to the presence of significant levels of non-infectious antigen particles which lack the DNA genome.
  • the various subtypes of human papilloma virus found in either pre-cancerous or benign cervical tumors can be distinguished only by the use of nucleic acid probe hybridization.
  • the microbiology of AIDS makes it certain that an assay based on the presence of AIDS specific nucleic acid sequence would be superior as a diagnostic.
  • One method to amplify is to 'grow out' the sample, that is, to arrange conditions so that the living biological material present in the sample can replicate itself. Replication increases the quantity of nucleic acid sequences to detectable levels.
  • food samples In the food industry, for example, in order to test processed food for the food-poisoning bacteria Salmonella, food samples must be incubated for a number of days to increase the quantity of nucleic acids. In clinical samples, pathogens must also be allowed to increase their number by growing out over some considerable time.
  • United States Patent No. 4,683,195 issued on July 28, 1987 to Cetus Corporation and United States Patent No. 4,683,202 issued on July 28, 1987 to Cetus Corporation are each directed to a process for amplifying a target nucleic acid sequence contained in a sample.
  • United States Patent No. 4,683,195 relates
  • a sample suspected of containing a target nucleic acid sequence is treated with oligonucleotide primers such that a primer extension product is synthesized which in turn serves as a template, resulting in amplification of the target nucleic acid sequence.
  • the primer extension product is separated from the template in the preferred embodiment using heat denaturation.
  • United States Patent No. 4,683,202 relates to a process for amplifying a target nucleic acid sequence having two separate complementary strands. The process includes treating the strands with primers to synthesize extension products, separating the primer extension products from the templates, and in turn using the primer extension products as templates.
  • each cycle of the amplification process takes place by the synthesis from a first template, of a second template, the second template in turn is used to synthesize the first template. This procedure is repeated, thus, each cycle of the amplification process is based on the synthesis of one product from one substrate.
  • This invention relates to an amplification process which is expedient and requires less participation and fewer manipulations by the user of the process than conventional amplification processes.
  • the amplification takes place at a relatively constant ambient temperature.
  • each cycle of the process generates a plurality of copies of product from one substrate.
  • the amplification process of this invention may be used to increase the quantity of a specific nucleic acid thus circumventing the copy number problem. Hence, probe assays may be more readily used.
  • the amplification process could also be used to increase the purity of a specific nucleic acid sequence as a substitute for conventional cloning methodology.
  • a process for amplifying a specific nucleic acid sequence involves the synthesis of single-stranded RNA, single-stranded DNA, and double stranded DNA.
  • the single stranded RNA is a first template for a first primer.
  • the single stranded DNA is a second template for a second
  • the double stranded DNA is a third template for the synthesis of a plurality of copies of the first template.
  • a sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence.
  • a 3 1 end of the first primer is oriented towards a 3 ' end of the second primer on complementary strands.
  • a process for amplifying a specific nucleic acid sequence is used.
  • the process involves:
  • the first primer has a DNA sequence which is sufficiently complementary to a RNA sequence of the first template
  • the second primer has a DNA sequence which is sufficiently complementary to a DNA sequence of the second template.
  • the second primer also has a sequence of a promoter and a sequence of a transcription initiation site for a RNA polymerase;
  • a sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence.
  • a 3' end of the first primer is oriented towards a 3' end of the second primer on complementary strands.
  • the second primer of DNA has a sequence at its 3• end which is sufficiently complementary to the DNA sequence of the second template.
  • the second primer has at its 5' end a sequence of a promoter and a sequence of a transcription initiation site for a RNA polymerase.
  • a process for amplifying a specific nucleic acid sequence involves combining a first primer, a second primer, ribonuclease H, a RNA-directed DNA polymerase, a DNA-directed DNA polymerase, a RNA polymerase, ribonucleoside triphosphates and deoxyribonucleoside triphosphates with a sample.
  • the first primer of DNA has a sequence which is sufficiently complementary to a first template of RNA.
  • the second primer of DNA has a sequence which is sufficiently complementary to a second template of DNA, and a sequence of a promoter and a sequence of a transcription initiation site which are recognized as substrate by the RNA polymerase.
  • a sequence of the first primer or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first primer or the second primer is sufficiently homologous to a sequence of the specific nucleic acid.
  • a 3' end of the first primer is oriented towards a 3' end of the second primer on complementary strands.
  • a process for amplifying a specific nucleic acid sequence involves adding a first
  • the first primer of DNA has a sequence which is sufficiently complementary to a first template of RNA.
  • the second primer of DNA has a sequence which is sufficiently complementary to a second template of DNA, and a sequence of a promoter and a sequence of a transcription initiation site which are recognized as substrate by T7 RNA polymerase.
  • a sequence of the first primer or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first primer or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence.
  • a 3 1 end of the first primer is oriented towards a 3' end of the second primer on complementary strands.
  • SUBST Figure 1 is a general illustration the nucleic acid amplification process
  • Figure 2 shows the synthetic oligonucleotides DNA sequences which are used for testing the amplification process: Figure 2A, the gag test sequence; Figure 2B, the gag2 test sequence;
  • Figure 3 is an autoradiogram of PAGE analysis of amplification reactions using different primer concentrations
  • SUBSTITUTE SHEET Figure 7 is a general illustration of the indirect nucleic acid amplification process.
  • This invention relates to a process for amplifying a specific nucleic acid sequence.
  • the amplification involves the alternate synthesis of DNA and RNA and is generally illustrated in Figure 1.
  • single-stranded RNA is converted to single-stranded DNA which in turn is converted to a functional template for the synthesis of a plurality of copies of the original single-stranded RNA.
  • a first primer and a second primer are used in the amplification process.
  • a sequence of the first primer or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence.
  • both the first primer and second primer are sufficiently complementary and sufficiently homologous to a sequence of the specific nucleic acid sequence, for example, if the specific nucleic acid sequence is double stranded DNA.
  • RNA is converted to single-stranded DNA by hybridizing an oligonucleotide primer (the first
  • RNA-directed DNA polymerase synthesizing a complementary strand of DNA from the first primer, (the first DNA sequence) by using a RNA-directed DNA polymerase.
  • the resulting single-stranded DNA (the second template) is separated from the first template by, for example, hydrolysis of the first template and by using a ribonuclease which is specific for RNA-DNA hybrids (for example, ribonuclease H) .
  • the second template is converted to a form which is capable of RNA synthesis by hybridizing a synthetic oligonucleotide (the second primer) , which contains at its 3' end a sequence which is sufficiently complementary to the 3* end of the second template and toward its 5' end a sequence of a promoter and a sequence of a transcription initiation site, and by synthesizing a second DNA sequence covalently attached to the 3 • end of the second primer using the second template as a template and synthesizing a third DNA sequence covalently attached to the 3* end of the second template using the second primer as a template, using DNA-directed DNA polymerase.
  • the resulting functional derivative of the second template which is a third template, is used for the synthesis of a plurality of copies of RNA, the first template, by
  • Each newly synthesized first template can be converted to further copies of the second template and the third template by repeating the cycle. In addition, repetition of the cycle does not require participation or manipulation by the user.
  • the amplification process commences with the addition of a suitable template nucleic acid to the appropriate enzymes, primers, and cofactors under the appropriate reaction conditions.
  • This template nucleic acid is in a form which is capable of homogenous and continuous amplification and can function as an intermediate in the cycle set forth in Figure 1.
  • the amplification process involves the net consumption of precursors (primers, ribonucleoside trifhosphates and deoxyribonucleoside trophosphates) and the net accumulation of products (RNA and DNA) .
  • precursors primary, ribonucleoside trifhosphates and deoxyribonucleoside trophosphates
  • RNA and DNA products
  • the processes of RNA and DNA synthesis will proceed asynchronously until sufficient levels of nucleic acids have been synthesized to allow detection.
  • the amplification process may be monitored by, for example, the synthesis of a labeled product from a labeled precursor.
  • the first primer is an oligodeoxyribonucleotide which has at its 3' end a sequence which is sufficiently complementary to the 3• end of the first template.
  • the sequence at the 3 1 end of the first primer has a particular length and base composition to allow specific and efficient synthesis of the first DNA sequence, under the given conditions of ionic strength and temperature.
  • the first primer may be sufficiently complementary to a region internal to the 3' end of the first template in the first cycle. In subsequent cycles, the 5' end of the first primer would be complementary to the 3' end of the first
  • the first primer may be composed partially or completely of nucleotides or nucleotide analogs other than the natural deoxyribonucleotides.
  • the 5' end of the first primer may contain sequences which are not complementary to the first template in the first cycle.
  • the non-complementary sequences may be complementary to a nucleic acid which can be immobilized, or to which can be bound a useful non-nucleic acid component, such as a reporter to facilitate detection.
  • the second primer is an oligodeoxyribonucleotide which contains at its 3' end a sequence which is sufficiently complementary to the 3 ' end of the second template.
  • the second primer has a particular length and base composition to allow specific and efficient synthesis of the second and third DNA sequences, under the given conditions of ionic strength and
  • the second primer contains the sequence of a functional promoter and the sequence of a transcription initiation site.
  • This sequence when used as a template for synthesis of the third DNA sequence, contains sufficient information to allow specific and efficient binding of a RNA polymerase and initiation of transcription at the desired site.
  • the promoter sequence may be derived from the antisence strand of a functional promoter.
  • the transcription initiation site may be derived from the 5'-terminal sequence of a natural RNA transcript.
  • the 5*-terminal sequence of the second primer is AATTCTAATACGACTCACTATAGGGAG. This sequence contains the sequence of the promoter and the sequence of the transcription initiation site for T7 RNA polymerase.
  • the transcription initiation site and promoter for another phage RNA polymerase may be used.
  • sequences which are unrelated to the promoter function may be included at the 5* end of the second primer or between the transcription initiation site and the sequence at the 3* end which hybridizes to the second template.
  • the second primer may be composed partially or completely of nucleotides or nucleotide analogs other than natural deoxyribonucleotides.
  • Each enzyme or enzyme preparation should be free of deleterious deoxyribonuclease (“DNase”) activities, such as the 5' or 3' exonuclease activities which are often associated with certain DNA polymerases and single-strand or double-strand specific exonuclease of endonucleases.
  • DNase deoxyribonuclease
  • Each enzyme or enzyme preparation should be free of deleterious ribonuclease (“RNase”) activities, with the exception of the preferred addition of a ribonuclease activity which is specific for hybrids of RNA and DNA (for example, ribonuclease H) .
  • RNase deleterious ribonuclease
  • each enzyme should be reasonably active under the common reaction conditions which are used for the other enzymatic processes, and non-enzymatic processes, such as hybridizing oligonucleotide primers to the RNA or DNA templates.
  • the DNA-directed RNA polymerase which is used in this invention may be any enzyme capable of binding to a particular DNA sequence called a promoter and specifically initiating in vitro RNA synthesis at a defined initiation site within close proximity to the promoter.
  • the promoter and the initiation site form part of the second primer.
  • SUBSTITUTE SHEET polymerase should be capable of synthesizing several copies of RNA per functional copy of template in a reasonable amount of time.
  • the bacteriophage T7 RNA polymerase is used.
  • other bacteriophage RNA polymerases such as phage T3, phage ll, salmonella phage sp6 ⁇ , or pseudomonas phage gn-1 may be used.
  • other prokaryotic or eukaryotic DNA-directed RNA polymerase may be used. It should be understood that if alternative RNA polymerases are used, then the necessary changes to the promoter and initiation sequences of the second primer should be made according to the template specificity of the particular RNA polymerase.
  • RNA-directed DNA polymerase which is used in this invention may be any enzyme capable of synthesizing DNA from an oligodeoxyribonucleotide primer and a RNA template.
  • this enzyme may contain activities for DNA-directed DNA polymerase and RNase H.
  • the avian myoblastosis viral polymerase (“AMV reverse transcriptase") is used.
  • the RNA-directed DNA polymerase could be from another retroviru ⁇ , such a Maloney murine leukemia virus.
  • the DNA-directed DNA polymerase which is used in this invention may be any enzyme capable of synthesizing DNA from an oligodeoxyribonucleotide primer and a DNA template. This enzyme should not contain either 5'- or 3'-exonuclease activities, which are associated with many types of DNA polymerase. In the preferred embodiment, the AMV reverse transcriptase is used. However, other DNA-directed DNA polymerase which naturally lack the 5'- or 3*-exonuclease activities could be used. These could include certain eukaryotic DNA polymerases, such as, DNA polymerase c or ⁇ those DNA polymerases which could be isolated from a mammalian tissue, such as calf thymus.
  • DNA polymerase could be made useful by removing the undesirable exonuclease activities either by alteration of the DNA polymerase gene followed by expression of the altered polymerase in a suitable host cell, or by chemical modification of the DNA polymerase protein.
  • Altered versions of DNA polymerase could be made from the Klenow fragment of E. coli DNA polymerase I or the bacteriophage T7 DNA
  • a labeled precursor may be added to the reaction mixture.
  • Amplification is determined by quantitive or qualitative analysis of labeled products, which can be separated from the labeled precursor by using methods known in the art.
  • a labeled precursor may be a ribonucleoside triphosphate for detecting RNA synthesis, or a deoxynucleoside triphosphate or an oligonucleotide primer for detecting DNA synthesis.
  • the type of label may be a radioisotope or a useful chemical group, such as biotin, a chro ophore, a fluorophore, or a hapten which could bind to an antibody, or possibly a protein or an enzyme.
  • the labeled products may be separated from the labeled precursors on the basis of solubility, charge, or size.
  • the labeled DNA or RNA may be hybridized to a nucleic acid which contains a complementary sequence and which can be immobilized.
  • the products of the amplification process may be bound to an immobilized support, hybridized to a nucleic acid probe containing a complementary sequence, and separated from the unhybridized nucleic acid probe which remains in solution.
  • the products, DNA or RNA may be bound directly to a solid support by any stable interaction, such as hydrophobic, electrostatic, or covalent interaction.
  • the products may contain certain chemical groups, for example, biotin, which may be incorporated into the products during the
  • the products may be hybridized to a nucleic acid which contains a complementary sequence and which can be immobilized.
  • the nucleic acid probe would contain a complementary sequence which forms a sufficiently stable interaction with a product of the amplification process to allow binding under the conditions of hybridization and sustained binding under the conditions used for removal of the unhybridized nucleic acid probe.
  • the complementary sequence would be derived from that part of the specific nucleic acid sequence which is between the sequences of the first primer and the second primer.
  • the nucleic acid probe may be a single-stranded DNA or RNA, or a double-stranded DNA or RNA which can be made single-stranded, or an oligonucleotide which can be composed of deoxyribonucleotides and/or ribonucleotides.
  • the nucleic acid probe may contain a chemical group which could covalently bind to a product DNA or RNA under the appropriate conditions.
  • the nucleic acid probe may be labeled with a radioisotope or a useful chemical group, such as biotin, a chromophore, a fluorophore, or a hapten
  • the products of the amplification process may be analyzed by methods which are typically used for nucleic acids that have been enriched by molecular cloning techniques.
  • the synthesis of a specific DNA sequence may be detected by digestion of the synthesized DNA with a restriction endonuclease, followed by electrophoretic separation and detection using methods known in the art.
  • the sequence of amplified RNA may be determined by DNA synthesis using a RNA-directed DNA polymerase, the first primer, and dideoxynucleoside triphosphates (Stoflet et al., 1988).
  • sequence of the amplified third template may be determined by RNA synthesis using the DNA-directed RNA polymerase used in the amplification process, and 3 '-deoxyribonucleoside triphosphates (Axelrod & Kramer, 1985) .
  • the amplified third template may be determined by RNA synthesis using the DNA-directed RNA polymerase used in the amplification process, and 3 '-deoxyribonucleoside triphosphates (Axelrod & Kramer, 1985) .
  • the amplified RNA synthesis using the DNA-directed RNA polymerase used in the amplification process and 3 '-deoxyribonucleoside triphosphates (Axelrod & Kramer, 1985) .
  • the amplified third template may be determined by RNA synthesis using the DNA-directed RNA polymerase used in the amplification process, and 3 '-deoxyribonucleoside triphosphates (Axelrod & Kramer, 1985
  • SUBSTITUTE SHEET RNA may encode a polypeptide which could be translated, in vitro.
  • the polypeptide product of the in vitro translation could be analyzed by using an antibody.
  • the template nucleic acid may be a single-stranded DNA which contains at its 3' end a sequence which is sufficiently complementary to at least the 3' end of the second primer, and contains a sequence which is sufficiently homologous to that which is at the 3' end of the first primer.
  • a template nucleic acid of this form would function as a
  • the template nucleic acid may be a double-stranded DNA, one strand of which contains at its 5• end the entire sequence of the second primer and contains a sequence which is sufficiently complementary to the first primer.
  • the double-stranded DNA functions as a third template in the amplification process.
  • a template nucleic acid which could function as a first template could be a naturally occurring RNA or a RNA fragment which could be generated from a larger RNA molecule by using site specific hydrolysis methods known in the art (Shibahara et al., 1987).
  • a template nucleic acid which could function as a second template could be generated from a double-stranded DNA by digestion with a restriction endonuclease which has a site immediately flanking the sequence which is sufficiently complementary to the 3' end of the second primer.
  • the resulting double-stranded DNA fragments could then be made single-stranded by using chemical or thermal denaturation methods.
  • a template nucleic acid which could function as a third template could be generated from a single-stranded DNA or RNA by DNA synthesis from the DNA or RNA template using the second primer.
  • the resulting synthesized DNA could then be separated from the original template by using chemical or thermal denaturation methods.
  • a RNA template could be hydrolyzed by using chemical or enzymatic methods.
  • the resulting single-stranded DNA has the sequence of the second primer covalently attached to its 5' end and contains a sequence which is sufficiently complementary to the first primer.
  • This single-stranded DNA could be converted to a transcriptionally functional double-stranded DNA by hybridizing the first primer to the single-stranded DNA, and by synthesizing a DNA sequence which is covalently attached to the first primer and complementary to the single-stranded DNA.
  • a single-stranded DNA or RNA template could be obtained from a double-stranded DNA, double-stranded RNA or a DNA-RNA hybrid by using chemical, thermal, or possibly enzymatic methods. Then, by using one of the alternative schemes proposed above, the resulting single-stranded DNA or RNA template could be obtained from a double-stranded DNA, double-stranded RNA or a DNA-RNA hybrid by using chemical, thermal, or possibly enzymatic methods. Then, by using one of the alternative schemes proposed above, the resulting
  • RNA single-stranded DNA or RNA could then be used to generate a template nucleic acid which could function as a first, second or third template.
  • a template nucleic acid which could function as a first, second or third template.
  • an alternative scheme involving the first primer and one strand of nucleic acid, and another alternative scheme involving the second primer and the other (complementary) strand of the nucleic acid may be used concurrently to generate template nucleic acids.
  • Oligonucleotides were synthesized using an Applied Biosystems 380A DNA synthesizer. Columns, phosphoramidites, and reagents used for oligonucleotide synthesis were obtained from Applied Biosystems, Inc. through Technical Marketing Associates. Oligonucleotides were purified by polyacrylamide gel electrophoresi ⁇ followed by DEAE cellulose chromatography. The radioisotope [ ⁇ -32p] UTP (800 Ci/mmol) was from Amersham. Enzymes for digesting and ligating DNA were purchased from New England Biolabs, and used according to the supplier's
  • Preparations containing the large fragment of DNA polymerase 1 were also purchased from New England Biolabs. RNasin and T7 RNA polymerase from Promega Biotec were purchased through Bio/Can Scientific Inc. Reverse transcriptase and RNase H were obtained from Pharmacia. The supplier for proteinase K was Boehringer Mannheim Canada. E. coli strain HB101 (ATCC 33694) was used for all transformations. The plasmid pUC19 (Norrander et al., 1983) was purchased from Bethesda Research Laboratories.
  • E. coli transformants were grown on YT medium (Miller, 1972) containing 50 ⁇ g/ml ampicillin. Plasmid DNA was purified by a rapid boiling method (Holmes and Quigley, 1981) . DNA fragments and vectors used for all constructions were separated by electrophoresis on low melting point agarose, and purified from the molten agarose by phenol extraction and ethanol precipitation (Maniatis et al., 1982). Plasmid DNA was sequenced using a modification (Hattori et al., 1985) of the dideoxy method (Sanger et al., 1977). Reactions were run using the -20 universal primer (New England Biolabs) .
  • RNA products separated by this procedure were visualized by autoradiography at room temperature.
  • Example l Design and synthesis of oligonucleotides for a gag test system
  • a synthetic DNA sequence ( Figure 2A) was designed to include an EcoRI site, a T7 phage promoter, a sequence required for initiation of transcription by T7 RNA polymerase and a 19 bp hybridization region (hybridization region 1) .
  • the 47 b strand oligonucleotide (T7H1.GAG) involved in the cloning of these elements also serves as primer.
  • Hybridization region 2 lies 53 bp away from hybridization region 1 and is 20 bp in length.
  • the primer made to this region (H2.GAG) is a 20 b oligonucleotide duplicate of the sense strand and is not used for cloning.
  • the sequence spanning and including the hybridization regions is a 92 bp segment of the gag portion of the HTLV-III genome. This particular gene segment was chosen because the primers were predicted to hybridize efficiently and because the distance between the two hybridization regions was relatively short. In addition, a Xbal site was placed at the end of the sequence for cloning ease.
  • the gag gene segment was chosen because the primers were predicted to hybridize efficiently and because the distance between the two hybridization regions was relatively short.
  • a Xbal site was placed at the end of the sequence for cloning ease.
  • test sequence also contains Sphl and Pstl sites which can aid in the screening of recombinants.
  • Nl.GAG used in the construction of both the gag test and the gag2 test sequence, completes the antisense strand and is used only in the cloning process.
  • T74.PRO is the sense strand component of the T7 promoter.
  • N2.GAG was used in the construction of both test fragments, and has also been used as an intermediate (second template) in two steps of the amplification cycle. The entire cloned gag test fragment can also represent an intermediate of the amplification cycle (third template) .
  • gag test DNA could be transcribed by T7 RNA polymerase to produce a RNA fragment (first template) useful as an amplification intermediate involved in three of the steps.
  • T7H1.GAG and H2.GAG serve as primers in the test system.
  • the gag2 test synthetic DNA fragment does not contain the T7 promoter, but the remainder of the sequence is identical to the gag test sequence and therefore, both Nl.GAG and N2.GAG were involved in its
  • the oligonucleotide required to complete the antisense strand is called HI.GAG.
  • the gag2 test fragment can be used as a template for testing amplification, using a DNA restriction fragment as template nucleic acid.
  • the oligonucleotides T74.PRO and Nl.GAG (2 ⁇ g each) were phosphorylated separately in 20 ⁇ l reactions containing 70 mM TrisHCl (pH 7.6), 10 mM MgCl 2 , 5 mM DTT, 0.5 mM ATP and 5 units T4 polynucleotide kinase, at 37 °C for 30 min.
  • Phosphorylated T74.PRO and Nl.GAG (10 ⁇ l of each) were mixed with 1 ⁇ g each of unphosphorylated T7H1.GAG and N2.GAG, and 3 ⁇ l 100 mM TrisHCl (pH7.8) - 500 mM NaCl, in a final volume of 29 ⁇ l for the gag test assembly.
  • the gag2 test mixture contained 10 ⁇ l phosphorylated Nl.GAG, 1 ⁇ g each of unphosphorylated HI.GAG and N2.GAG, and 1.8 ⁇ l 100 mM TrisHCl (pH 7.8) - 500 mM NaCl, in a final volume of 18 ⁇ l.
  • oligonucleotide mixtures were hybridized separately by placing them at 90 °C for 10 min followed by slow cooling to room temperature for 10 to 16 h 60 ⁇ l reactions containing 50 mM TrisHCl (pH 7.8), 10 M MgCl 2 , 20 mM DTT, 1 mM
  • the isolated and purified synthetic DNA segments were mixed with plasmid pUC19 which had been linearized by digestion at restriction enzyme sites within the polylinker region.
  • T4 DNA ligase was used to ligate the gag test sequence into the EcoRI- Xbal fragment of pUC19, while the gag2 test sequence was ligated to the Smal-Xbal fragment.
  • Plasmid DNA from transformants obtained after these reactions were used to transform E. coli were screened by restriction analysis, and the final plasmids (pGAG.TEST and pGAG2.TEST) were determined to be correct by sequence analysis.
  • the primers T7H1.GAG and H2.GAG were each added at final concentrations of 3.4 ⁇ M or 0.34 ⁇ M to reactions containing either N2.GAG or no template.
  • the reactions were incubated at 42 °C for 2 h. Total synthesis of RNA was monitored by determining the incorporation of TCA insoluble cpm at 30 min intervals.
  • the effect of the primer concentration on template- dependent RNA synthesis is shown in Table 1. Aliquots of each reaction, containing equal amounts of synthesized RNA, were analyzed by PAGE and autoradiography ( Figure 3, lanes 1-4 numbered the same as the reactions) .
  • Table 1 RNA amplification from N2.GAG after 2 h.
  • reaction 2 resulted in the greatest incorporation of isotope, the no template control, reaction 2, was also high (73% of reaction 1) and produced a very similar electrophoretic profile. It would therefore appear that in the presence of high primer concentrations, a RNA transcript of identical size to that expected in amplification is produced in the absence of any template. Results using samples with a 10-fold decrease in primer concentrations were dramatically different. The amount of RNA produced in reaction 3 was 2.6 times that of reaction 4, but while virtually all of the transcript was found in a single band of the expected size in reaction 3, no fragments greater than 60 to 70 b were found in reaction 4. Primer concentration therefore plays a significant role in the accuracy and efficiency of RNA amplification.
  • RNA transcript used to represent the size of fragment expected to be generated by the amplification system (lane 0 of Figure 3) was prepared by transcription from the test plasmid.
  • pGAG.TEST was linearized by digestion with Xbal, proteinase K treated (Maniatis et al., 1982), phenol extracted and ethanol precipitated. T7 RNA polymerase was then used
  • Example 4 Effect of template concentration on RNA amplification.
  • the standard 50 ⁇ l reaction mixture used to amplify RNA transcribed from the gag test oligonucleotides contained 0.34 ⁇ M T7H1.GAG, 0.34 ⁇ M H2.GAG, 50 mM TrisHCl (pH 8.45), 6 mM MgCl 2 , 40 mM KC1, 10 mM DTT, 0.5 mM NTP, 1 mM dNTP, 40 units RNasin, 20 units T7 RNA polymerase, 20 units reverse transcriptase, 0.8 units RNase H and 10 - 20 ⁇ Ci [ ⁇ -32p] UTP.
  • the reactions contained amounts of template (N2.GAG) varying from 1 ng to 1 fg. One reaction contained no template.
  • RNA per starting template generally increased with decreasing template concentration.
  • Amplification of 8 x 10° fold was achieved by synthesis of 0.8 ⁇ g RNA from 1 fg of N2.GAG template.
  • One fg of the 102-b N2.GAG oligonucleotide represents approximately 2 x 10 molecules.
  • Table 2 RNA amplification from N2.GAG after 3 h.
  • Example 5 Hybridization analysis of RNA products.
  • Amplification reactions containing amounts of N2.GAG template varying from 1 pg to 0.1 fg were performed following the teaching of example 4, except the radiolabeled UTP was omitted.
  • the reactions were incubated at 42 °C for 3 h. Aliquots were removed from each reaction at 30 min intervals and applied to a nylon membrane (Amersham) . The nucleic acids that were contained in these reaction aliquots were fixed by exposure to ultraviolet light.
  • the membrane was prehybridized at 50 °C for 1 h in prehybridization buffer consisting of a final concentration of 50% v/v formamide, 5 x SSC and 5 x Denhardt's solution (Maniatis et al.. 1982; Southern et al..
  • oligonucleotide 5' GATCTGGGATAGAGTACATCCA 3' which had been labeled at the 5' end using T4 polynucleotide kinase and ( -32p) ATP.
  • T4 polynucleotide kinase and ( -32p) ATP was washed at 50 °C in a series of 2, 3 min. washes consisting of 2 X SSC, 0.1% v/v SDS and 0.2 X SSC, 0.1% v/v SDS (Southern et al. , 1975; Maniatis et al. , 1982; Szostak et al.. 1979).
  • Figure 5 shows the results of the hybridization analysis performed on the amplification reactions, containing various amounts of N2.GAG template, which were sampled at different times of incubation.
  • Each column of Figure 5 represents a different time point (1, 30 min; 2, 60 min; 3, 90 min; 4, 120 min; 5, 150 min; 6, 180 min) and each row represents a different amount of added N2.
  • GAG template (1, lpg; 2, 100 fg; 3, 10 fg; 4, 1 fg; 5, 0.1 fg; 6, no template) .
  • Amplification of nucleic acids which hybridized to the labeled probe were observed for rows 1-3 (1 pg - 10 fg) , however the hybridization to specific nucleic acids in rows 4 - 5 (1 fg, 0.1 fg) was not higher than row 6 (no template) .
  • the apparent non-specific binding of labeled probe in row 6 seems to be related to DNA or RNA synthesis since the hybridization signal increases with increasing time.
  • the plasmid pGAG2.TEST was digested with Mspl and proteinase K, purified by phenol extraction and ethanol precipitation, and denatured by boiling for 5 min. Amplification reactions were performed and analyzed following the teaching of Example 4, except the Mspl digested pGAG2.TEST was used as a template instead of the N2.GAG oligonucleotide. The amounts of plasmid added to each reaction varied from 55 ng to 5.5 pg, and no template. To simulate additional DNA which would be present in an actual sample, alternate reactions contained 1 ng of calf thymus DNA which had been similarly digested, purified and denatured.
  • RNA synthesis was determined by TCA precipitation and PAGE analysis. As indicated in Table 3, total RNA synthesis was higher than the no template controls for all template concentrations tested. The degree of amplification was calculated based on RNA synthesis from the actual template which was 1.8% of the total plasmid DNA.
  • the total RNA synthesis (degree of amplification) from a particular initial level template concentration
  • RNA which was synthesized after a reaction time of 3 h was analyzed by PAGE ( Figure 6, lanes 1-6, 11 and 12. numbered the same as the reactions) .
  • the major band representing a RNA of about 100 b was present in reactions (lanes) 1-6 but absent in the no template reactions (lanes 11 and 12) .
  • the RNA in lane 0 was a standard, which was prepared following the teaching of Example 3. There was no apparent qualitative difference in the synthesized RNA either with (lanes 2, 4 and 6) or without (lanes 1, 3, and 5) the additional of 1 ⁇ g of Mspl-degested calf thymus DNA.
  • a pGEM.4-gag plasmid and an M13-Mpl8-gag plasmid each containing a 1422 base pair Xbal-EcoRI restriction fragment from HIV 1 (strain BH10) were constructed from a Sacl-Bglll subclone obtained as a gift from Dr. P. Gill, President of the Canadian Red Cross Society. This restriction fragment contains the majority of the HIV1 gag gene (Ratner,
  • E. coli strain HB101 was transformed with the pGEM4-gag plasmid and E. coli strain TGI was transformed with the M13-gag plasmid. Plasmid DNA was prepared by methods described in Maniatis et al. (Maniatis, I., Fritsch, E.F. and Sambrook, J.).
  • gag-RNA template the pGEM.gag plasmid was linearized with Xbal, extracted with phenol-chloroform and precipitated in ethanol. Purified DNA was transcribed using SP6 RNA polymerase (Promega) according to the method of Melton (Melton, D.A. et al.) . 5 units of RNase-free DNasel (Promega) was added and the mixture incubated at 37 °C for 30 minutes. The RNA product was extracted with phenol-chloroform and precipitated with ethanol. The yield of RNA was determined spectrophotometrically.
  • Oligonucleotides were synthesized on an Applied Biosystems Model 380-A DNA synthesizer. DNA oligomers were purified by polyacrylamide gel electrophoresis
  • the first primer was a 20-mer; the second primer was 45 bases in length (the T7 promoter sequence is underlined) and the probe was a 53-mer.
  • the 53-base oligonucleotide probe was complimentary to the amplification product sequence and was labelled by Polynucleotide Kinase (BRL) in the presence of X-32P ATP (Amersham) .
  • RNA targets induced the indirect amplification reaction in the milieu containing 50 mM Tris-HCl, pH 8.3. 6 mM MgCl 2 , 40 mM KC1, 10 mM DTT, 1 mM deoxyribonucleotides (Pharmacia) 0.5 mM ribonucleotides (Pharmacia) 40 units of AMV-reverse transcriptase (Seikagaku) . 0.4 units RNase H (Pharmacia), 20 units T7 RNA polymerase (Pharmacia) and 0.5 units per ⁇ l RNA-GuardTM (Pharmacia) . The concentration of each primer was 0.35 ⁇ M and the final reaction volume was 25 ⁇ l. Standard reactions were run at 42 °C for 3 hours and were terminated with the addition of EDTA to a final concentration of 5 mM.
  • DNA targets were amplification-induced as for RNA with the following modifications.
  • Double-stranded DNA was mixed with buffer, nucleotides and primers, heated to 95 °C for 3 minutes, and then placed on ice.
  • T7-DNA polymerase (Sequenase -1 - 11 from United States Biochemical) was added to a final concentration of 0.5 units per ⁇ l and incubated for 15 minutes at 37 °C. The mixture was heated to 95 °C for 3 minutes and then cooled, whereupon DTT, reverse transcriptase, RNase H, T7 RNA polymerase and RNA-GuardTM were added, and the reaction run at 42 °C for 3 hours.
  • the indirect amplification process is shown in Figure 7.
  • a natural RNA target mRNA, nRNA, tRNA, etc.
  • the indirect amplification reaction proceeds with the annealing of the second primer which contains a T7-RNA polymerase promoter sequence at its 5' end (19,20).
  • Reverse transcriptase present in the reaction mix generates a complementary DNA strand from the 3' end of the second primer.
  • the RNA strand — the natural RNA target — of the RNA/DNA duplex is degraded by RNase H present in the mix.
  • the first primer anneals to the resultant single strand of cDNA and second-stranded synthesis occurs, rendering the promoter sequence double-stranded.
  • the T7-RNA polymerase present in the mix generates multiple copies of RNA, antisense to the original target, which serve as new templates for cDNA synthesis in the cyclic phase of the indirect amplification reaction.
  • This cyclic phase is characterized by the primers annealing in the reverse order to the non-cyclic phase: that is, the first primer anneals first, initiating the reverse transcriptase and RNase H reactions, followed by the second primer priming double-stranded DNA synthesis, again creating a functionally active T7 promoter.
  • Figure 7 also illustrates where DNA intermediates occur in the indirect amplification process and therefore how DNA targets themselves can be the subject of exponential amplification via the indirect amplification reaction.
  • Double-stranded target DNA is cut with a restriction enzyme and denatured to create molecules with defined ends, whereupon the second primer anneals and initiates cDNA synthesis, thus creating a functionally active T7 promoter which generates RNA competent to induce the cyclic portion of the indirect amplification process.
  • both the first primer and the second primer are required to generate a functionally active T7 promoter. Nevertheless, the same indirect amplification process generates the amplified product, whether RNA or DNA is the target.
  • RNA and DNA templates were tested.
  • the pGEM-gag plasmid served as the source of double-stranded DNA template.
  • the pGEM-gag plasmid was linearized using Xbal, which cuts at the end of the inserted DNA.
  • the linearized plasmid was transcribed by SP6 RNA polymerase to yield an RNA product 1422 bases in
  • Primer sites were selected such that the amplified product from either the DNA or RNA target was 140 bases in length.
  • RNA and DNA templates are 1422 bases in length.
  • Amplification product is 140 bases in length.
  • the specificity of the indirect amplification reaction was also examined.
  • One nanogram and 1 picogram of RNA or DNA were targets in the indirect amplification reaction in the presence or absence of 1 ⁇ g of heterologous RNA or DNA under standard conditions.
  • the reactionproducts were examined by ethidium bromide staining. Only a single amplification product of approximately 140 bases in length was obtained in any of these reactions, thus indicating that the primer sequences selected were specific for the correct segment of the gag gene.
  • the presence of heterologous total RNA isolated from HL60 cells had no effect on the specificity of the indirect amplification reaction.
  • the lfg sample was readily datactable by hybridization.
  • the sensitivity of the indirect amplification reaction was determined for both DNA and RNA targets.
  • Stock solutions of each target were diluted serially in sterile water containing 20 ⁇ g/ml RNase-free E. coli tRNA. Aliquots of these dilutions were subjected to standard indirect amplification conditions for 3 hours at 42 °C.
  • the 32P-end-labelled oligonucleotide probe was used to detect amplification products bound to nylon membranes. Both DNA and RNA targets were detectable starting with as few as 10 initial molecules.
  • RNA product sequence was examined.
  • One picogram of either DNA or RNA target was subjected to indirect amplification conditions for 3 hours at 42 °C and the products were sequenced by extension from 32P-labelled P2 primer in the presence of didebxynucleotides.
  • the products of the sequencing reactions were separated in an 8% acryla ide gel. Analysis of the sequence obtained indicated that not only was the product of correct length (140 bases) ,
  • This indirect amplification process amplifies a small number of nucleic acid molecules greater than
  • the entire indirect amplification reaction is homogenous, that is, no additions are made to the reaction once it is begun;
  • the principal product of the indirect amplification reaction is RNA complementary to the original target. This single-stranded product is readily detected without further manipulation;
  • the second primer is used to initiate cDNA synthesis, whereas in the cyclic phase of the indirect amplification reaction, cDNA synthesis is initiated with the first primer (see Figure 7) ;
  • the simple indirect amplification format is accomplished by the simultaneous enzymatic synthesis and degradation of RNA in such a way that transcriptionally functional DNA accumulates.
  • S nucleic acid present the detection system used, and the amount of detectable product which gives significant signal to background ratios.

Abstract

This invention relates to a process for amplifying a specific nucleic acid sequence. The process involves synthesizing single-stranded RNA, single-stranded DNA and double-stranded DNA. The single-stranded RNA is a first template for a first primer, the single-stranded DNA is a second template for a second primer, and the double-stranded DNA is a third template for synthesis of a plurality of copies of the first template. A sequence of the first primer or the second primer is complementary to a sequence of the specific nucleic acid and a sequence of the first primer or the second primer is homologous to a sequence of the specific nucleic acid. The amplification process may be used to increase the quantity of the specific nucleic acid sequence to allow detection, or to increase the purity of the specific nucleic acid sequence as a substitute for conventional cloning methodology.

Description

NUCLEIC ACID AMPLIFICATION PROCESS
FIELD OF THE INVENTION
This invention relates to a process for amplifying a specific nucleic acid sequence.
BACKGROUND OF THE INVENTION
The detection of a specific nucleic acid sequence present in a sample by probing the sample with a complementary sequence of nucleic acids is a known diagnostic technique. Nucleic acids are highly specific in binding to complementary nucleic acids and are thus useful to determine whether a specific nucleic acid is present in a sample. One must know the sequence of the specific nucleic acid to be detected and then construct a probe having a complementary nucleic acid sequence to the specific nucleic acid sequence.
In this application, the phrase "specific nucleic acid sequence" means a single stranded or double
stranded nucleic acid which one wishes to amplify; "sample" means a mixture containing nucleic acids; "sufficiently complementary" means that two nucleic acids, a primer and a template, are capable of specific interaction which allows efficient, primer-dependent and template-directed synthesis of DNA, under given conditions of ionic strength and temperature.
Since nucleic acid probes are highly specific, it is preferable in some situations to probe the nucleic acid sequence itself rather than the protein produced by the nucleic acid sequence. As a particular example, a diagnostic method based solely on protein detection would be unreliable for determining the presence of infectious particles of hepatitis B virus, due to the presence of significant levels of non-infectious antigen particles which lack the DNA genome. In another example, the various subtypes of human papilloma virus found in either pre-cancerous or benign cervical tumors can be distinguished only by the use of nucleic acid probe hybridization. Also, the microbiology of AIDS makes it certain that an assay based on the presence of AIDS specific nucleic acid sequence would be superior as a diagnostic.
The greatest difficulty with applying existing nucleic acid probe technology, and the reason that the utility of the existing probe technology is limited, is the copy number problem. In a virus of cell, for example, there is usually a single copy of a particular gene. This one copy may give rise to many copies of gene product, either RNA or protein. For this reason, diagnostic techniques have often involved probing the protein, since the specific sequence of nucleic acid to be detected may give rise to many thousand copies of protein.
The naturally-occurring high number of ribosomal RNA, up to 100,000 copies per cell, has been used by GenProbe to facilitate diagnosis of certain bacterial pathogens, such as Legionella and Mycoplasma, using nucleic acid probes. However, this strategy cannot be used with non-cellular pathogens, such as viruses. Copy number is a particular problem with the development of a nucleic acid probe method for the detection of AIDS virus, where the integrated provirus may be present in less than one of ten thousand peripheral blood lymphocytes. Thus, if the particular nucleic acid sequence suspected to be present in a sample could be amplified, the copy number problem could be circumvented and probe assays could be more readily used.
In a normal biological sample, containing only a few cells, and consequently only a few copies of a particular gene, it is necessary to utilize an amplification process in order to overcome the copy number problem.
One method to amplify is to 'grow out' the sample, that is, to arrange conditions so that the living biological material present in the sample can replicate itself. Replication increases the quantity of nucleic acid sequences to detectable levels. In the food industry, for example, in order to test processed food for the food-poisoning bacteria Salmonella, food samples must be incubated for a number of days to increase the quantity of nucleic acids. In clinical samples, pathogens must also be allowed to increase their number by growing out over some considerable time.
United States Patent No. 4,683,195 issued on July 28, 1987 to Cetus Corporation and United States Patent No. 4,683,202 issued on July 28, 1987 to Cetus Corporation are each directed to a process for amplifying a target nucleic acid sequence contained in a sample. United States Patent No. 4,683,195 relates
to a process in which a sample suspected of containing a target nucleic acid sequence is treated with oligonucleotide primers such that a primer extension product is synthesized which in turn serves as a template, resulting in amplification of the target nucleic acid sequence. The primer extension product is separated from the template in the preferred embodiment using heat denaturation. Similarly, United States Patent No. 4,683,202 relates to a process for amplifying a target nucleic acid sequence having two separate complementary strands. The process includes treating the strands with primers to synthesize extension products, separating the primer extension products from the templates, and in turn using the primer extension products as templates.
Both of the above United States patents require either manual or mechanical participation and multi-step operations by the user in the amplification process. The steps involved in these patents require the user to heat the sample, cool the sample, add appropriate enzymes and then repeat the steps. The temperature changes cause the enzymes to loose their activity. Hence, the user is required to repeatedly supplement the amplification mixture with aliquots of appropriate enzymes during the amplification process.
In addition, in United States Patents Nos. 4,683,195 and 4,683,202 each cycle of the amplification process takes place by the synthesis from a first template, of a second template, the second template in turn is used to synthesize the first template. This procedure is repeated, thus, each cycle of the amplification process is based on the synthesis of one product from one substrate.
Notwithstanding the amplification processes disclosed in the prior art, a need exists for improvements to the amplification process. It would be preferable if the amplification process required less participation and fewer manipulations by the user. Further, it would be advantageous if the amplification took place at a relatively constant ambient temperature so that the activity of the enzymes involved in the process would not be affected. It would be more expedient if a template could be used to generate more than one product from one substrate in each cycle of the amplification process.
SUMMARY OF THE INVENTION
This invention relates to an amplification process which is expedient and requires less participation and fewer manipulations by the user of the process than conventional amplification processes. The amplification takes place at a relatively constant ambient temperature. In addition, each cycle of the process generates a plurality of copies of product from one substrate. The amplification process of this invention may be used to increase the quantity of a specific nucleic acid thus circumventing the copy number problem. Hence, probe assays may be more readily used. The amplification process could also be used to increase the purity of a specific nucleic acid sequence as a substitute for conventional cloning methodology.
According to one aspect of the invention, a process for amplifying a specific nucleic acid sequence is used. The process involves the synthesis of single-stranded RNA, single-stranded DNA, and double stranded DNA. The single stranded RNA is a first template for a first primer. The single stranded DNA is a second template for a second
primer. The double stranded DNA is a third template for the synthesis of a plurality of copies of the first template. A sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence. A 31 end of the first primer is oriented towards a 3 ' end of the second primer on complementary strands.
According to another aspect of the invention, a process for amplifying a specific nucleic acid sequence is used. The process involves:
(a) hybridizing a first primer to a first template. The first primer has a DNA sequence which is sufficiently complementary to a RNA sequence of the first template;
(b) synthesizing a first DNA sequence covalently attached to the first primer and complementary to the RNA sequence of the first template. The first DNA sequence and the first primer comprise a second template;
(c) separating the first template from the second template to allow hybridization of a second primer;
(d) hybridizing the second primer to the second template. The second primer has a DNA sequence which is sufficiently complementary to a DNA sequence of the second template. The second primer also has a sequence of a promoter and a sequence of a transcription initiation site for a RNA polymerase;
(e) synthesizing a second DNA sequence covalently attached to the second primer and complementary to the DNA sequence of the second template and synthesizing a third DNA sequence covalently attached to the second template and complementary to the DNA sequence of the second primer. The second and third DNA sequences, the second primer and the second template comprise a third template;
(f) synthesizing a plurality of copies of the RNA sequence of the first template from the third template.
A sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence. A 3' end of the first primer is oriented towards a 3' end of the second primer on complementary strands.
In a further alternative of the invention, the second primer of DNA has a sequence at its 3• end which is sufficiently complementary to the DNA sequence of the second template. The second primer has at its 5' end a sequence of a promoter and a sequence of a transcription initiation site for a RNA polymerase.
In another alternative of the invention, a process for amplifying a specific nucleic acid sequence is used. The process involves combining a first primer, a second primer, ribonuclease H, a RNA-directed DNA polymerase, a DNA-directed DNA polymerase, a RNA polymerase, ribonucleoside triphosphates and deoxyribonucleoside triphosphates with a sample. The first primer of DNA has a sequence which is sufficiently complementary to a first template of RNA. The second primer of DNA has a sequence which is sufficiently complementary to a second template of DNA, and a sequence of a promoter and a sequence of a transcription initiation site which are recognized as substrate by the RNA polymerase. A sequence of the first primer or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first primer or the second primer is sufficiently homologous to a sequence of the specific nucleic acid. A 3' end of the first primer is oriented towards a 3' end of the second primer on complementary strands.
In a further alternative of the invention, a process for amplifying a specific nucleic acid sequence is used. The process involves adding a first
primer, a second primer, avian myoblastosis viral polymerase, E. coli ribonuclease H, bacteriophage T7 RNA polymerase, ribonucleoside triphosphates and deoxyribonucleoside triphosphates to a sample. The first primer of DNA has a sequence which is sufficiently complementary to a first template of RNA. The second primer of DNA has a sequence which is sufficiently complementary to a second template of DNA, and a sequence of a promoter and a sequence of a transcription initiation site which are recognized as substrate by T7 RNA polymerase. A sequence of the first primer or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first primer or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence. A 31 end of the first primer is oriented towards a 3' end of the second primer on complementary strands.
BRIEF DESCRIPTION OF THE DRAWINGS
In drawings which illustrate embodiments of the invention,
SUBST Figure 1 is a general illustration the nucleic acid amplification process;
Figure 2 shows the synthetic oligonucleotides DNA sequences which are used for testing the amplification process: Figure 2A, the gag test sequence; Figure 2B, the gag2 test sequence;
Figure 3 is an autoradiogram of PAGE analysis of amplification reactions using different primer concentrations;
Figure 4 is an autoradiogram of PAGE analysis of amplification reactions using different template concentrations;
Figure 5 is an autoradiogram of Dot-blot hybridization on amplification reactions;
Figure 6 is an autoradiogram of PAGE analysis of amplification reaction using restriction fragments as template;
SUBSTITUTE SHEET Figure 7 is a general illustration of the indirect nucleic acid amplification process.
SUBSTIT . -lb_
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
This invention relates to a process for amplifying a specific nucleic acid sequence. The amplification involves the alternate synthesis of DNA and RNA and is generally illustrated in Figure 1. In this process, single-stranded RNA is converted to single-stranded DNA which in turn is converted to a functional template for the synthesis of a plurality of copies of the original single-stranded RNA. A first primer and a second primer are used in the amplification process. A sequence of the first primer or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence. In some instances, both the first primer and second primer are sufficiently complementary and sufficiently homologous to a sequence of the specific nucleic acid sequence, for example, if the specific nucleic acid sequence is double stranded DNA.
The RNA is converted to single-stranded DNA by hybridizing an oligonucleotide primer (the first
S primer) to the RNA (the first template) and synthesizing a complementary strand of DNA from the first primer, (the first DNA sequence) by using a RNA-directed DNA polymerase. The resulting single-stranded DNA (the second template) is separated from the first template by, for example, hydrolysis of the first template and by using a ribonuclease which is specific for RNA-DNA hybrids (for example, ribonuclease H) . The second template is converted to a form which is capable of RNA synthesis by hybridizing a synthetic oligonucleotide (the second primer) , which contains at its 3' end a sequence which is sufficiently complementary to the 3* end of the second template and toward its 5' end a sequence of a promoter and a sequence of a transcription initiation site, and by synthesizing a second DNA sequence covalently attached to the 3 end of the second primer using the second template as a template and synthesizing a third DNA sequence covalently attached to the 3* end of the second template using the second primer as a template, using DNA-directed DNA polymerase. The resulting functional derivative of the second template, which is a third template, is used for the synthesis of a plurality of copies of RNA, the first template, by
using a RNA polymerase which is specific for the promoter and transcription initiation site defined by the second primer. Each newly synthesized first template can be converted to further copies of the second template and the third template by repeating the cycle. In addition, repetition of the cycle does not require participation or manipulation by the user.
The amplification process commences with the addition of a suitable template nucleic acid to the appropriate enzymes, primers, and cofactors under the appropriate reaction conditions. This template nucleic acid is in a form which is capable of homogenous and continuous amplification and can function as an intermediate in the cycle set forth in Figure 1. The amplification process involves the net consumption of precursors (primers, ribonucleoside trifhosphates and deoxyribonucleoside trophosphates) and the net accumulation of products (RNA and DNA) . The processes of RNA and DNA synthesis will proceed asynchronously until sufficient levels of nucleic acids have been synthesized to allow detection. The amplification process may be monitored by, for example, the synthesis of a labeled product from a labeled precursor.
o
It is contemplated that amplification may involve another process either in addition to or in place of the one generally illustrated in Figure 1. Also possible are certain counter-productive enzymatic reactions which occur at permissibly low rates. Included among the possible non-productive side reactions is the synthesis of RNA and/or DNA in the absence of an added template nucleic acid. Such RNA and/or DNA products can be discriminated from desired products by determining whether a particular sequence which would be found only between the two priming sites of the specific nucleic acid sequence is present.
The first primer is an oligodeoxyribonucleotide which has at its 3' end a sequence which is sufficiently complementary to the 3• end of the first template. The sequence at the 31 end of the first primer has a particular length and base composition to allow specific and efficient synthesis of the first DNA sequence, under the given conditions of ionic strength and temperature. The first primer may be sufficiently complementary to a region internal to the 3' end of the first template in the first cycle. In subsequent cycles, the 5' end of the first primer would be complementary to the 3' end of the first
SUBSTITUTE SHEET template. It is contemplated that the first primer may be composed partially or completely of nucleotides or nucleotide analogs other than the natural deoxyribonucleotides. The 5' end of the first primer may contain sequences which are not complementary to the first template in the first cycle. The non-complementary sequences may be complementary to a nucleic acid which can be immobilized, or to which can be bound a useful non-nucleic acid component, such as a reporter to facilitate detection.
The second primer is an oligodeoxyribonucleotide which contains at its 3' end a sequence which is sufficiently complementary to the 3 ' end of the second template. The second primer has a particular length and base composition to allow specific and efficient synthesis of the second and third DNA sequences, under the given conditions of ionic strength and
SUBSTITUTE SHEET temperature. In addition, the second primer contains the sequence of a functional promoter and the sequence of a transcription initiation site. This sequence, when used as a template for synthesis of the third DNA sequence, contains sufficient information to allow specific and efficient binding of a RNA polymerase and initiation of transcription at the desired site. The promoter sequence may be derived from the antisence strand of a functional promoter. The transcription initiation site may be derived from the 5'-terminal sequence of a natural RNA transcript. In the preferred embodiment, the 5*-terminal sequence of the second primer is AATTCTAATACGACTCACTATAGGGAG. This sequence contains the sequence of the promoter and the sequence of the transcription initiation site for T7 RNA polymerase. Alternatively, the transcription initiation site and promoter for another phage RNA polymerase may be used. In addition, sequences which are unrelated to the promoter function may be included at the 5* end of the second primer or between the transcription initiation site and the sequence at the 3* end which hybridizes to the second template. It is contemplated that the second primer may be composed partially or completely of nucleotides or nucleotide analogs other than natural deoxyribonucleotides.
All of the enzymes used in this invention should meet certain practical specifications. Each enzyme or enzyme preparation should be free of deleterious deoxyribonuclease ("DNase") activities, such as the 5' or 3' exonuclease activities which are often associated with certain DNA polymerases and single-strand or double-strand specific exonuclease of endonucleases. Each enzyme or enzyme preparation should be free of deleterious ribonuclease ("RNase") activities, with the exception of the preferred addition of a ribonuclease activity which is specific for hybrids of RNA and DNA (for example, ribonuclease H) . In addition, each enzyme should be reasonably active under the common reaction conditions which are used for the other enzymatic processes, and non-enzymatic processes, such as hybridizing oligonucleotide primers to the RNA or DNA templates.
The DNA-directed RNA polymerase which is used in this invention may be any enzyme capable of binding to a particular DNA sequence called a promoter and specifically initiating in vitro RNA synthesis at a defined initiation site within close proximity to the promoter. The promoter and the initiation site form part of the second primer. In addition the RNA
SUBSTITUTE SHEET polymerase should be capable of synthesizing several copies of RNA per functional copy of template in a reasonable amount of time. In the preferred embodiment, the bacteriophage T7 RNA polymerase is used. In addition other bacteriophage RNA polymerases, such as phage T3, phage ll, salmonella phage sp6~, or pseudomonas phage gn-1 may be used. In another embodiment, other prokaryotic or eukaryotic DNA-directed RNA polymerase may be used. It should be understood that if alternative RNA polymerases are used, then the necessary changes to the promoter and initiation sequences of the second primer should be made according to the template specificity of the particular RNA polymerase.
The RNA-directed DNA polymerase which is used in this invention may be any enzyme capable of synthesizing DNA from an oligodeoxyribonucleotide primer and a RNA template. In addition this enzyme may contain activities for DNA-directed DNA polymerase and RNase H. In the preferred embodiment, the avian myoblastosis viral polymerase ("AMV reverse transcriptase") is used. In addition, the RNA-directed DNA polymerase could be from another retroviruε, such a Maloney murine leukemia virus.
SUBSTITUTESHEET Alternatively, other eukaryotic RNA-directed DNA polymerases could be used.
The DNA-directed DNA polymerase which is used in this invention may be any enzyme capable of synthesizing DNA from an oligodeoxyribonucleotide primer and a DNA template. This enzyme should not contain either 5'- or 3'-exonuclease activities, which are associated with many types of DNA polymerase. In the preferred embodiment, the AMV reverse transcriptase is used. However, other DNA-directed DNA polymerase which naturally lack the 5'- or 3*-exonuclease activities could be used. These could include certain eukaryotic DNA polymerases, such as, DNA polymerase c or β those DNA polymerases which could be isolated from a mammalian tissue, such as calf thymus. An otherwise unsuitable DNA polymerase could be made useful by removing the undesirable exonuclease activities either by alteration of the DNA polymerase gene followed by expression of the altered polymerase in a suitable host cell, or by chemical modification of the DNA polymerase protein. Altered versions of DNA polymerase could be made from the Klenow fragment of E. coli DNA polymerase I or the bacteriophage T7 DNA
polymerase. It should be understood that such alternative DNA-directed DNA polymerase activities are added to supplement the activity contributed by the RNA-directed DNA polymerase, since in the preferred embodiment, both RNA-directed and DNA-directed DNA polymerase activities are supplied by the same enzyme.
The RNase H which could be used in this invention may be any enzyme capable of hydrolyzing a RNA which is annealed to a complementary DNA. This enzyme should not be capable of hydrolyzing single or double-stranded RNA or any DNA. In the preferred embodiment, the E. coli RNase H is used. In addition, other RNase H enzymes could be used, such as calf thymus RNase H. Since RNase H is an intrinsic activity of AMV reverse transcriptase, the E. coli RNase H will be supplemented in the preferred embodiment by the RNase H of AMV reverse transcriptase. Alternatively, any other enzyme capable of separating the second template from the first template could be used.
The abovementioned enzymes and primers are mixed together in a reaction vessel which contains the necessary buffers and cofactors for both DNA and RNA
SUBSTITUTE S synthesis. In addition, the ionic conditions and reaction temperature should be compatible with specific hybridization of the primers to the DNA and RNA templates as is known to those skilled in the art. The reaction mixture should be free of such agents which would interfere with the amplification process, specifically substances which could greatly inhibit the activity of the enzymes, interfere with the hybridizing of primers and templates, or degrade non-productively the nucleic acid intermediates and products.
The description of possible detection schemes may be useful to the application of the amplification process. It should be understood that schemes which may be used for detecting the nucleic acids which are synthesized in the amplification process are not limited to those described herein, and it is contemplated that other methods may be used.
In one embodiment, a labeled precursor may be added to the reaction mixture. Amplification is determined by quantitive or qualitative analysis of labeled products, which can be separated from the labeled precursor by using methods known in the art.
SUBSTITUTE SHEET A labeled precursor may be a ribonucleoside triphosphate for detecting RNA synthesis, or a deoxynucleoside triphosphate or an oligonucleotide primer for detecting DNA synthesis. The type of label may be a radioisotope or a useful chemical group, such as biotin, a chro ophore, a fluorophore, or a hapten which could bind to an antibody, or possibly a protein or an enzyme. The labeled products may be separated from the labeled precursors on the basis of solubility, charge, or size. In addition, the labeled DNA or RNA may be hybridized to a nucleic acid which contains a complementary sequence and which can be immobilized.
In another embodiment, the products of the amplification process may be bound to an immobilized support, hybridized to a nucleic acid probe containing a complementary sequence, and separated from the unhybridized nucleic acid probe which remains in solution. The products, DNA or RNA, may be bound directly to a solid support by any stable interaction, such as hydrophobic, electrostatic, or covalent interaction. In addition, the products may contain certain chemical groups, for example, biotin, which may be incorporated into the products during the
amplification process to allow binding to an immobilized protein, for example, avidin or streptavidin. In addition, the products may be hybridized to a nucleic acid which contains a complementary sequence and which can be immobilized. The nucleic acid probe would contain a complementary sequence which forms a sufficiently stable interaction with a product of the amplification process to allow binding under the conditions of hybridization and sustained binding under the conditions used for removal of the unhybridized nucleic acid probe. In the preferred embodiment the complementary sequence would be derived from that part of the specific nucleic acid sequence which is between the sequences of the first primer and the second primer. The nucleic acid probe may be a single-stranded DNA or RNA, or a double-stranded DNA or RNA which can be made single-stranded, or an oligonucleotide which can be composed of deoxyribonucleotides and/or ribonucleotides. In addition, the nucleic acid probe may contain a chemical group which could covalently bind to a product DNA or RNA under the appropriate conditions. The nucleic acid probe may be labeled with a radioisotope or a useful chemical group, such as biotin, a chromophore, a fluorophore, or a hapten
SUBSTITUTE SHEET which could bind to an antibody. In addition, the nucleic acid probe could be conjugated to a protein or enzyme, for example, a phosphatase or a peroxidase. In addition, the nucleic acid probe may contain sequences which would allow in vitro replication of the probe.
It is contemplated that the products of the amplification process may be analyzed by methods which are typically used for nucleic acids that have been enriched by molecular cloning techniques. In one alternative, the synthesis of a specific DNA sequence may be detected by digestion of the synthesized DNA with a restriction endonuclease, followed by electrophoretic separation and detection using methods known in the art. In another alternative, the sequence of amplified RNA may be determined by DNA synthesis using a RNA-directed DNA polymerase, the first primer, and dideoxynucleoside triphosphates (Stoflet et al., 1988). In another alternative, the sequence of the amplified third template may be determined by RNA synthesis using the DNA-directed RNA polymerase used in the amplification process, and 3 '-deoxyribonucleoside triphosphates (Axelrod & Kramer, 1985) . In another alternative, the amplified
SUBSTITUTE SHEET RNA may encode a polypeptide which could be translated, in vitro. The polypeptide product of the in vitro translation could be analyzed by using an antibody.
A sample suspected of containing or known to contain the specific nucleic acid sequence is added to the reaction mixture in the form of a template nucleic acid which is capable of homogeneous and continuous amplification and may be any intermediate in the cycle set forth in Figure l. In particular, the template nucleic acid may be a single-stranded RNA which contains at its 5' end a sequence which is sufficiently homologous to that which is at the 3 ' end of the second primer, and contains a sequence which is sufficiently complementary to the first primer. A template nucleic acid of this form would function as a first template in the amplification process. Alternatively, the template nucleic acid may be a single-stranded DNA which contains at its 3' end a sequence which is sufficiently complementary to at least the 3' end of the second primer, and contains a sequence which is sufficiently homologous to that which is at the 3' end of the first primer. A template nucleic acid of this form would function as a
second template in the amplification process. Alternatively, the template nucleic acid may be a double-stranded DNA, one strand of which contains at its 5• end the entire sequence of the second primer and contains a sequence which is sufficiently complementary to the first primer. The double-stranded DNA functions as a third template in the amplification process.
Although the preparation of a template nucleic acid is not part of the amplification process, the description of possible schemes for generating template nucleic acids may be useful to the application of the amplification process. It should be understood that the schemes which may be used for obtaining the template nucleic acid are not limited to the alternatives which are described herein, and it is contemplated that other methods may be used.
In one alternative, a template nucleic acid which could function as a first template could be a naturally occurring RNA or a RNA fragment which could be generated from a larger RNA molecule by using site specific hydrolysis methods known in the art (Shibahara et al., 1987).
In another alternative, a template nucleic acid which could function as a second template could be generated from a double-stranded DNA by digestion with a restriction endonuclease which has a site immediately flanking the sequence which is sufficiently complementary to the 3' end of the second primer. The resulting double-stranded DNA fragments could then be made single-stranded by using chemical or thermal denaturation methods.
In another alternative, a template nucleic acid which could function as a second template could be generated from a single-stranded DNA or RNA to which has been hybridized an oligonucleotide which is capable of blocking DNA synthesis. This blocking oligonucleotide may contain a chemical group, which could covalently bind to the template, under the appropriate conditions. DNA synthesis from this blocked template using the first primer could result in a synthesized DNA with the same 3' end as the second template. If the original template is RNA, then the resulting DNA-RNA hybrid may be used directly as a template nucleic acid. If the original template is DNA, then the resulting copy of the second template could then be separated from the original template by using chemical or thermal denaturation methods.
In another alternative, a template nucleic acid which could function as a third template could be generated from a single-stranded DNA or RNA by DNA synthesis from the DNA or RNA template using the second primer. The resulting synthesized DNA could then be separated from the original template by using chemical or thermal denaturation methods. In addition, a RNA template could be hydrolyzed by using chemical or enzymatic methods. The resulting single-stranded DNA has the sequence of the second primer covalently attached to its 5' end and contains a sequence which is sufficiently complementary to the first primer. This single-stranded DNA could be converted to a transcriptionally functional double-stranded DNA by hybridizing the first primer to the single-stranded DNA, and by synthesizing a DNA sequence which is covalently attached to the first primer and complementary to the single-stranded DNA.
In a further alternative, a single-stranded DNA or RNA template could be obtained from a double-stranded DNA, double-stranded RNA or a DNA-RNA hybrid by using chemical, thermal, or possibly enzymatic methods. Then, by using one of the alternative schemes proposed above, the resulting
single-stranded DNA or RNA could then be used to generate a template nucleic acid which could function as a first, second or third template. In addition, an alternative scheme involving the first primer and one strand of nucleic acid, and another alternative scheme involving the second primer and the other (complementary) strand of the nucleic acid may be used concurrently to generate template nucleic acids.
MATERIALS AND METHODS
Materials
Oligonucleotides were synthesized using an Applied Biosystems 380A DNA synthesizer. Columns, phosphoramidites, and reagents used for oligonucleotide synthesis were obtained from Applied Biosystems, Inc. through Technical Marketing Associates. Oligonucleotides were purified by polyacrylamide gel electrophoresiε followed by DEAE cellulose chromatography. The radioisotope [α-32p] UTP (800 Ci/mmol) was from Amersham. Enzymes for digesting and ligating DNA were purchased from New England Biolabs, and used according to the supplier's
recommendations. Preparations containing the large fragment of DNA polymerase 1 (Klenow) were also purchased from New England Biolabs. RNasin and T7 RNA polymerase from Promega Biotec were purchased through Bio/Can Scientific Inc. Reverse transcriptase and RNase H were obtained from Pharmacia. The supplier for proteinase K was Boehringer Mannheim Canada. E. coli strain HB101 (ATCC 33694) was used for all transformations. The plasmid pUC19 (Norrander et al., 1983) was purchased from Bethesda Research Laboratories.
Isolation of DNA and sequencing
E. coli transformants were grown on YT medium (Miller, 1972) containing 50 μg/ml ampicillin. Plasmid DNA was purified by a rapid boiling method (Holmes and Quigley, 1981) . DNA fragments and vectors used for all constructions were separated by electrophoresis on low melting point agarose, and purified from the molten agarose by phenol extraction and ethanol precipitation (Maniatis et al., 1982). Plasmid DNA was sequenced using a modification (Hattori et al., 1985) of the dideoxy method (Sanger et al., 1977). Reactions were run using the -20 universal primer (New England Biolabs) .
„35 m.
TCA precipitation
Aliquots (5μl) of amplification reactions were quenched in 20μl 10 mM EDTA and placed on ice until all time point samples had been collected. The quenched samples were then applied to glass filter discs, and immediately dropped into ice-cold 5% trichloroacetic acid ("TCA") - 1% sodium pyrophosphate for 10 min with occasional mixing. Two 5 min washes with ice-cold 5% TCA were followed by two additional washes with 95% ethanol and lyophilization to dryness. Radioactivity was determined in a liquid scintillation counter.
Polyacrylamide gel electrophoresis
Samples (1 to 6 μl) were mixed with 4-5 μl formamide dye (90% deionized formamide, 10 mM TrisHCl (pH 8.0), 1 mM EDTA, xylene cyanol and bromophenol blue) , and applied to a pre-run 12-cm- long 7% denaturing polyacrylamide gel. Gels were run at 350 volts until the bromophenol blue dye had reached the bottom. In some cases the gels were fixed and dried prior to autoradiography. Fixing involved a 15 min wash in 10% methanol- 7% acetic acid. The profiles of
the RNA products separated by this procedure were visualized by autoradiography at room temperature.
Example l: Design and synthesis of oligonucleotides for a gag test system
A synthetic DNA sequence (Figure 2A) was designed to include an EcoRI site, a T7 phage promoter, a sequence required for initiation of transcription by T7 RNA polymerase and a 19 bp hybridization region (hybridization region 1) . The 47 b strand oligonucleotide (T7H1.GAG) involved in the cloning of these elements also serves as primer. Hybridization region 2 lies 53 bp away from hybridization region 1 and is 20 bp in length. The primer made to this region (H2.GAG) is a 20 b oligonucleotide duplicate of the sense strand and is not used for cloning. The sequence spanning and including the hybridization regions is a 92 bp segment of the gag portion of the HTLV-III genome. This particular gene segment was chosen because the primers were predicted to hybridize efficiently and because the distance between the two hybridization regions was relatively short. In addition, a Xbal site was placed at the end of the sequence for cloning ease. The gag
test sequence also contains Sphl and Pstl sites which can aid in the screening of recombinants.
A total of four oligonucleotides were used in the cloning of this fragment. Nl.GAG, used in the construction of both the gag test and the gag2 test sequence, completes the antisense strand and is used only in the cloning process. Similarly, T74.PRO is the sense strand component of the T7 promoter. N2.GAG however, was used in the construction of both test fragments, and has also been used as an intermediate (second template) in two steps of the amplification cycle. The entire cloned gag test fragment can also represent an intermediate of the amplification cycle (third template) . Once cloned into an appropriate vector the gag test DNA could be transcribed by T7 RNA polymerase to produce a RNA fragment (first template) useful as an amplification intermediate involved in three of the steps. In addition, T7H1.GAG and H2.GAG serve as primers in the test system.
The gag2 test synthetic DNA fragment (Figure 2B) does not contain the T7 promoter, but the remainder of the sequence is identical to the gag test sequence and therefore, both Nl.GAG and N2.GAG were involved in its
SUBSTITUTE SHEET construction. The oligonucleotide required to complete the antisense strand is called HI.GAG. Once cloned, the gag2 test fragment can be used as a template for testing amplification, using a DNA restriction fragment as template nucleic acid.
Exam le 2: Construction of the gag test plasmids
The oligonucleotides T74.PRO and Nl.GAG (2 μg each) , were phosphorylated separately in 20 μl reactions containing 70 mM TrisHCl (pH 7.6), 10 mM MgCl2, 5 mM DTT, 0.5 mM ATP and 5 units T4 polynucleotide kinase, at 37 °C for 30 min. Phosphorylated T74.PRO and Nl.GAG (10 μl of each) were mixed with 1 μg each of unphosphorylated T7H1.GAG and N2.GAG, and 3 μl 100 mM TrisHCl (pH7.8) - 500 mM NaCl, in a final volume of 29 μl for the gag test assembly. The gag2 test mixture contained 10 μl phosphorylated Nl.GAG, 1 μg each of unphosphorylated HI.GAG and N2.GAG, and 1.8 μl 100 mM TrisHCl (pH 7.8) - 500 mM NaCl, in a final volume of 18 μl. The oligonucleotide mixtures were hybridized separately by placing them at 90 °C for 10 min followed by slow cooling to room temperature for 10 to 16 h 60 μl reactions containing 50 mM TrisHCl (pH 7.8), 10 M MgCl2, 20 mM DTT, 1 mM
SUBSTITUTE SHEET ATP and 50 μg/ml BSA were used to ligate the hybridized oligonucleotides together. 400 units T4 DNA ligase was added to the gag test reaction and it was incubated at 15 °C for 2 h while the gag2 test reaction was incubated for 14 to 16 h with 200 units T4 DNA ligase.
The isolated and purified synthetic DNA segments were mixed with plasmid pUC19 which had been linearized by digestion at restriction enzyme sites within the polylinker region. T4 DNA ligase was used to ligate the gag test sequence into the EcoRI- Xbal fragment of pUC19, while the gag2 test sequence was ligated to the Smal-Xbal fragment. Plasmid DNA from transformants obtained after these reactions were used to transform E. coli were screened by restriction analysis, and the final plasmids (pGAG.TEST and pGAG2.TEST) were determined to be correct by sequence analysis.
Example 3: Effect of primer concentration on RNA amplification
The reaction mixtures (25 μl) which were used to amplify RNA transcribed from the gag test
SUBSTITUTE SHEET oligonucleotides contained 50 mM TrisHCl (pH 8.45), 6 mM MgCl2, 40 mM KC1, 10 mM dithiothreitol, 0.5 mM NTP (ATP, CTP, GTP, UTP) , 1 mM dNTP (dATP, dCTP, dGTP) dTTP) , 20 units RNasin, 10 units T7 RNA polymerase, 10 units reverse transcriptase, 0.4 units RNase H, and 10 μCl [α-32p] UTP. Two of the reactions contained 0.5 ng (0.015 pmoles) N2.GAG while the other two reactions contained no template. The primers T7H1.GAG and H2.GAG were each added at final concentrations of 3.4 μM or 0.34 μM to reactions containing either N2.GAG or no template. The reactions were incubated at 42 °C for 2 h. Total synthesis of RNA was monitored by determining the incorporation of TCA insoluble cpm at 30 min intervals. The effect of the primer concentration on template- dependent RNA synthesis is shown in Table 1. Aliquots of each reaction, containing equal amounts of synthesized RNA, were analyzed by PAGE and autoradiography (Figure 3, lanes 1-4 numbered the same as the reactions) .
Table 1: RNA amplification from N2.GAG after 2 h.
Concentration of S nthesized Reaction each primer (iM)
Figure imgf000042_0001
Figure imgf000042_0002
It was found that while reaction 1 resulted in the greatest incorporation of isotope, the no template control, reaction 2, was also high (73% of reaction 1) and produced a very similar electrophoretic profile. It would therefore appear that in the presence of high primer concentrations, a RNA transcript of identical size to that expected in amplification is produced in the absence of any template. Results using samples with a 10-fold decrease in primer concentrations were dramatically different. The amount of RNA produced in reaction 3 was 2.6 times that of reaction 4, but while virtually all of the transcript was found in a single band of the expected size in reaction 3, no fragments greater than 60 to 70 b were found in reaction 4. Primer concentration therefore plays a significant role in the accuracy and efficiency of RNA amplification.
A control RNA transcript used to represent the size of fragment expected to be generated by the amplification system (lane 0 of Figure 3) was prepared by transcription from the test plasmid. pGAG.TEST was linearized by digestion with Xbal, proteinase K treated (Maniatis et al., 1982), phenol extracted and ethanol precipitated. T7 RNA polymerase was then used
according to the supplier's recommendations to transcribe 0.5 μg of the resulting fragment in a 25 μl reaction mixture containing 10 μCi [α-32p] UTP.
Example 4: Effect of template concentration on RNA amplification.
The standard 50 μl reaction mixture used to amplify RNA transcribed from the gag test oligonucleotides contained 0.34 μM T7H1.GAG, 0.34 μM H2.GAG, 50 mM TrisHCl (pH 8.45), 6 mM MgCl2, 40 mM KC1, 10 mM DTT, 0.5 mM NTP, 1 mM dNTP, 40 units RNasin, 20 units T7 RNA polymerase, 20 units reverse transcriptase, 0.8 units RNase H and 10 - 20 μCi [α-32p] UTP. The reactions contained amounts of template (N2.GAG) varying from 1 ng to 1 fg. One reaction contained no template. The reactions were incubated at 42 °C for 3 h, during which total synthesis of RNA was monitored by determining the incorporation of TCA insoluble cpm at 30 min intervals. As indicated in Table 2, total RNA synthesis was higher than the no template control for all template concentrations tested. Although the total synthesis of RNA generally decreased with decreasing template concentration, this decrease in synthesis was not
quantitative. Thus, the degree of amplification of RNA per starting template generally increased with decreasing template concentration. Amplification of 8 x 10° fold was achieved by synthesis of 0.8 μg RNA from 1 fg of N2.GAG template. One fg of the 102-b N2.GAG oligonucleotide represents approximately 2 x 10 molecules.
Table 2: RNA amplification from N2.GAG after 3 h.
Figure imgf000045_0001
The RNA which was synthesized after a reaction time of 3 h was analyzed by PAGE, for each template concentration (Figure 4 lanes 1-8, numbered the same as the reactions) . A major band representing a RNA of about 100 b was present in all reactions except the ones containing 1 fg template and no template. The reaction containing 1 fg template did not have much of this 100 b product at 3 h but the overall RNA
synthesis was higher than and qualitatively different from the no template reaction.
Example 5: Hybridization analysis of RNA products.
Amplification reactions containing amounts of N2.GAG template varying from 1 pg to 0.1 fg were performed following the teaching of example 4, except the radiolabeled UTP was omitted. The reactions were incubated at 42 °C for 3 h. Aliquots were removed from each reaction at 30 min intervals and applied to a nylon membrane (Amersham) . The nucleic acids that were contained in these reaction aliquots were fixed by exposure to ultraviolet light. The membrane was prehybridized at 50 °C for 1 h in prehybridization buffer consisting of a final concentration of 50% v/v formamide, 5 x SSC and 5 x Denhardt's solution (Maniatis et al.. 1982; Southern et al.. 1975) at a volume equivalent to 5 mis of solution per 100 cm and hybridized with a radiolabeled probe with a specific activity of 106 cpm/ml of hybridization solution. Hybridization was performed at 50 °C for 16 h in 50% formamide, 5 X SSC and 5 X Denhardt's solution (Maniatis et al. , 1982; Southern et al. , 1975) . The radiolabeled probe was the synthetic
oligonucleotide 5' GATCTGGGATAGAGTACATCCA 3' which had been labeled at the 5' end using T4 polynucleotide kinase and ( -32p) ATP. After the membrane was washed at 50 °C in a series of 2, 3 min. washes consisting of 2 X SSC, 0.1% v/v SDS and 0.2 X SSC, 0.1% v/v SDS (Southern et al. , 1975; Maniatis et al. , 1982; Szostak et al.. 1979).
Figure 5 shows the results of the hybridization analysis performed on the amplification reactions, containing various amounts of N2.GAG template, which were sampled at different times of incubation.
Each column of Figure 5 represents a different time point (1, 30 min; 2, 60 min; 3, 90 min; 4, 120 min; 5, 150 min; 6, 180 min) and each row represents a different amount of added N2.GAG template (1, lpg; 2, 100 fg; 3, 10 fg; 4, 1 fg; 5, 0.1 fg; 6, no template) . Amplification of nucleic acids which hybridized to the labeled probe were observed for rows 1-3 (1 pg - 10 fg) , however the hybridization to specific nucleic acids in rows 4 - 5 (1 fg, 0.1 fg) was not higher than row 6 (no template) . The apparent non-specific binding of labeled probe in row 6 seems to be related to DNA or RNA synthesis since the hybridization signal increases with increasing time.
SUBSTITUTE SHEET Example 6: Use of DNA restriction fragment as template.
The plasmid pGAG2.TEST was digested with Mspl and proteinase K, purified by phenol extraction and ethanol precipitation, and denatured by boiling for 5 min. Amplification reactions were performed and analyzed following the teaching of Example 4, except the Mspl digested pGAG2.TEST was used as a template instead of the N2.GAG oligonucleotide. The amounts of plasmid added to each reaction varied from 55 ng to 5.5 pg, and no template. To simulate additional DNA which would be present in an actual sample, alternate reactions contained 1 ng of calf thymus DNA which had been similarly digested, purified and denatured. After a 3 h incubation at 42 °C, the synthesis of RNA was determined by TCA precipitation and PAGE analysis. As indicated in Table 3, total RNA synthesis was higher than the no template controls for all template concentrations tested. The degree of amplification was calculated based on RNA synthesis from the actual template which was 1.8% of the total plasmid DNA.
The total RNA synthesis (degree of amplification) from a particular initial level template concentration
was consistenyly lower for the restriction fragment (Table 3) as compared to that for the synthetic oligonucleotide template (Table 2) . This could be due to competition with the complementary strand of the restriction fragment template under the conditions used.
Table 3: RNA amplification from Mspl-digested pGAG2.TEST
RNA ^^ Fold AA
Reaction Template Synthesized— amplification—
1 55.0 ng [1 ng] 3.65 3.7 x 103
2 (4.05) (4.1 x 103)
3 5.5 ng [100 pg] 3.54 3.5 x 104
4 (3.16) (3.2 X 104)
5 550.0 pg [10 pg] 2.29 2.3 X 105
6 (2.79) (2.8 X 105)
7 55.0 pg [1 pg] 2.62 2.6 X 106
8 (0.67) (0.7 X 106)
9 5.5 pg [100 fg] 1.37 1.4 X 10^
10 (2.26) (2.3 X 107)
11 - 1.25
12 (0.08)
* Numbers in brackets indicate equivalent amounts of N2.GAG. ** Numbers in parentheses indicate RNA synthesis in presence of μg Mapl-digested calf thymus DNA.
TE SHEET The RNA which was synthesized after a reaction time of 3 h was analyzed by PAGE (Figure 6, lanes 1-6, 11 and 12. numbered the same as the reactions) . The major band representing a RNA of about 100 b was present in reactions (lanes) 1-6 but absent in the no template reactions (lanes 11 and 12) . The RNA in lane 0 was a standard, which was prepared following the teaching of Example 3. There was no apparent qualitative difference in the synthesized RNA either with (lanes 2, 4 and 6) or without (lanes 1, 3, and 5) the additional of 1 μg of Mspl-degested calf thymus DNA.
Example 7: Indirect Amplification
MATERIALS AND METHODS
(a) Bacterial Strains and Plasmids
A pGEM.4-gag plasmid and an M13-Mpl8-gag plasmid each containing a 1422 base pair Xbal-EcoRI restriction fragment from HIV 1 (strain BH10) were constructed from a Sacl-Bglll subclone obtained as a gift from Dr. P. Gill, President of the Canadian Red Cross Society. This restriction fragment contains the majority of the HIV1 gag gene (Ratner,
L.). E. coli strain HB101 was transformed with the pGEM4-gag plasmid and E. coli strain TGI was transformed with the M13-gag plasmid. Plasmid DNA was prepared by methods described in Maniatis et al. (Maniatis, I., Fritsch, E.F. and Sambrook, J.).
(b) Synthesis of RNA Template
To obtain gag-RNA template, the pGEM.gag plasmid was linearized with Xbal, extracted with phenol-chloroform and precipitated in ethanol. Purified DNA was transcribed using SP6 RNA polymerase (Promega) according to the method of Melton (Melton, D.A. et al.) . 5 units of RNase-free DNasel (Promega) was added and the mixture incubated at 37 °C for 30 minutes. The RNA product was extracted with phenol-chloroform and precipitated with ethanol. The yield of RNA was determined spectrophotometrically.
(c) Synthesis of Oligonucleotides and Preparation of End-Labelled Probe
Oligonucleotides were synthesized on an Applied Biosystems Model 380-A DNA synthesizer. DNA oligomers were purified by polyacrylamide gel electrophoresis
SUBSTITUTE HEE and DE 52 column chromatography. Synthesis yields were determined spectrophotometrically using a conversion factor of 40 μg/A260 unit.
The first primer was a 20-mer; the second primer was 45 bases in length (the T7 promoter sequence is underlined) and the probe was a 53-mer. These sequences were as follows:
FIRST PRIMER: 5' ACA TCA AGC CAT GCA AA 3'
SECOND PRIMER: 5' AAT TCT AAT ACG ACT CAC TAA AGG GAG
TAG TTC CTG CTA TGT CAC 3'
probe: 5' TGT TAA AAG AGA CCA TCA ATG AGC AAG CTG CAG AAT GGG ATA GAG TAC ATC CA 3'
The 53-base oligonucleotide probe was complimentary to the amplification product sequence and was labelled by Polynucleotide Kinase (BRL) in the presence of X-32P ATP (Amersham) .
,_„
51
Amplification Reactions
RNA targets induced the indirect amplification reaction in the milieu containing 50 mM Tris-HCl, pH 8.3. 6 mM MgCl2, 40 mM KC1, 10 mM DTT, 1 mM deoxyribonucleotides (Pharmacia) 0.5 mM ribonucleotides (Pharmacia) 40 units of AMV-reverse transcriptase (Seikagaku) . 0.4 units RNase H (Pharmacia), 20 units T7 RNA polymerase (Pharmacia) and 0.5 units per μl RNA-Guard™ (Pharmacia) . The concentration of each primer was 0.35 μM and the final reaction volume was 25 μl. Standard reactions were run at 42 °C for 3 hours and were terminated with the addition of EDTA to a final concentration of 5 mM.
DNA targets were amplification-induced as for RNA with the following modifications. Double-stranded DNA was mixed with buffer, nucleotides and primers, heated to 95 °C for 3 minutes, and then placed on ice. T7-DNA polymerase (Sequenase-1-11 from United States Biochemical) was added to a final concentration of 0.5 units per μl and incubated for 15 minutes at 37 °C. The mixture was heated to 95 °C for 3 minutes and then cooled, whereupon DTT, reverse transcriptase, RNase H, T7 RNA polymerase and RNA-Guard™ were added, and the reaction run at 42 °C for 3 hours.
Hybridization Analysis of Amplification Products
A 5 μl sample of each reaction was glyoxylated by the method recommended in Maniatis et al. (Maniatis, I., Fritsch, E.F. and Sambrook, J.), mixed with 200 μl of 6 X SSC and bound to a nylon membrane (Amersham) using a slot-blot apparatus (Bio-Rad ) . The nucleic acid was fixed to the membrane by an 8-minute treatment of the filter in 0.1 N NaOH. The filter was hybridized with 32 P-end-labelled oligonucleotide in 50% formamide, 3 X SSC and 5 X Denhardt's solution (Denhardt, D.T.) at 42 °C for 2 hours. Hybridized filters were washed for 10 minutes at room temperature in 2 X SSC and 0.5% SDS followed by 1 hour in 0.1% SSC, 0.5% SDS at 50 °C. Autoradiography was performed using Kodak XAR-5 film.
Sequence Analysis of Amplification Products
Amplification reactions were treated with 2 units of RNase-free DNasel for 30 minutes at 37 °C, followed by phenolchlorofor extraction and ethanol precipitation. Purified RNA was hybridized with a 32P end-labelled primer and sequenced using reverse transcriptase in the presence of dideoxynucleotides (Lane, D.J. , Pace, B. , Olsen, G.J. , Stahl, D.A. , Sogin, M.L. and Pace, N.R.).
RESULTS
The indirect amplification process is shown in Figure 7. With a natural RNA target (mRNA, nRNA, tRNA, etc.) the indirect amplification reaction proceeds with the annealing of the second primer which contains a T7-RNA polymerase promoter sequence at its 5' end (19,20). Reverse transcriptase present in the reaction mix generates a complementary DNA strand from the 3' end of the second primer. The RNA strand — the natural RNA target — of the RNA/DNA duplex is degraded by RNase H present in the mix. The first primer anneals to the resultant single strand of cDNA and second-stranded synthesis occurs, rendering the promoter sequence double-stranded. From this functional promoter, the T7-RNA polymerase present in the mix generates multiple copies of RNA, antisense to the original target, which serve as new templates for cDNA synthesis in the cyclic phase of the indirect amplification reaction. This cyclic phase is characterized by the primers annealing in the reverse order to the non-cyclic phase: that is, the first primer anneals first, initiating the reverse transcriptase and RNase H reactions, followed by the second primer priming double-stranded DNA synthesis, again creating a functionally active T7 promoter.
Figure 7 also illustrates where DNA intermediates occur in the indirect amplification process and therefore how DNA targets themselves can be the subject of exponential amplification via the indirect amplification reaction. Double-stranded target DNA is cut with a restriction enzyme and denatured to create molecules with defined ends, whereupon the second primer anneals and initiates cDNA synthesis, thus creating a functionally active T7 promoter which generates RNA competent to induce the cyclic portion of the indirect amplification process. If unrestricted double-stranded DNA is used as a target, then, as Figure 7 illustrates, both the first primer and the second primer are required to generate a functionally active T7 promoter. Nevertheless, the same indirect amplification process generates the amplified product, whether RNA or DNA is the target.
In order to demonstrate the feasibility of this indirect amplification system, both RNA and DNA templates were tested. The pGEM-gag plasmid served as the source of double-stranded DNA template. To obtain RNA template, the pGEM-gag plasmid was linearized using Xbal, which cuts at the end of the inserted DNA. The linearized plasmid was transcribed by SP6 RNA polymerase to yield an RNA product 1422 bases in
length. Primer sites were selected such that the amplified product from either the DNA or RNA target was 140 bases in length.
The kinetics of amplification was determined for various amounts of RNA template under standard reaction conditions (see Materials and Methods) . Table 4 shows that the indirect amplification reaction generates product from either RNA or DNA targets in an exponential fashion.
TABLE 4 PRODUCT GENERATED BY INDIRECT AMPLIFICATION
INITIAL RNA TEMPLATE+ RNA PRODUCT AMPLIFICATION MASS #MOL. MASS #MOL.
1.0 ng 1.2 X 10- 4.2 μg 5.0 X 10 13 4.2 X 10 1.0 pg 1.2 X 10( 2.75 μg 3.3 x 1013 2.75 X 10' 1.0 fg 1.2 X 10: 0.8 μg 9.6 X 1012 8.0 X 10
INITIAL DNA TEMPLATE+ RNA PRODUCT AMPLIFICATION MASS #MOL. MASS #MOL.
1.0 ng 1.2 X 10- 4.0 μg 4.7 X 10 13 4.0 X 10-
1.0 pg 1.2 X 10' 2.6 μg 3.1 x 10 13 2.6 X 10 1.0 fg 1.2 X 10: 0.72 μg 8.6 X 1012 7.2 X 10 8
+ RNA and DNA templates are 1422 bases in length. * Amplification product is 140 bases in length.
The specificity of the indirect amplification reaction was also examined. One nanogram and 1 picogram of RNA or DNA were targets in the indirect amplification reaction in the presence or absence of 1 μg of heterologous RNA or DNA under standard conditions. Following agarose gel electrophoresis, the reactionproducts were examined by ethidium bromide staining. Only a single amplification product of approximately 140 bases in length was obtained in any of these reactions, thus indicating that the primer sequences selected were specific for the correct segment of the gag gene. The presence of heterologous total RNA isolated from HL60 cells had no effect on the specificity of the indirect amplification reaction. Densitometer scans of the 140 base product indicated that a 1000-fold reduction in template lpg → Ifg) resulted in only a 50% reduction in product yield. The presence of HL60 RNA reduced the yield by approximately 5-fold. Similar experiments with gag-RNA amplified in the presence of 1 μg of calf thymus DNA showed less than a 2-fold reduction in product compared to gag-RNA alone. Similar quantitative results were obtained when the reaction products were analyzed by hybridization. Even with a five-fold decrease in product due to the
D __ /
HL60 RNA, the lfg sample was readily datactable by hybridization.
The sensitivity of the indirect amplification reaction was determined for both DNA and RNA targets. Stock solutions of each target were diluted serially in sterile water containing 20 μg/ml RNase-free E. coli tRNA. Aliquots of these dilutions were subjected to standard indirect amplification conditions for 3 hours at 42 °C. The 32P-end-labelled oligonucleotide probe was used to detect amplification products bound to nylon membranes. Both DNA and RNA targets were detectable starting with as few as 10 initial molecules.
The nucleotide sequence of the RNA product from standard indirect amplification reactions was examined. One picogram of either DNA or RNA target was subjected to indirect amplification conditions for 3 hours at 42 °C and the products were sequenced by extension from 32P-labelled P2 primer in the presence of didebxynucleotides. The products of the sequencing reactions were separated in an 8% acryla ide gel. Analysis of the sequence obtained indicated that not only was the product of correct length (140 bases) ,
J O
but also the sequence obtained was identical to the correct segment of the gag gene.
This indirect amplification process amplifies a small number of nucleic acid molecules greater than
108°, i•n an i•ndirect manner, in three hours in the presence of greater than a million-fold excess of heterologous nucleic acid.
The following are the features of this indirect nucleic acid amplification process:
First, the entire indirect amplification reaction is homogenous, that is, no additions are made to the reaction once it is begun;
Second, the indirect amplification reaction takes place at a single temperature;
Third, the principal product of the indirect amplification reaction is RNA complementary to the original target. This single-stranded product is readily detected without further manipulation;
Fourth, while the majority of the reaction product is RNA, there are formed during the indirect
O KQS
amplification reactions double-stranded DNA molecules which are essential to the process. Sufficient DNA is generated to allow cloning directly from the reaction;
Fifth, in the vectorial phase of the indirect amplification reaction, the second primer is used to initiate cDNA synthesis, whereas in the cyclic phase of the indirect amplification reaction, cDNA synthesis is initiated with the first primer (see Figure 7) ;
Sixth, the simple indirect amplification format is accomplished by the simultaneous enzymatic synthesis and degradation of RNA in such a way that transcriptionally functional DNA accumulates.
While the overall amplification of the indirect amplification process is difficult to quantify mathematically, it most likely involves a third-order polynomial expansion.
Although the indirect amplification reaction reported here was run for a standard three-hour period, this time could be reduced (to as little as 30 minutes) for diagnostic purposes. The time of reaction depends upon the estimated amount of target
S nucleic acid present, the detection system used, and the amount of detectable product which gives significant signal to background ratios.
Although preferred embodiments of the invention have been described in detail, it will be understood by those skilled in the art that variations may be made thereto without departing from either the spirit of the invention or the scope of the appended claims.
References
Axelrod, V.D. and Kramer, F.R. (1985) Biochemistry 24:5716-5723.
Hattori, M. , Hidaka, S., and Sakaki, Y. (1985) Nucleic Acids Res. 13:7813-7827.
Holmes, D.S. and Quigley, M. (1981) Anal. Biochem. 114:193-197.
Maniatis, T. , Fritsch, E.F., and Sambrook, J. (1982) Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
Miller, J.H. (1972) Experiments in Molecular Genetics, p. 433. cold Spring Harbor Laboratory, Cold Spring Harbor,
N.Y.
Sanger, F. , Nicklen, S., and Coulson, A.R. (1977) Proc. Natl. Acad. Sci. U.S.A. 74:5463-5467.
Shibahara, S., Mukai, S., Nishihara, T. , Inoue, H. , Ohtsuka, E. , and Morisawa, H. (1987) Nucleic Acid Res. 15:4403-4415.
Southern, E. (1975) J. Mol. Biol. 98:503.
Stoflet, E.S., Koebarl, D.D., Sarkar, 6, and Sommer, 5.5. (1988) Science 239:491-494.
Szostak, J.W. , Stiles, J.I., Tye, B.-K., Chiu, P., Shemran, F., and Wu, R. (1979) Methods in Enzymology 68:419.
SUBSTITUTE SHEET References for Example 7
1. Mullis, K.B. and Faloona, F.A. (1987) Methods Enzymology 155. 335-350
2. Saiki, R.K., Galtaud, D.H. , Stoffel, S., Scharf, S.J., Higuchi, R. , Horn, G.T., Mullis, K.B. and Erlich, H.A. (1988) Science 239. 487-491
3. Saiki, R.K., Scharf, S., Faloona, F. , Mullis, K.B., Horn, G.T. , Erlich, H.A. and Arnheim, N. (1985) Science 230, 1350-1354
4. Saiki, R.K., Bugawan, T.L., Horn, G.T. , Mullis, K.B. and Erlich, H.A. (1966) Nature 324. 163-166
5. Bugawan, T.L., Saiki, R.K. , Levenson, CH. , Watson, R.M. and Erlich, H.A. (1988) Biotechnology 6., 943-947
6. Ou, C.Y., Kwok, S., Mitchell, S.W., Mack, D.H., Sninsky, J.J. , Krebs, J.W. , Feorino, P., Warfield, D. and Schochetman, G. (1988) Science 239, 295-297
7. Shibata, D.K., Arnheim, N. and Martin, W.J. (1988) J. Exp. Med. 16) , 225-230
8. Murakawa, G.J. , Zaia, J.A. , Spallone, P.A. , Stephens, D.A. , Kaplan, B.E. , Wallace, R.B. and Rossi, J.J. (1988) DNA 2, 287-295
9. Harbarth, P. and Vosberg, H.P. (1988) DNA 1_, 297-306
10. Kawaski, E.S., Clark, S.S., Coyne, M.Y., Smith, S.D., Champlin, R. , Witte, O.N. and McCormick, F.P. (1988) Proc. Nat'l. Acad. Sc. U.S.A. 85, 5698-5702
11. Chu, B.C.F., Kramer, F.R. and Orgel, L.E. (1986) Nucleic Acids Res. 14., 5591-5603
12. Lizardi, R.M. , Guerra, C.E. , Lomeli, H. , Tussie-Luna, I. and Kramer, F.R. (1988) Biotechnology 6., 1197-1202
13. Biebricher, C.K. (1987) Cold Spring Harbor Symp. Quant. Biol. 52., 299-306
14. Ratner, L. et al. (1985) Nature 31^. 277-284
15. Maniatis, I., Fritsch, E.F. and Sambrook, J. (1982) Molecular Cloning - A Laboratory Manual. (Cold Spring Harbor) . p. 86 16. Melton, D.A. et al. (1984) Nucleic Acids Res. JL2, 7035-7056
17. Denhardt, D.T. (1966) Biochem. Bophy. Res. Commun. 23, 641-646
18. Lane, D. . , Pace, B., Olsen, G.J., Stahl, D.A. , Sogin, M.L. and Pace, N.R. (1985) Proc. Nat;l. Acad. Sc. U.S.A. 82, 6955-6959
19. Rosa, M.D. (1979) Cell 16, 815-825
20. Dunn, J.J. and Studier, F.W. (1983) J. Mol. Biol. 16, 47-535
21. Abbott, M.A. et al. (1988), J. Inf. Diseases 158 1158
22. Klenow, H. and I. Hemingsen (1970) PNAS 65 168
SUBSTITUTE SHEET

Claims

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for amplifying a specific nucleic acid sequence comprising:
synthesizing single-stranded RNA, single-stranded DNA and double stranded DNA in which the single stranded RNA is a first template for a first primer, the single stranded DNA is a second template for a second primer, the double stranded DNA is a third template for synthesis of a plurality of copies of the first template, where a sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence, a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence, and a 3' end of the first primer is oriented towards a 3' end of the second primer on complementary strands.
2. A process as set forth in claim 1 in which the first primer selectively hybridizes to the first template and promotes the synthesis of DNA covalently attached to the first primer and complementary to the first
SUBSTITUTE SHEE 6 ,5_.
template; and the second primer; having a sequence for a promoter and a sequence for a transcription initiation site for a RNA polymerase, selectively hybridizes to the second template thereby permitting the synthesis of DNA covalently attached to the second primer and complementary to the second template.
3. A process for amplifying a specific nucleic acid sequence comprising:
(a) hybridizing a first primer of DNA to a first template, the first primer having a sequence sufficiently complementary to a RNA sequence of the first template;
(b) synthesizing a first DNA sequence covalently attached to the first primer and complementary to the RNA sequence of the first template, wherein the first DNA sequence and the first primer comprise a second template;
(c) separating the first template from the second template to allow hybridization of a second primer;
(d) hybridizing the second primer of DNA to the second template, the second primer having a sequence sufficiently complementary to a DNA sequence of the second template, the second primer having a sequence of a promoter and a sequence of a transcription initiation site for a RNA polymerase;
(e) synthesizing a second DNA sequence covalently attached to the second primer and complementary
SUBSTITUTE SHEET 4 o ,b, PCI7EP89/00981
to the DNA sequence of the second template and synthesizing a third DNA sequence covalently attached to the second template and complementary to the DNA sequence of the second primer wherein the second and third DNA sequences, the second primer and the second template comprise a third template;
(f) synthesizing a plurality of copies of the RNA sequence of the first template from the third template;
where a sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence, a sequence of the
SUBSTITUTE SHEET first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence, and a 3 ' end of the first primer is oriented towards a 3 end of the second primer on complementary strands.
4. A process as set forth in claim 3 in which the second primer has a sequence at its 3 ' end sufficiently complementary to the DNA sequence of the second template and has at its 5' end a DNA sequence of a promoter and a sequence of a transcription initiation site for a RNA polymerase.
5. A process as set forth in claim 4 in which the third DNA sequence covalently attached to the second template is complementary to the DNA sequence at the 5' end of the second primer.
6. A process as set forth in claim 3 in which the first DNA sequence is synthesized by a RNA directed DNA polymerase.
7. A process as set forth in claim 3 in which the first template is separated from the second template by a ribonuclease specific for hybrids of RNA-DNA.
SUBSTITUTE SHEET
8. A process as set forth in claim 7 in which the ribonuclease is E. coli ribonuclease H.
9. A process as set forth in claim 7 in which the ribonuclease is calf thymus ribonuclease H.
10. A process as set forth in claim 3 in which the second and third DNA sequences are synthesized by a DNA directed DNA polymerase.
11. A process as set forth in claim 3 which the first template is synthesized from the third template by a DNA directed RNA polymerase.
12. A process as set forth in claim 3 in which the first primer has a sequence of a promoter and a sequence of a transcription initiation site.
13. A process as set forth in claim 3 in which the first primer has a sequence which hybridizes to a support means.
14. A process as set forth in claim 3 in which the second primer has from its 3' to its 5' end, a sufficiently complementary sequence, a sequence of a transcription initiation site, and a sequence of a promoter.
SUBSTITUTE SHEET
15. A process as set forth in claim 14 in which the sequence of the transcription initiation site and the promoter sequence bind a bacteriophage RNA polymerase.
16. A process as set forth in claim 14 in which the sequence of the transcription initiation site and the promoter sequence bind T7 RNA polymerase.
17. A process as set forth in claim 14 in which the sequence of the transcription initiation site and the sequence of the promoter is AATTCTAATACGACTCACTATAGGGAG.
18. A process as set forth in claim 11 in which the DNA directed RNA polymerase is T7 RNA polymerase.
19. A process as set forth in claim 11 in which the DNA directed RNA polymerase is a bacteriophage RNA polymerase.
20. A process as set forth in claim 11 in which the DNA directed RNA polymerase is a phage T3 polymerase.
21. A process as set forth in claim 11 in which the DNA directed RNA polymerase is phage φll polymerase.
UTE SHEET
22. A process as set forth in claim 11 in which the DNA directed RNA polymerase is salmonella phage sp6 polymerase.
23. A process as set forth in claim 11 in which the DNA directed RNA polymerase is Pseudomonas phage gh-1 polymerase.
24. A process as set forth in claim 6 in which the RNA directed DNA polymerase is a retroviral polymerase.
25. A process as set forth in claim 24 in which the retroviral polymerase is an avian myoblastosis viral polymerase.
26. A process as set forth in claim 24 in which the retroviral polymerase is a Maloney murine leukemia viral polymerase.
27. A process as set forth in claim 6, 10 or 11 in which the polymerase lacks exonuclease or endonuclease activity.
28. A process as set forth in claim 10 in which the DNA directed DNA polymerase is an avian myoblastosis viral polymerase.
SUBSTITUTE SHEET
29. A process for amplifying a specific nucleic acid sequence comprising:
combining a first primer, a second primer, ribonuclease H, RNA-directed DNA polymerase, DNA directed DNA polymerase, RNA polymerase, ribonucleoside triphosphates and deoxyribonucleoside triphosphates with a sample, where the first primer of DNA has a sequence sufficiently complementary to a first template of RNA; the second primer of DNA has a sequence sufficiently complementary to a second template of DNA, a sequence of a promoter, a sequence of a transcription initiation site which are recognized as substrate by the RNA polymerase;
where a sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence, a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence, and a 3 * end of the first primer is oriented towards a 3 ' end of the second primer on complementary strands.
SUBSTITUTE SHEET
30. A process for amplifying a specific nucleic acid sequence comprising:
combining a first primer, a second primer, avian myoblastosis viral polymerase, E. coli ribonuclease H, bacteriophage T7 RNA polymerase, ribonucleoside triphosphates and deoxyribonucleoside triphosphates with a sample, where the first primer has a sequence sufficiently complementary to a first template of RNA; the second primer has a sequence sufficiently complementary to a second template of DNA, a sequence of a promoter and a sequence of a transcription initiation site which are recognized as substrate by T7 RNA polymerase;
where a sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence, a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence, and a 3' end of the first primer is oriented towards a 3' end of the second primer on complementary strands.
SUBSTITUTE SHEET
31. A process as set forth in claim 1 or 3 further comprising detecting the presence of the specific nucleic acid sequence by a comparison between an amount of amplification of a first sample suspected to contain the nucleic acid sequence and an amount of amplification of a second sample in which the nucleic acid sequence is not present.
32. A process as set forth in claims 29 or 30 further comprising detecting the presence of the specific nucleic acid sequence by a comparison between an amount of amplification of a first sample suspected to contain the nucleic acid sequence and an amount of amplification of a second sample in which the nucleic acid sequence is not present.
33. A process as set forth in claims 1 or 3 further comprising detecting the presence of the specific nucleic acid sequence with a probe which hybridizes to the specific nucleic acid sequence or a product of the specific nucleic acid sequence.
34. A process as set forth in claims 1 or 3 further comprising detecting the presence of the specific nucleic acid sequence using restriction endonucleases and electrophoretic separation.
SUBSTITUTE SHEET
35. A process as set forth in claims 31 or 32 further comprising detecting the presence of the specific nucleic acid sequence using restriction endonucleases and electrophoretic separation.
36. A process as set forth in claims 31 or 32 further comprising detecting the presence of the specific nucleic acid sequence with a probe which hybridizes to the specific nucleic acid sequence or a product of the specific nucleic acid sequence.
37. The specific nucleic acid sequence amplified by the process set forth in claim 1.
38. The specific nucleic acid sequence amplified by the process set forth in claim 3.
39. The specific nucleic acid sequence amplified by the process set forth in claim 29.
40. The specific nucleic acid sequence amplified by the process set forth in claim 30.
41. A kit for amplifying a specific nucleic acid sequence comprising:
SUBSTITUTE SHEET -_
(a) first primer having a DNA sequence sufficiently complementary to a RNA sequence of a first template;
(b) second primer having a DNA sequence complementary to a DNA sequence of a second template;
(c) ribonuclease H;
(d) RNA-directed DNA polymerase;
(e) DNA-directed RNA polymerase;
(f) DNA directed DNA polymerase;
(g) ribonucleoside triphosphates; and
(h) deoxyribonucleoside triphosphates;
where a sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence, a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence, and a 3 ' end of the first primer is oriented towards
SUBSTITUTE SHEET a 3 * end of the second primer on complementary strands.
42. A kit for amplifying a specific nucleic acid sequence comprising:
(a) first primer having a DNA sequence sufficiently complementary to a RNA sequence of a first template;
(b) second primer having a DNA sequence sufficiently complementary to a DNA sequence of a second template;
(c) bacteriophage T7 RNA polymerase;
(d) E. coli ribonuclease H;
(e) avian myoblastosis viral polymerase;
(f) ribonucleoside triphosphates; and
(g) deoxyribonucleoside triphosphates;
where a sequence of the first or the second primer is sufficiently complementary to a sequence of the
specific nucleic acid sequence, a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence, and a 3 * end of the first primer is oriented towards a 3 ' end of the second primer on complementary strands.
43. A process for amplifying nucleic acid sequences, without serial addition of reagents or temperature recycling, comprising the steps of
(A) providing a single reaction medium containing a first oligonucleotide primer and a second oligonucleotide primer, at least one of which primers contains a sequence that is sequence of a functional promoter; an RNA-directed DNA polymerase; a DNA-directed DNA polymerase; a DNA-directed RNA polymerase; a ribonuclease that releases DNA of a RNA/DNA hybrid without attacking single- or double-stranded RNA or DNA; and ribonucleoside and deoxyribonucleoside triphosphates,
(B) adding to said reaction medium one or more of the following:
SUBSTITUTE SHEET V o
(i) an RNA molecule;
(ii) a single-stranded DNA molecule comprising
(a) a 3 '-end sequence that hybridizes to a region at the 3 ' end of said first oligonucleotide primer; or
(b) a 5'-end sequence that is a sequence of a functional promoter; or
(c) a 3 '-end sequence that hybridizes to a region at the 3 ' end of said second oligonucleotide primer,
(iii) a double-stranded DNA molecule comprising:
(i) at least one single stranded DNA described in B(ii) ; or
(ii) an amplifiable region and a functional promoter, the functional promoter being adjacent to said region and being oriented to control transcription of said region,
SHEET (C) at a relatively constant temperature, establishing conditions such that a cycle of events is initiated in said reaction medium, said cycle comprising at least one of the following sets of events:
FIRST SET OF EVENTS
(i) said first oligonucleotide primer hybridizes to a region at the 3' end of an RNA molecule, and an RNA/DNA hybrid is formed by action of said RNA-directed DNA polymerase, said RNA/DNA hybrid comprising a first DNA segment, said first DNA segment being covalently attached to said first oligonucleotide primer and being complementary to at least a part of said RNA molecule;
(ii) said ribonuclease acts on said RNA/DNA hybrid to digest at least some of said RNA molecule, releasing said first DNA segment from said RNA/DNA hybrid, and said first DNA segment hybridizes with said second oligonucleotide primer to form a duplex that is acted upon by said DNA-directed DNA polymerase to produce (a) a second DNA segment which is covalently
SUBSTITUTE SHEET attached to said second oligonucleotide primer and which is complementary to at least a part of said first DNA segment and (b) a third DNA segment which is covalently attached to said first DNA segment and which is complementary to at least a part of said second primer; and
(iii) said RNA polymerase produces a plurality of RNA molecules that correspond to the RNA molecule of (C) (i) ; and
SECOND SET OF EVENTS
(i') said second oligonucleotide primer hybridizes to a region at the 3' end of an RNA molecule, and an RNA/DNA hybrid is formed by action of said RNA-directed DNA polymerase, said RNA/DNA hybrid comprising a second DNA segment, said second DNA segment being covalently attached to said second oligonucleotide primer, and complementary to at least part of said RNA molecule;
SUBSTITUTE SHEET (ii1) said ribonuclease acts on said RNA/DNA hybrid to digest at least some of said RNA molecule, releasing said second DNA segment from said RNA/DNA hybrid, and said second DNA segment hybridizes with said first oligonucleotide primer, forming a duplex that is acted upon by said DNA-directed DNA polymerase to produce a first DNA segment which is covalently attached to said first oligonucleotide primer and which is complementary to at least a part of said second DNA segment; and
(iii1) said RNA polymerase produces a plurality of RNA molecules that correspond to a molecule complementary to the RNA molecule of C(i')
and then
(D) maintaining said conditions until a predetermined concentration of at least one from the grou[ consisting of; said RNA molecules of (C) (iii) or (C)(iii'), said first DNA segment, said second DNA segment, and said double-stranded DNA is detectable.
SUBSTITUTE SHEET
44. A process according to Claim 43, wherein step (B) comprises adding an RNA molecule antisense to the RNA molecule of (C) (i) .
45. A process according to Claim 43, wherein step (B) comprises adding an RNA molecule antisense to the RNA molecule of (C)(i').
46. A process according to Claim 43, wherein step (B) comprises adding an RNA molecule to said reaction medium.
47. A process according to Claim 43, wherein step (B) comprises adding a single-stranded DNA molecule to said reaction medium.
48. A process according to Claim 43, wherein step (B) comprises adding a double-stranded DNA molecule to said reaction medium.
49. A process according to Claim 43, wherein step (C) comprises said first set of events.
50. A process according to Claim 43, wherein step (C) comprises said second set of events.
SUBSTITUTE SHEET
51. A process according to Claim 43, wherein step (D) comprises monitoring the concentration of RNA molecules of (C) (iii) .
52. A process according to Claim 43, wherein step (D) comprises monitoring the concentration of RNA molecules of (C)(iii*).
53. A process according to Claim 43, wherein step (D) comprises monitoring the concentration of first DNA segments.
54. A process according to Claim 43, wherein step (D) comprises monitoring the concentration of second DNA segments.
55. A process according to Claim 43, wherein step (D) comprises monitoring the concentration of double-stranded DNA.
56. A process according to Claim 43, wherein step (D) comprises maintaining said conditions for a period of time between 30 minutes and 4 hours.
57. A process according to Claim 43, wherein an RNA polymerase recognizes said sequence of a transcription initiation site and said
S T TE SHEET sequence of a functional promoter such that transcription is initiated.
58. A process according to Claim 43, wherein said DNA-directed DNA polymerase is DNA polymerase or S.
59. A process according to Claim 43, wherein said DNA-directed DNA polymerase is calf thymus DNA polymerase.
60. A process according to Claim 43, wherein said DNA-directed DNA polymerase is a DNA polymerase lacking exonuclease activity.
61. An RNA molecule or DNA molecule comprising a nucleic acid sequence amplified by the process according to Claim 43.
62. A process according to Claim 43, further comprising the steps of ligating said amplified nucleic acid sequence into a cloning vector and then cloning said nucleic acid sequence or expressing the product encoded by said nucleic acid sequence in an expression system.
SUBSTITUTESHEET
63. A kit for amplifying nucleic acid molecules, comprising an assemblage of
(a) a receptacle containing a solution of a first oligonucleotide primer,
(b) a receptacle containing a solution of a second oligonucleotide primer,
(c) a receptacle containing a solution of a ribonuclease that hydrolyses RNA of an RNA/DNA hybrid without attacking single- or double-stranded RNA or DNA,
(d) a receptacle containing a solution of an RNA-directed DNA polymerase,
(e) a receptacle containing a solution of a DNA-directed RNA polymerase,
(f) a receptacle containing a solution of a DNA-directed DNA polymerase,
(g) a receptacle containing a solution of ribonucleoside triphosphates and,
(h) a receptacle containing a solution of deoxyribonucleoside triphosphates.
SUBSTITUTE SHEET.
64. A process for amplifying nucleic acid sequences, at a relatively constant temperature comprising:
(A) providing a single reaction medium containing a first oligonucleotide primer and a second oligonucleotide primer, which second primer comprises a sequence that is a single stranded sequence of a functional promoter; an RNA-directed DNA polymerase; a DNA-directed DNA polymerase; a DNA-directed RNA polymerase; a ribonuclease that releases DNA of a RNA/DNA hybrid without attacking ribonucleoside and deoxyribonucleoside triphosphates,
(B) adding to said reaction medium
(i) an RNA molecule; or
(ii) a single-stranded DNA molecule comprising
a) a 3 • end sequence that hybridizes to a region at the 3 *-end of said first oligonucleotide primer; or
b) a 5'-end sequence that is a single-stranded sequence of a functional promoter; or
c) a 3 '-end sequence that hybridizes to a region at the 3 '-end of said second oligonucleotide primer; or
SUBSTITUTE SHEET (iii) a double-stranded DNA molecule comprising: an amplifiable region and a functional promoter, the functional promoter being adjacent to said region and being oriented to control transcription of said region,
(C) establishing conditions such that a number of events is initiated in said reaction medium comprising at least the following steps:
(i) said first oligonucleotide primer hybridizes to a region at the 3'-end of an RNA molecule, and an RNA/DNA hybrid is formed by action of said RNA-directed DNA polymerase, said RNA/DNA hybrid comprising a first DNA segment, said first DNA segment being covalently attached to said first oligonucleotide primer and being complementary to at least a part of said RNA molecule;
(ii) said ribonuclease acts on said RNA/DNA hybrid to digest at least some of said RNA molecule, releasing said first DNA segment from said RNA/DNA hybrid, and said first DNA segment hybridizes with said second oligonucleotide primer at the 3'-end of said first DNA segment to form a duplex that is acted upon by said DNA-directed DNA polymerase to produce (a) a second DNA segment which is covalently attached to said second oligonucleotide primer and which is complementary to at least a part of said first DNA segment; and (b) a third DNA segment which is covalently attached to said first DNA segment and which is complementary to at least a part of said second primer, and
(iii) said RNA polymerase produces a plurality of RNA molecules homologous to the RNA molecule of C(i) .
EE
PCT/EP1989/000981 1988-02-24 1989-08-19 Nucleic acid amplification process WO1991002814A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1019910700397A KR920702866A (en) 1988-02-24 1989-08-19 Nucleic Acid Amplification Method
JP50909789A JPH04501057A (en) 1989-08-19 1989-08-19 Nucleic acid amplification method
DK068591A DK68591A (en) 1989-08-19 1991-04-16 PROCEDURE FOR NUCLEIC ACID AMPLIFICATION
FI911877A FI911877A0 (en) 1989-08-19 1991-04-18 FOERFARANDE FOER AMPLIFIKERING AV NUKLEINSYROR.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA000559709A CA1340807C (en) 1988-02-24 1988-02-24 Nucleic acid amplification process

Publications (1)

Publication Number Publication Date
WO1991002814A1 true WO1991002814A1 (en) 1991-03-07

Family

ID=4137506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1989/000981 WO1991002814A1 (en) 1988-02-24 1989-08-19 Nucleic acid amplification process

Country Status (8)

Country Link
US (1) US5409818A (en)
EP (1) EP0329822B1 (en)
KR (2) KR960015744B1 (en)
AT (1) ATE106948T1 (en)
CA (1) CA1340807C (en)
DE (1) DE3850093T2 (en)
ES (1) ES2053648T3 (en)
WO (1) WO1991002814A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002818A1 (en) * 1989-08-23 1991-03-07 Cangene Corporation Enhanced nucleic acid amplification process
WO1996002668A1 (en) * 1994-07-15 1996-02-01 Azco Nobel N.V. Use of rna polymerase to improve nucleic acid amplification process
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
EP1485501A2 (en) * 2002-02-22 2004-12-15 Ortho-McNeil Pharmaceutical, Inc. Method for generating amplified rna
WO2007016275A2 (en) 2005-08-02 2007-02-08 Focus Diagnostics, Inc. Methods and compositions for detecting bk virus
WO2011139721A1 (en) 2010-04-27 2011-11-10 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
EP2442109A1 (en) 2006-07-14 2012-04-18 The Regents of the University of California Cancer biomarkers and methods of use thereof
US11543411B2 (en) 2014-12-05 2023-01-03 Prelude Corporation DCIS recurrence and invasive breast cancer
US11821900B2 (en) 2018-09-14 2023-11-21 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer

Families Citing this family (704)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5418149A (en) * 1990-07-24 1995-05-23 Hoffmann-La Roche Inc. Reduction of non-specific amplification glycosylase using DUTP and DNA uracil
CA1340807C (en) * 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
JP2650159B2 (en) * 1988-02-24 1997-09-03 アクゾ・ノベル・エヌ・ベー Nucleic acid amplification method
ATE169341T1 (en) * 1988-12-09 1998-08-15 Amrad Corp Ltd AMPLIFIED DNA ASSAY
CA2005589C (en) * 1988-12-16 2001-02-06 Thomas Raymond Gingeras Self-sustained, sequence replication system
IE66597B1 (en) * 1989-05-10 1996-01-24 Akzo Nv Method for the synthesis of ribonucleic acid (RNA)
US6589734B1 (en) 1989-07-11 2003-07-08 Gen-Probe Incorporated Detection of HIV
AU650622B2 (en) * 1989-07-11 1994-06-30 Gen-Probe Incorporated Nucleic acid sequence amplification methods utilizing a transcription complex
CA2020958C (en) * 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5766849A (en) * 1989-07-11 1998-06-16 Gen-Probe Incorporated Methods of amplifying nucleic acids using promoter-containing primer sequence
WO1991004340A1 (en) * 1989-09-20 1991-04-04 Cambridge Biotech Corporation In vitro, isothermal nucleic acid amplification
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US7049102B1 (en) 1989-09-22 2006-05-23 Board Of Trustees Of Leland Stanford University Multi-gene expression profile
IE65771B1 (en) * 1990-01-25 1995-11-15 Zeneca Ltd Amplification of nucleotide sequences using vectorette units
US6013431A (en) 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
WO1991013994A1 (en) * 1990-03-13 1991-09-19 Commonwealth Scientific And Industrial Research Organisation Gene expression
US7585512B1 (en) 1990-05-08 2009-09-08 Thomas Jefferson University Composition and method of using tumor cells
US5194370A (en) * 1990-05-16 1993-03-16 Life Technologies, Inc. Promoter ligation activated transcription amplification of nucleic acid sequences
DE69106998T2 (en) 1990-10-05 1995-05-24 Akzo Nobel Nv Antibodies against hepatitis virus non-A, non-B immunochemically reactive peptides.
NZ240079A (en) * 1990-10-09 1993-07-27 Boehringer Mannheim Gmbh Method for the detection of a nucleic acid or part thereof
RU2017821C1 (en) * 1990-10-10 1994-08-15 Анатолий Михайлович Онищенко Method of dna amplification and a device for its realization
IL100040A (en) * 1990-11-13 1995-12-31 Siska Diagnostics Inc Nucleic acid amplification by two enzyme self-sustained sequence replication
US5518900A (en) * 1993-01-15 1996-05-21 Molecular Tool, Inc. Method for generating single-stranded DNA molecules
WO1992018521A1 (en) * 1991-04-10 1992-10-29 Life Technologies, Inc. Method for amplifying and altering an rna sequence
WO1992020820A1 (en) * 1991-05-15 1992-11-26 Vanderbilt University Method to determine metastatic potential of tumor cells
EP0517361A1 (en) * 1991-05-30 1992-12-09 Amoco Corporation A method for detecting and identifying pathogenic organisms using target sequences as detectors
US5169766A (en) * 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5137814A (en) * 1991-06-14 1992-08-11 Life Technologies, Inc. Use of exo-sample nucleotides in gene cloning
US5229283A (en) * 1991-06-14 1993-07-20 Life Technologies, Inc. Use of exo-sample nucleotides in gene cloning
ATE257860T1 (en) * 1991-08-02 2004-01-15 Biomerieux Bv QUANTIFICATION OF NUCLEIC ACIDS
DE4129653A1 (en) * 1991-09-06 1993-03-11 Boehringer Mannheim Gmbh PROCESS FOR DETECTION OF SIMILAR NUCLEIC ACIDS
DE69214243T2 (en) * 1991-09-23 1997-02-06 Pfizer Methods for the detection of specific mRNA and DNA in cells
DE4132133A1 (en) * 1991-09-26 1993-04-01 Boehringer Mannheim Gmbh METHOD FOR THE SPECIFIC PRODUCTION OF RIBONUCLEIC ACIDS
DE4213029A1 (en) * 1991-09-26 1993-04-01 Boehringer Mannheim Gmbh METHOD FOR THE SPECIFIC REPRODUCTION OF NUCLEIN'S SEQUENCES
US5981179A (en) * 1991-11-14 1999-11-09 Digene Diagnostics, Inc. Continuous amplification reaction
WO1993014217A1 (en) 1992-01-10 1993-07-22 Life Technologies, Inc. Use of predetermined nucleotides having altered base pairing characteristics in the amplification of nucleic acid molecules
EP0675965A4 (en) * 1992-01-29 1999-01-20 Hitachi Chemical Co Ltd Polynucleotide immobilized support.
US6100099A (en) * 1994-09-06 2000-08-08 Abbott Laboratories Test strip having a diagonal array of capture spots
IT1262937B (en) * 1992-04-13 1996-07-22 Enichem Spa IN VITRO GENE SELECTION BY RNA CARRIERS
CA2135073C (en) * 1992-05-06 2002-11-19 Daniel L. Kacian Nucleic acid sequence amplification method, composition and kit
ATE189003T1 (en) * 1992-05-11 2000-02-15 Joerg Schuepbach METHOD FOR DETECTING REVERSER TRANSCRIPTASE
US5843640A (en) * 1992-06-19 1998-12-01 Northwestern University Method of simultaneously detecting amplified nucleic acid sequences and cellular antigens in cells
US5580971A (en) * 1992-07-28 1996-12-03 Hitachi Chemical Company, Ltd. Fungal detection system based on rRNA probes
WO1994002636A1 (en) * 1992-07-28 1994-02-03 Hitachi Chemical Company Ltd. Gene detection system
US6261808B1 (en) 1992-08-04 2001-07-17 Replicon, Inc. Amplification of nucleic acid molecules via circular replicons
WO1994003624A1 (en) * 1992-08-04 1994-02-17 Auerbach Jeffrey I Methods for the isothermal amplification of nucleic acid molecules
US5733733A (en) * 1992-08-04 1998-03-31 Replicon, Inc. Methods for the isothermal amplification of nucleic acid molecules
US5834202A (en) * 1992-08-04 1998-11-10 Replicon, Inc. Methods for the isothermal amplification of nucleic acid molecules
US5614389A (en) * 1992-08-04 1997-03-25 Replicon, Inc. Methods for the isothermal amplification of nucleic acid molecules
ZA936015B (en) * 1992-08-24 1994-03-10 Akzo Nv Elimination of false negatives in nuleic acid detection.
ZA936016B (en) * 1992-08-24 1994-03-10 Akzo Nv Method for nucleic acid amplification
DE4236708A1 (en) * 1992-10-30 1994-05-05 Bayer Ag Specific gene probes and methods for the diagnosis of Candida albicans
DE4302459A1 (en) * 1993-01-29 1994-08-04 Bayer Ag Nucleotides containing sulfocoumarin and their use in detection methods for nucleic acids
ES2056028B1 (en) * 1993-02-18 1995-04-01 Inia PROCEDURE FOR THE SELECTION OF OLIGONUCLEOTIDES FOR THE SPECIFIC AMPLIFICATION OF HIGHLY VARIABLE GENOMES.
DE4344742A1 (en) * 1993-06-09 1994-12-15 Boehringer Mannheim Gmbh Method for the immobilization of nucleic acids
WO1995003430A1 (en) * 1993-07-23 1995-02-02 Gen-Probe Incorporated Methods for enhancing nucleic acid amplification
FR2708288B1 (en) 1993-07-26 1995-09-01 Bio Merieux Method for amplification of nucleic acids by transcription using displacement, reagents and necessary for the implementation of this method.
GB2284209A (en) * 1993-11-25 1995-05-31 Ole Buchardt Nucleic acid analogue-induced transcription of RNA from a double-stranded DNA template
EP1251182A3 (en) 1993-12-01 2002-11-27 Toyo Boseki Kabushiki Kaisha Method of amplifying and detecting target nucleic acid sequence by using thermostable enzymes
CA2185239C (en) * 1994-03-16 2002-12-17 Nanibhushan Dattagupta Isothermal strand displacement nucleic acid amplification
AU2215995A (en) * 1994-04-07 1995-10-30 Akzo Nobel N.V. Freeze-dried compositions comprising rna
US5863724A (en) * 1994-04-13 1999-01-26 Baylor College Of Medicine Methods of screening for persistent hyperinsulinemic hypoglycemia of infancy
WO2000033244A2 (en) * 1998-11-27 2000-06-08 Synaptics (Uk) Limited Position sensor
DE4421901A1 (en) * 1994-06-23 1996-01-04 Bayer Ag A rapid DNA test for the detection of quinolone-resistant Staphylococcus aureus pathogens in clinical specimens
US6010847A (en) * 1994-08-18 2000-01-04 Akzo Nobel N.V. Oligonucleotides that can be used in the amplification and detection of CMV nucleic acid
JPH09504182A (en) * 1994-08-18 1997-04-28 アクゾ・ノベル・エヌ・ベー Primer and probe for amplification and detection of CMV nucleic acid
US5656427A (en) * 1994-08-29 1997-08-12 Gen-Probe Incorporated Nucleic acid hybridization assay probes, helper probes and amplification oligonucleotides targeted to Mycoplasma pneumoniae nucleic acid
FR2724934B1 (en) * 1994-09-26 1997-01-24 Bio Merieux CHIMERIC OLIGONUCLEOTIDE AND ITS USE IN OBTAINING NUCLEIC ACID TRANSCRIPTS
EP0710724A2 (en) 1994-10-06 1996-05-08 Akzo Nobel N.V. Toxoplasma gondii antigens
FR2726277B1 (en) 1994-10-28 1996-12-27 Bio Merieux OLIGONUCLEOTIDE FOR USE AS PRIMER IN AN AMPLIFICATION METHOD BASED ON REPLICATION WITH MOVEMENT OF STRAND
US5606043A (en) * 1994-11-03 1997-02-25 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5849879A (en) * 1994-11-03 1998-12-15 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5789169A (en) * 1994-11-03 1998-08-04 Regents Of The University Of California Methods for the diagnosis of glaucoma
US5654141A (en) * 1994-11-18 1997-08-05 Thomas Jefferson University Amplification based detection of bacterial infection
US6001610A (en) * 1994-11-23 1999-12-14 Roche Diagnostics, Gmbh Method for the particularly sensitive detection of nucleic acids
DE4441626A1 (en) * 1994-11-23 1996-05-30 Boehringer Mannheim Gmbh Method for the particularly sensitive detection of nucleic acids
US5665545A (en) * 1994-11-28 1997-09-09 Akzo Nobel N.V. Terminal repeat amplification method
CA2206451C (en) * 1994-12-09 2002-11-26 Wakunaga Seiyaku Kabushiki Kaisha Method for suppressing nonspecific hybridization in primer extension method
CA2139070C (en) * 1994-12-23 2010-03-30 Burton W. Blais Method for enhancing detection ability of nucleic acid assays employing polymerase chain reaction
US5925518A (en) * 1995-05-19 1999-07-20 Akzo Nobel N.V. Nucleic acid primers for amplification of a mycobacteria RNA template
US5856096A (en) * 1995-09-20 1999-01-05 Ctrc Research Foundation Rapid and sensitive assays for detecting and distinguishing between processive and non-processive telomerase activities
US5747255A (en) * 1995-09-29 1998-05-05 Lynx Therapeutics, Inc. Polynucleotide detection by isothermal amplification using cleavable oligonucleotides
US5854033A (en) * 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
DE69612013T2 (en) 1995-11-21 2001-08-02 Univ Yale New Haven UNIMOLECULAR SEGMENT AMPLIFICATION AND DETERMINATION
US6048688A (en) * 1996-11-12 2000-04-11 Kimberly-Clark Corporation Method for detection of Pseudomonas aeruginosa using polymerase chain reaction
US20080160524A1 (en) * 1996-01-24 2008-07-03 Third Wave Technologies, Inc. Methods and Compositions for Detecting Target Sequences
US7195871B2 (en) * 1996-01-24 2007-03-27 Third Wave Technologies, Inc Methods and compositions for detecting target sequences
WO1997035026A1 (en) * 1996-03-18 1997-09-25 Molecular Biology Resources, Inc. Target nucleic acid sequence amplification
ES2347854T5 (en) * 1996-03-26 2014-07-24 Michael S. Kopreski Method that allows the use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate a cancer
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
JPH09289900A (en) * 1996-04-26 1997-11-11 Toyobo Co Ltd Amplifier of nucleic acid of cytomegalovirus (cmv) utilizing nucleic sequence (beta 2.7) and reagent kit for detection
US5712127A (en) 1996-04-29 1998-01-27 Genescape Inc. Subtractive amplification
US5770368A (en) * 1996-05-09 1998-06-23 Metropolitan Water District Of Southern California Cryptosporidium detection method
US6436638B1 (en) 1996-05-09 2002-08-20 Metropolitan Water District Of Southern California Cryptosporidium detection method
US5876992A (en) 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
US6117635A (en) * 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
JPH1028585A (en) * 1996-07-16 1998-02-03 Toyobo Co Ltd Amplification of nucleic acid using heat-stable ribonuclease h
US5866336A (en) * 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
CA2262019C (en) 1996-08-02 2011-11-15 Bio Merieux Target nucleic acid sequence amplification method
EP0942917B1 (en) 1996-08-14 2015-02-25 Life Technologies Corporation Method for nucleic acid amplification and sequencing using stable compositions
US6132954A (en) * 1996-08-20 2000-10-17 Baylor College Of Medicine Methods of screening for agents that delay a cell cycle and compositions comprising era and an analogue of wild-type era
EP1007730A4 (en) 1996-08-30 2004-04-28 Invitrogen Corp METHODS FOR IDENTIFICATION AND ISOLATION OF SPECIFIC NUCLEOTIDE SEQUENCES IN cDNA AND GENOMIC DNA
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
US6071493A (en) 1996-09-20 2000-06-06 Baylor College Of Medicine Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
US7381525B1 (en) * 1997-03-07 2008-06-03 Clinical Micro Sensors, Inc. AC/DC voltage apparatus for detection of nucleic acids
US6096273A (en) * 1996-11-05 2000-08-01 Clinical Micro Sensors Electrodes linked via conductive oligomers to nucleic acids
US6379929B1 (en) 1996-11-20 2002-04-30 The Regents Of The University Of Michigan Chip-based isothermal amplification devices and methods
US20040142327A1 (en) * 1996-11-22 2004-07-22 Jhy-Jhu Lin Methods for identifying and isolating DNA polymorphisms or genetic markers
DE69735445T2 (en) 1996-12-10 2006-08-10 Sequenom, Inc., San Diego NON-VOLATILE, NON-VOLATILE MOLECULES FOR MASS MARKING
US6025133A (en) * 1996-12-30 2000-02-15 Gen-Probe Incorporated Promoter-sequestered oligonucleoside and method of use
US5861295A (en) 1997-01-02 1999-01-19 Life Technologies, Inc. Nucleic acid-free thermostable enzymes and methods of production thereof
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
US6262242B1 (en) 1997-01-30 2001-07-17 Board Of Regents, The University Of Texas System Tumor suppressor designated TS10Q23.3
US6306588B1 (en) * 1997-02-07 2001-10-23 Invitrogen Corporation Polymerases for analyzing or typing polymorphic nucleic acid fragments and uses thereof
US6713300B1 (en) 1997-02-27 2004-03-30 University Of Utah Research Foundation Nucleic acid and amino acid sequences for ATP-binding cassette transporter and methods of screening for agents that modify ATP-binding cassette transporter
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
CA2287542A1 (en) 1997-04-22 1998-10-29 Life Technologies, Inc. Methods for the production of aslv reverse transcriptases composed of multiple subunits
CA2299275C (en) 1997-08-08 2009-07-07 Jaap Goudsmit Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of hiv-1
US6204024B1 (en) 1997-09-12 2001-03-20 Akzo Nobel N.V. CCR5 RNA transcription based amplification assay
JP4306957B2 (en) 1997-09-12 2009-08-05 ピーエイチアールアイ プロパティーズ,インコーポレイテッド Non-competitive co-amplification method
US6225097B1 (en) 1997-09-17 2001-05-01 Toyota Jidosha Kabushiki Kaisha Decaprenyl diphosphate synthetase gene
JP2001521765A (en) 1997-11-04 2001-11-13 ロシュ ダイアグノスティックス ゲーエムベーハー Specific and sensitive nucleic acid detection method
ZA989950B (en) * 1997-11-17 1999-05-04 Akzo Nobel Nv Transcription based amplification of double stranded DNA targets
CN100340666C (en) 1997-12-18 2007-10-03 孟山都技术有限公司 Insect-risistant transgenic plants and methods for improving 'delta' -endotoxin activity against target insects
US5968732A (en) * 1997-12-31 1999-10-19 Akzo Nobel, N.V. Isothermal transcription based assay for the detection and genotyping of dengue virus
US6093542A (en) * 1998-01-09 2000-07-25 Akzo Nobel N.V. Isothermal transcription based amplification assay for the detection and quantitation of macrophage derived chemokine RNA
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
US6121023A (en) 1998-01-22 2000-09-19 Akzo Nobel N.V. Isothermal transcription based assay for the detection and quantification of the chemokine rantes
US6686150B1 (en) 1998-01-27 2004-02-03 Clinical Micro Sensors, Inc. Amplification of nucleic acids with electronic detection
CA2319170A1 (en) 1998-01-27 1999-07-29 Clinical Micro Sensors, Inc. Amplification of nucleic acids with electronic detection
USH1825H (en) * 1998-01-30 1999-12-07 Akzo Nobel N.V. Isothermal transcription based assay for the detection of HTLV I and HTLV II RNA
US6365346B1 (en) * 1998-02-18 2002-04-02 Dade Behring Inc. Quantitative determination of nucleic acid amplification products
KR100718028B1 (en) * 1998-03-04 2007-05-16 악조 노벨 엔.브이. Oligonucleotides for the amplification and detection of epstein barr virus ebv nucleic acid
US6787305B1 (en) 1998-03-13 2004-09-07 Invitrogen Corporation Compositions and methods for enhanced synthesis of nucleic acid molecules
JP4196236B2 (en) 1998-03-17 2008-12-17 東洋紡績株式会社 Nucleic acid amplification reagent and sequence-specific nucleic acid amplification method
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20050244954A1 (en) * 1998-06-23 2005-11-03 Blackburn Gary F Binding acceleration techniques for the detection of analytes
JP4438110B2 (en) * 1998-07-01 2010-03-24 東ソー株式会社 Quantification method of target nucleic acid
US6316229B1 (en) 1998-07-20 2001-11-13 Yale University Single molecule analysis target-mediated ligation of bipartite primers
US7029861B1 (en) 1998-09-15 2006-04-18 Board Of Regents, The University Of Texas System LPS-response gene compositions and methods
EP1114184A2 (en) * 1998-09-15 2001-07-11 Yale University Molecular cloning using rolling circle amplification
JP2002525078A (en) 1998-09-15 2002-08-13 イェール ユニバーシティ Artificial long terminal repeat
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20090233276A1 (en) * 1998-09-22 2009-09-17 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
US6743906B1 (en) 1998-10-02 2004-06-01 Board Of Regents, The University Of Texas PPP2R1B is a tumor suppressor
US6153411A (en) * 1998-10-30 2000-11-28 American Water Works Company, Inc. Methods and kits for detection of Cryptosporidium parvum using immunomagnetic separation and amplification
EP1129064B1 (en) * 1998-11-12 2008-01-09 Invitrogen Corporation Transfection reagents
AU2150900A (en) 1998-11-16 2000-06-05 Board Of Regents, The University Of Texas System Hiv-specific t-cell induction
US6156515A (en) * 1999-02-09 2000-12-05 Urocor, Inc. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
US6187566B1 (en) 1999-03-09 2001-02-13 Applied Gene Technologies, Inc. Method of labeling a nucleic acid amplicon with simultaneous contamination prevention
JP5095888B2 (en) * 1999-03-18 2012-12-12 エクシコン エ/エス Detection of mutations within genes with specific LNA primers
US6630333B1 (en) 1999-03-23 2003-10-07 Invitrogen Corporation Substantially pure reverse transriptases and methods of production thereof
US6582906B1 (en) 1999-04-05 2003-06-24 Affymetrix, Inc. Proportional amplification of nucleic acids
US6235479B1 (en) 1999-04-13 2001-05-22 Bio Merieux, Inc. Methods and devices for performing analysis of a nucleic acid sample
DE19916929A1 (en) 1999-04-15 2000-10-19 Bayer Ag New oligonucleotide primers, useful for amplifying human telomerase RNA for diagnosis, prognosis and monitoring of cancer
EP1923472B1 (en) 1999-04-20 2012-04-11 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
US20030215821A1 (en) * 1999-04-20 2003-11-20 Kevin Gunderson Detection of nucleic acid reactions on bead arrays
US20060275782A1 (en) * 1999-04-20 2006-12-07 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
EP1183389A2 (en) 1999-04-30 2002-03-06 University of Florida Adeno-associated virus-delivered ribozyme compositions and methods of use
AU5008900A (en) * 1999-05-12 2000-11-21 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
WO2000071757A1 (en) * 1999-05-21 2000-11-30 Invitrogen Corporation Compositions and methods for labeling of nucleic acid molecules
US8481268B2 (en) 1999-05-21 2013-07-09 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
US8080380B2 (en) * 1999-05-21 2011-12-20 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
ATE490777T1 (en) 1999-06-01 2010-12-15 Baylor College Medicine COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE OF A SEQUENCE ASSOCIATED WITH THE GENE ATONAL
AU5882000A (en) 1999-06-22 2001-01-09 Invitrogen Corporation Improved primers and methods for the detection and discrimination of nucleic acids
US6830902B1 (en) 1999-07-02 2004-12-14 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
US6495320B1 (en) 1999-07-21 2002-12-17 Affymetrix, Inc. Even length proportional amplification of nucleic acids
EP1218541B1 (en) 1999-07-26 2008-12-10 Clinical Micro Sensors, Inc. Sequence determination of nucleic acids using electronic detection
US6379930B1 (en) 1999-07-30 2002-04-30 Applied Gene Technologies, Inc. Stabilization of nucleic acid amplification cocktails
US6242188B1 (en) 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
US6864050B2 (en) * 1999-07-30 2005-03-08 Affymetrix, Inc. Single-phase amplification of nucleic acids
US6692918B2 (en) 1999-09-13 2004-02-17 Nugen Technologies, Inc. Methods and compositions for linear isothermal amplification of polynucleotide sequences
US6958225B2 (en) 1999-10-27 2005-10-25 Affymetrix, Inc. Complexity management of genomic DNA
DK1250453T3 (en) 1999-12-10 2008-08-11 Invitrogen Corp Use of multiple recombination sites with unique specificity in recombination cloning
US6582938B1 (en) 2001-05-11 2003-06-24 Affymetrix, Inc. Amplification of nucleic acids
US6794138B1 (en) * 1999-12-16 2004-09-21 Affymetrix, Inc. Methods of small sample amplification
US7582420B2 (en) 2001-07-12 2009-09-01 Illumina, Inc. Multiplex nucleic acid reactions
US8076063B2 (en) * 2000-02-07 2011-12-13 Illumina, Inc. Multiplexed methylation detection methods
US7955794B2 (en) 2000-09-21 2011-06-07 Illumina, Inc. Multiplex nucleic acid reactions
US20050214825A1 (en) * 2000-02-07 2005-09-29 John Stuelpnagel Multiplex sample analysis on universal arrays
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001064959A1 (en) * 2000-03-02 2001-09-07 Akzo Nobel N.V. Detection of hepatitis b virus rna
JP4832694B2 (en) 2000-03-07 2011-12-07 アクゾ・ノベル・エヌ・ベー RNA polymerase variants with increased thermostability
ES2303525T3 (en) 2000-04-21 2008-08-16 Corixa Corporation COMPOUNDS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF INFECTION BY CHLAMYDIA.
US6291187B1 (en) 2000-05-12 2001-09-18 Molecular Staging, Inc. Poly-primed amplification of nucleic acid sequences
EP1158055A1 (en) 2000-05-26 2001-11-28 Xu Qi University of Teaxs Laboratoire de Leucémie Chen Method for diagnosing cancers
US7078208B2 (en) 2000-05-26 2006-07-18 Invitrogen Corporation Thermostable reverse transcriptases and uses thereof
CN1430670A (en) 2000-05-26 2003-07-16 茵维特罗根公司 Thermostable reverse transcriptases and uses thereof
US20060166227A1 (en) * 2000-06-20 2006-07-27 Stephen Kingsmore Protein expression profiling
US7846733B2 (en) * 2000-06-26 2010-12-07 Nugen Technologies, Inc. Methods and compositions for transcription-based nucleic acid amplification
WO2002000938A2 (en) * 2000-06-26 2002-01-03 Nugen Technologies, Inc. Methods and compositions for transcription-based nucleic acid amplification
US6323009B1 (en) * 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
AU7172201A (en) 2000-06-30 2002-01-14 Molecular Staging Inc Signal amplification with lollipop probes
AU2001273337B2 (en) 2000-07-10 2006-06-29 Board Of Regents, The University Of Texas System Chromosome 3p21.3 genes are tumor suppressors
JP2002142765A (en) * 2000-07-14 2002-05-21 Tosoh Corp New method for analyzing genom
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
JP4965793B2 (en) 2000-09-01 2012-07-04 ジェン−プローブ・インコーポレーテッド Amplification of HIV-1 sequences for detection of sequences associated with drug resistance mutations
US6858412B2 (en) * 2000-10-24 2005-02-22 The Board Of Trustees Of The Leland Stanford Junior University Direct multiplex characterization of genomic DNA
JP4472253B2 (en) * 2000-12-04 2010-06-02 プリマゲン ベー.フェー. Examination of internal symbiotic organelles and compounds identifiable thereby
DE60141533D1 (en) 2000-12-08 2010-04-22 Life Technologies Corp UKLEINE ACID MOLECULAR USING MULTIPLE DETECTION CENTERS
WO2002048402A2 (en) * 2000-12-13 2002-06-20 Nugen Technologies, Inc. Methods and compositions for generation of multiple copies of nucleic acid sequences and methods of detection thereof
US6794141B2 (en) 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
CN1491285A (en) * 2000-12-26 2004-04-21 �����﹤����ʽ���� Method of detecting pathogenic microorganism
US6893847B2 (en) * 2001-01-17 2005-05-17 Tosoh Corporation Oligonucleotide for detecting Salmonella and method of detecting Salmonella
CN1500144A (en) * 2001-02-06 2004-05-26 �����﹤����ʽ���� Amplified nucleic acids and immobilized products thereof
JP3681729B2 (en) * 2001-02-15 2005-08-10 タカラバイオ株式会社 Detection method of base substitution
US6620586B2 (en) * 2001-02-20 2003-09-16 Applied Gene Technologies, Inc. Methods and compositions for analyzing nucleic acids
NZ528348A (en) * 2001-02-27 2007-07-27 Virco Bvba Circular probe amplification (CPA) using closed circular padlock probe molecules and energy-transfer primers
US7094536B2 (en) * 2001-03-09 2006-08-22 Nugen Technologies, Inc. Methods and compositions for amplification of RNA sequences
ZA200210369B (en) 2001-03-09 2004-07-08 Nugen Technologies Inc Methods and compositions for amplification or RNA sequences.
US6573051B2 (en) 2001-03-09 2003-06-03 Molecular Staging, Inc. Open circle probes with intramolecular stem structures
US20030092157A1 (en) * 2001-03-16 2003-05-15 Hayden Michael R. Compositions, screening systems and methods for modulating HDL cholesterol and triglyceride levels
US6596489B2 (en) 2001-03-30 2003-07-22 Applied Gene Technologies Methods and compositions for analyzing nucleotide sequence mismatches using RNase H
WO2002095002A2 (en) 2001-05-22 2002-11-28 University Of Chicago N4 virion single-stranded dna dependent rna polymerase
US7838270B2 (en) * 2001-05-22 2010-11-23 The University Of Chicago Target-dependent transcription using deletion mutants of N4 RNA polymerase
US8137911B2 (en) * 2001-05-22 2012-03-20 Cellscript, Inc. Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences
AU2002305019A1 (en) * 2001-05-25 2002-12-09 University Of British Columbia Diagnostic methods for cardiovascular disease, low hdl-cholesterol levels, and high triglyceride levels
EP1396538A4 (en) * 2001-06-12 2005-10-26 Takara Bio Inc Method of stabilizing reagent for amplifying or detecting nucleic acid and storage method
NZ530343A (en) * 2001-06-22 2007-01-26 Marshfield Clinic Methods and oligonucleotides for the detection of E. coli 0157:H7
EP1421175B1 (en) * 2001-06-28 2008-11-19 Mountain View Pharmaceuticals, Inc. Polymer stabilized proteinases
US9261460B2 (en) 2002-03-12 2016-02-16 Enzo Life Sciences, Inc. Real-time nucleic acid detection processes and compositions
US20040161741A1 (en) * 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
US9777312B2 (en) * 2001-06-30 2017-10-03 Enzo Life Sciences, Inc. Dual polarity analysis of nucleic acids
EP1481076A4 (en) 2001-07-12 2005-05-11 Illumina Inc Multiplex nucleic acid reactions
US7297778B2 (en) * 2001-07-25 2007-11-20 Affymetrix, Inc. Complexity management of genomic DNA
US6872529B2 (en) * 2001-07-25 2005-03-29 Affymetrix, Inc. Complexity management of genomic DNA
DK1421215T3 (en) * 2001-07-25 2011-06-27 Oncomedx Inc Methods for evaluating pathological conditions using extracellular RNA
DE60237696D1 (en) 2001-08-01 2010-10-28 Univ Utah AT N-TERMINUS TRUNCATED ISOFORMS OF CYCLIC PHOSPHODIESTERASES PDE3A
TWI335938B (en) * 2001-08-15 2011-01-11 Rna replication and amplification
AU2002325538B2 (en) * 2001-08-20 2007-03-22 Takara Bio Inc. Nucleic acid amplification methods
US7432084B2 (en) * 2001-08-31 2008-10-07 Rosetta Inpharmatics Llc Methods for preparing nucleic acid samples
EP1908851A3 (en) 2001-09-19 2008-06-25 Intergenetics Incorporated Genetic analysis for stratification of cancer risk
WO2003025141A2 (en) 2001-09-19 2003-03-27 Intergenetics Incorporated Genetic analysis for stratification of cancer risk
US20030165859A1 (en) 2001-10-23 2003-09-04 Invitrogen Corporation Primers and methods for the detection and discrimination of nucleic acids
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
ATE503845T1 (en) 2001-12-10 2011-04-15 Novartis Pharma Gmbh METHOD FOR THE TREATMENT OF PSYCHOSES AND SCHIZOPHRENIA BASED ON A POLYMORPHISM IN THE CNTF GENE
ES2405405T3 (en) 2001-12-17 2013-05-31 Corixa Corporation Compositions and procedures for the therapy and diagnosis of inflammatory bowel disease
EP1458486B1 (en) * 2001-12-19 2008-09-17 Affymetrix, Inc. Array plates and method for constructing array plates
AU2003208959A1 (en) * 2002-01-30 2003-09-02 Id Biomedical Corporation Methods for detecting vancomycin-resistant microorganisms and compositions therefor
US7553619B2 (en) * 2002-02-08 2009-06-30 Qiagen Gmbh Detection method using dissociated rolling circle amplification
US9353405B2 (en) 2002-03-12 2016-05-31 Enzo Life Sciences, Inc. Optimized real time nucleic acid detection processes
AU2003220249A1 (en) * 2002-03-15 2003-09-29 Arcturus Bioscience, Inc. Improved nucleic acid amplification
US20040005614A1 (en) * 2002-05-17 2004-01-08 Nurith Kurn Methods for fragmentation, labeling and immobilization of nucleic acids
US20030219754A1 (en) * 2002-05-23 2003-11-27 Oleksy Jerome E. Fluorescence polarization detection of nucleic acids
US20030219755A1 (en) * 2002-05-24 2003-11-27 Nanibhushan Dattagupta Compositions and methods for performing hybridization assays using target enhanced signal amplification (TESA)
US6916474B2 (en) 2002-07-15 2005-07-12 Board Of Regents, The University Of Texas System Antibodies with increased affinities for anthrax antigens
EP1543128A4 (en) * 2002-07-18 2008-02-20 Invitrogen Corp Viral vectors containing recombination sites
US20040011650A1 (en) * 2002-07-22 2004-01-22 Frederic Zenhausern Method and apparatus for manipulating polarizable analytes via dielectrophoresis
US7462448B2 (en) * 2002-08-02 2008-12-09 Stratatech Corporation Species specific DNA detection
WO2004013290A2 (en) * 2002-08-05 2004-02-12 Invitrogen Corporation Compositions and methods for molecular biology
KR101170653B1 (en) 2002-08-12 2012-08-03 제네렉스, 인코포레이티드 Methods and compositions concerning poxviruses and cancer
AU2003270310A1 (en) * 2002-09-05 2004-03-29 Invitrogen Corporation Compositions and methods for synthesizing nucleic acids
WO2004024749A2 (en) 2002-09-13 2004-03-25 Invitrogen Corporation Thermostable reverse transcriptases and uses thereof
AU2002951411A0 (en) 2002-09-16 2002-09-26 The University Of Sydney Genotype screen
EP1546170A4 (en) 2002-09-20 2007-08-29 Univ Yale Riboswitches, methods for their use, and compositions for use with riboswitches
US20040259105A1 (en) * 2002-10-03 2004-12-23 Jian-Bing Fan Multiplex nucleic acid analysis using archived or fixed samples
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US7074561B2 (en) * 2002-10-22 2006-07-11 Biomerieux, Inc. Isothermal amplification based assay for the detection and quantitation of alpha-fetoprotein mRNA
US20040096829A1 (en) * 2002-11-14 2004-05-20 Allaire Normand E. Absolute quantitation of nucleic acids by RT-PCR
ATE411400T1 (en) 2002-11-21 2008-10-15 Epict Technologies METHOD FOR USING RIBOPRIMERS FOR STRAND DISPLACEMENT REPLICATION OF TARGET SEQUENCES
CN1230531C (en) * 2002-12-09 2005-12-07 清华大学 Method and kit for separating cell particle from sample
CN1223680C (en) * 2002-12-10 2005-10-19 清华大学 Method and kit for amplifying nucleic acid of target cell or virus
ATE525469T1 (en) 2002-12-18 2011-10-15 Third Wave Tech Inc DETECTION OF SMALL NUCLEIC ACIDS
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US7955795B2 (en) * 2003-06-06 2011-06-07 Qiagen Gmbh Method of whole genome amplification with reduced artifact production
US6977153B2 (en) * 2002-12-31 2005-12-20 Qiagen Gmbh Rolling circle amplification of RNA
US7297780B2 (en) 2003-01-06 2007-11-20 Third Wave Technologies, Inc. Reactive functional groups for preparation of modified nucleic acid
EP1589934B1 (en) 2003-01-06 2015-09-23 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US6852494B2 (en) * 2003-01-10 2005-02-08 Linden Technologies, Inc. Nucleic acid amplification
WO2004083806A2 (en) 2003-01-22 2004-09-30 University Of South Florida Autonomous genosensor apparatus and methods for use
AU2004254552B2 (en) 2003-01-29 2008-04-24 454 Life Sciences Corporation Methods of amplifying and sequencing nucleic acids
US6943768B2 (en) 2003-02-21 2005-09-13 Xtellus Inc. Thermal control system for liquid crystal cell
EP2390352A1 (en) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US20060192960A1 (en) * 2003-03-24 2006-08-31 Rencs Erik V Polarization detection
CA2520538C (en) 2003-03-31 2014-04-29 F. Hoffmann-La Roche Ag Compositions and methods for detecting certain flaviviruses, including members of the japanese encephalitis virus serogroup
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
US20040265870A1 (en) * 2003-04-09 2004-12-30 Invitrogen Corporation Methods of synthesizing and labeling nucleic acid molecules
WO2004092418A2 (en) * 2003-04-14 2004-10-28 Nugen Technologies, Inc. Global amplification using a randomly primed composite primer
EP2327796A1 (en) 2003-06-10 2011-06-01 The Trustees Of Boston University Detection methods for disorders of the lung
US20050059024A1 (en) 2003-07-25 2005-03-17 Ambion, Inc. Methods and compositions for isolating small RNA molecules
EP1654361B2 (en) 2003-07-25 2023-01-18 Life Technologies Corporation Methods and compositions for preparing rna from a fixed sample
EP2311994A1 (en) * 2003-08-01 2011-04-20 Life Technologies Corporation Compositions and methods for preparing short RNA molecules and other nucleic acids
WO2005025409A2 (en) 2003-09-12 2005-03-24 University Of Cincinnati Methods for risk assessment, survival prediction and treatment of heart failure and other conditions based on adrenergic receptor polymorphisms
JP4790621B2 (en) 2003-11-26 2011-10-12 アドバンディーエックス, インコーポレイテッド Peptide nucleic acid probes for analysis of specific Staphylococcus species
EP1697534B1 (en) 2003-12-01 2010-06-02 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
EP1711591A4 (en) 2003-12-29 2010-04-28 Nugen Technologies Inc Methods for analysis of nucleic acid methylation status and methods for fragmentation, labeling and immobilization of nucleic acids
EP1725680B1 (en) * 2004-02-04 2009-12-23 QIAGEN North American Holdings, Inc. Dutp based compositions for reducing primer-aggregate formation during nucleic acid amplification
US20050191682A1 (en) 2004-02-17 2005-09-01 Affymetrix, Inc. Methods for fragmenting DNA
CA2556911C (en) 2004-02-19 2013-07-30 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
EP1574583A1 (en) * 2004-03-10 2005-09-14 Roche Diagnostics GmbH Methods for isolation of bacteria from biological samples
US7462451B2 (en) * 2004-04-26 2008-12-09 Third Wave Technologies, Inc. Compositions for modifying nucleic acids
WO2005103249A1 (en) 2004-04-26 2005-11-03 Wako Pure Chemical Industries, Ltd. Probe and primer for tubercle bacillus detection, and method of detecting human tubercle bacillus therewith
EP2527447A1 (en) 2004-06-03 2012-11-28 Athlomics Pty Ltd Agents and methods for diagnosing stress
JP4911722B2 (en) 2004-06-07 2012-04-04 フルイディグム コーポレイション Optical lens system and method for microfluidic devices
US7776530B2 (en) * 2004-06-29 2010-08-17 Wallac Oy Integrated nucleic acid analysis
WO2006000647A1 (en) * 2004-06-29 2006-01-05 Wallac Oy Integrated non-homogeneous nucleic acid amplification and detection
JPWO2006006722A1 (en) 2004-07-13 2008-05-01 武田薬品工業株式会社 How to regulate cell function
US7713697B2 (en) * 2004-08-27 2010-05-11 Gen-Probe Incorporated Methods and kits for amplifying DNA
EP2071031B1 (en) * 2004-08-27 2013-10-09 Gen-Probe Incorporated Single-primer nucleic acid amplification methods
ES2345993T3 (en) 2004-09-14 2010-10-07 The Regents Of The University Of Colorado, A Body Corporate METHOD FOR TREATMENT WITH BUCINDOLOL BASED ON GENETIC ADDRESSING.
US20060073506A1 (en) 2004-09-17 2006-04-06 Affymetrix, Inc. Methods for identifying biological samples
US20060068430A1 (en) * 2004-09-20 2006-03-30 Sigma-Aldrich Co. Purification of biomolecules from contaminating intact nucleic acids
US20060073511A1 (en) 2004-10-05 2006-04-06 Affymetrix, Inc. Methods for amplifying and analyzing nucleic acids
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
CA2524964A1 (en) 2004-10-29 2006-04-29 Affymetrix, Inc. Automated method of manufacturing polymer arrays
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
EP1836317A2 (en) * 2004-12-06 2007-09-26 BioVeris Corporation Methods and compositions for detecting bacillus anthracis
KR20070093992A (en) * 2004-12-11 2007-09-19 사이토제닉, 인크. Cell free biosynthesis of high-quality nucleic acid and uses thereof
EP1841879A4 (en) 2005-01-25 2009-05-27 Population Genetics Technologi Isothermal dna amplification
US9505846B2 (en) 2005-01-28 2016-11-29 Life Technologies Corporation Multi-component inhibitors of nucleic acid polymerases
EP2332408B1 (en) 2005-02-17 2013-11-13 Biogen Idec MA Inc. Treating neurological disorders
US9127305B2 (en) 2005-02-28 2015-09-08 Bioquest, Inc. Methods for performing direct enzymatic reactions involving nucleic acid molecules
PT1856257E (en) 2005-03-05 2012-01-02 Seegene Inc Processes using dual specificity oligonucleotide and dual specificity oligonucleotide
WO2006095941A1 (en) 2005-03-05 2006-09-14 Seegene, Inc. Processes using dual specificity oligonucleotide and dual specificity oligonucleotide
CN102989012B (en) 2005-03-31 2015-05-13 通用医疗公司 Monitoring and modulating hgf/hgfr activity
US20060223071A1 (en) * 2005-04-01 2006-10-05 Wisniewski Michele E Methods, compositions, and kits for detecting nucleic acids in a single vessel
US8309303B2 (en) 2005-04-01 2012-11-13 Qiagen Gmbh Reverse transcription and amplification of RNA with simultaneous degradation of DNA
CA2605158A1 (en) 2005-04-14 2006-10-26 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
US20060240442A1 (en) * 2005-04-20 2006-10-26 Vevea Dirk N Methods and oligonucleotides for the detection of Salmonella SP., E coli 0157:H7, and Listeria monocytogenes
AU2006246975B2 (en) 2005-05-17 2011-08-11 Ozgene Pty Ltd Sequential cloning system
US7550264B2 (en) 2005-06-10 2009-06-23 Datascope Investment Corporation Methods and kits for sense RNA synthesis
EP1910565A4 (en) 2005-07-07 2009-10-28 Athlomics Pty Ltd Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
US7494788B2 (en) 2005-07-11 2009-02-24 Molecular Kinetics, Inc. Entropic bristle domain sequences and their use in recombinant protein production
US7838646B2 (en) 2005-08-18 2010-11-23 Quest Diagnostics Investments Incorporated Cystic fibrosis transmembrane conductance regulator gene mutations
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
CA2621267A1 (en) 2005-09-07 2007-03-15 Nugen Technologies, Inc. Improved nucleic acid amplification procedure
EP1762627A1 (en) 2005-09-09 2007-03-14 Qiagen GmbH Method for the activation of a nucleic acid for performing a polymerase reaction
EP2377929A1 (en) * 2005-10-06 2011-10-19 Lucigen Corporation Thermostable viral polymerases and methods of use
US8609829B2 (en) 2005-10-17 2013-12-17 Gen-Probe Incorporated Compositions and methods to detect Legionella pneumophila nucleic acid
EP1945816B1 (en) 2005-10-21 2011-07-27 GeneNews Inc. Method and apparatus for correlating levels of biomarker products with disease
WO2007053358A2 (en) 2005-10-28 2007-05-10 Praecis Pharmaceuticals, Inc. Methods for identifying compounds of interest using encoded libraries
US7422857B2 (en) 2005-10-28 2008-09-09 University Of South Florida Detection of polyketide synthetase gene expression in Karenia brevis
CA2627966A1 (en) 2005-11-16 2007-05-24 Novartis Ag Biomarkers for anti-nogo-a antibody treatment in spinal cord injury
WO2007059348A2 (en) * 2005-11-17 2007-05-24 Third Wave Technologies, Inc. Compositions and methods for detecting an hcv-1 subtype
JP2009524411A (en) 2005-12-21 2009-07-02 イェール ユニバーシティー Methods and compositions related to the regulation of riboswitches
US7981606B2 (en) * 2005-12-21 2011-07-19 Roche Molecular Systems, Inc. Control for nucleic acid testing
US8030080B2 (en) 2006-01-18 2011-10-04 Argos Therapeutics, Inc. Systems and methods for processing samples in a closed container, and related devices
WO2007087262A2 (en) * 2006-01-23 2007-08-02 Population Genetics Technologies Ltd. Selective genome amplification
US20110143344A1 (en) * 2006-03-01 2011-06-16 The Washington University Genetic polymorphisms and substance dependence
US20090176878A1 (en) * 2007-10-05 2009-07-09 Washington University In St. Louis Genetic polymorphisms and substance dependence
AU2007223788B2 (en) 2006-03-09 2012-11-29 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
WO2007106579A2 (en) 2006-03-15 2007-09-20 Micronics, Inc. Integrated nucleic acid assays
WO2007120869A2 (en) * 2006-04-14 2007-10-25 University Of South Florida Molecular detection and quantification of enterococci
WO2008054546A2 (en) 2006-05-25 2008-05-08 Monsanto Technology Llc A method to identify disease resistant quantitative trait loci in soybean and compositions thereof
JP5260503B2 (en) 2006-06-01 2013-08-14 サード ウェーブ テクノロジーズ,インコーポレーテッド Nucleic acid detection
US11001881B2 (en) 2006-08-24 2021-05-11 California Institute Of Technology Methods for detecting analytes
WO2007149269A2 (en) 2006-06-12 2007-12-27 Oncomethylome Sciences S.A. Methylation markers for early detection and prognosis of colon cancers
CA2656315A1 (en) * 2006-06-30 2008-01-10 Nugen Technologies, Inc. Methods for fragmentation and labeling of nucleic acids
US11525156B2 (en) 2006-07-28 2022-12-13 California Institute Of Technology Multiplex Q-PCR arrays
WO2008014485A2 (en) 2006-07-28 2008-01-31 California Institute Of Technology Multiplex q-pcr arrays
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
US11560588B2 (en) 2006-08-24 2023-01-24 California Institute Of Technology Multiplex Q-PCR arrays
US8481023B2 (en) 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
EP1914303A1 (en) * 2006-10-09 2008-04-23 Qiagen GmbH Thermus eggertssonii DNA polymerases
US9845494B2 (en) 2006-10-18 2017-12-19 Affymetrix, Inc. Enzymatic methods for genotyping on arrays
WO2008066655A2 (en) 2006-11-02 2008-06-05 Yale University Assessment of oocyte competence
ATE555128T1 (en) 2006-11-30 2012-05-15 Res Dev Foundation IMPROVED IMMUNOLOBULIN LIBRARIES
WO2008079972A2 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc 4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
US7794937B2 (en) 2006-12-22 2010-09-14 Quest Diagnostics Investments Incorporated Cystic fibrosis transmembrane conductance regulator gene mutations
WO2008089286A1 (en) * 2007-01-17 2008-07-24 Meridian Bioscience Inc. Stable reagents and kits useful in loop-mediated isothermal amplification (lamp)
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
SI2118312T1 (en) 2007-01-29 2015-03-31 Scientific Institute Of Public Health (Iph) Transgenic plant event detection
EP1956097A1 (en) 2007-02-06 2008-08-13 bioMerieux B.V. Method for discriminating single nucleotide polymorphisms (SNPs)
JP2010520750A (en) * 2007-03-01 2010-06-17 ジェン−プロウブ インコーポレイテッド Method and kit for amplifying DNA
US8183359B2 (en) * 2007-03-01 2012-05-22 Gen-Probe Incorporated Kits for amplifying DNA
EP1970440A1 (en) * 2007-03-06 2008-09-17 Qiagen GmbH Polymerase stabilization by ionic detergents
EP2191001B1 (en) 2007-04-09 2016-06-08 University of Florida Research Foundation, Inc. Raav vector compositions having tyrosine-modified capsid proteins and methods for use
AU2008247819B2 (en) 2007-05-01 2013-02-14 Research Development Foundation Immunoglobulin Fc libraries
EP2173872B1 (en) 2007-06-29 2014-04-02 CellScript, Inc. Copy dna and sense rna
GB0713183D0 (en) * 2007-07-06 2007-08-15 King S College London Method
ES2547053T3 (en) * 2007-08-01 2015-10-01 Dana Farber Cancer Institute Enrichment of a target sequence
US8420315B2 (en) 2007-08-06 2013-04-16 Orion Genomics Llc Single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene
WO2009033156A2 (en) * 2007-09-07 2009-03-12 Third Wave Technologies, Inc. Methods and applications for target quantification
CA2639416C (en) 2007-09-11 2019-12-31 F. Hoffmann-La Roche Ag Diagnostic test for susceptibility to b-raf kinase inhibitors
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
WO2009059317A2 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
EP2071034A1 (en) 2007-12-12 2009-06-17 bioMérieux Method for treating a solution in order to destroy any ribonucleic acid after amplification
EP2657351B1 (en) 2007-12-21 2018-06-20 Biomerieux Sa Detection of methicillin-resistant Staphylococcus aureus
US8034568B2 (en) * 2008-02-12 2011-10-11 Nugen Technologies, Inc. Isothermal nucleic acid amplification methods and compositions
CA2715774A1 (en) 2008-02-19 2009-08-27 Oncomethylome Sciences Sa Detection and prognosis of lung cancer
US20090253142A1 (en) * 2008-03-15 2009-10-08 Hologic, Inc. Compositions and methods for analysis of nucleic acid molecules during amplification reactions
EP2626435B1 (en) 2008-03-21 2016-06-01 MDxHealth S.A. Detection and prognosis of cervical cancer
GB2470672B (en) 2008-03-21 2012-09-12 Nugen Technologies Inc Methods of RNA amplification in the presence of DNA
EP2113574A1 (en) 2008-04-28 2009-11-04 Biotype AG Substances and methods for a DNA based profiling assay
JP2009268665A (en) * 2008-05-07 2009-11-19 Canon Inc Inhalation device
US20110177509A1 (en) * 2008-07-23 2011-07-21 The Washington University Risk factors and a therapeutic target for neurodegenerative disorders
GB0814570D0 (en) 2008-08-08 2008-09-17 Diagnostics For The Real World Isolation of nucleic acid
US20100240024A1 (en) * 2008-09-03 2010-09-23 Abbott Laboratories Assays And Kits For Determining HIV-1 Tropism
CA2679750A1 (en) 2008-09-23 2010-03-23 Nexus Dx, Inc. Methods for detecting nucleic acids in a sample
EP2172563A1 (en) 2008-09-24 2010-04-07 bioMérieux S.A. Method for lowering the dependency towards sequence variation of a nucleic acid target in a diagnostic hybridization assay
PL2963709T3 (en) 2008-10-24 2017-11-30 Epicentre Technologies Corporation Transposon end compositions and methods for modifying nucleic acids
US9080211B2 (en) 2008-10-24 2015-07-14 Epicentre Technologies Corporation Transposon end compositions and methods for modifying nucleic acids
EP2396429B1 (en) 2009-02-11 2015-05-27 Orion Genomics, LLC Combinations of polymorphisms for determining allele-specific expression of igf2
EP2396661A4 (en) 2009-02-11 2013-10-30 Caris Mpi Inc Molecular profiling of tumors
ES2618881T3 (en) 2009-04-22 2017-06-22 Indiana University Research And Technology Corporation Collagen V for use in the treatment of asthma
WO2010124257A2 (en) * 2009-04-24 2010-10-28 Colby Pharmaceutical Company Methods and kits for determining oxygen free radical (ofr) levels in animal and human tissues as a prognostic marker for cancer and other pathophysiologies
WO2010126913A1 (en) 2009-04-27 2010-11-04 Gen-Probe Incorporated Methods and kits for use in the selective amplification of target sequences
EP2427576B1 (en) 2009-05-08 2016-06-22 Seqirus UK Limited Generic assays for detection of influenza viruses
WO2011008530A2 (en) 2009-06-29 2011-01-20 Luminex Corporation Chimeric primers with hairpin conformations and methods of using same
JP6193570B2 (en) 2009-07-17 2017-09-13 バイオアトラ、エルエルシー Simultaneously integrated selection and evolution of antibody / protein performance and expression in the production host
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
US8614062B1 (en) 2009-07-24 2013-12-24 University Of South Florida RNA-based system and method to differentiate seafood
US10174368B2 (en) 2009-09-10 2019-01-08 Centrillion Technology Holdings Corporation Methods and systems for sequencing long nucleic acids
WO2011032040A1 (en) 2009-09-10 2011-03-17 Centrillion Technology Holding Corporation Methods of targeted sequencing
US9512481B2 (en) 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
KR101838472B1 (en) 2009-09-14 2018-03-15 신라젠(주) Oncolytic vaccinia virus combination cancer therapy
WO2011036173A1 (en) 2009-09-24 2011-03-31 Oncomethylome Sciences S.A. Detection and prognosis of cervical cancer
US20160186266A1 (en) 2009-10-27 2016-06-30 Carislife Sciences, Inc. Molecular profiling for personalized medicine
DK2501716T3 (en) 2009-11-19 2015-04-07 Solis Biodyne Oü Formations to increase polypeptidstabilitet and activity and related practices
JP2013511991A (en) * 2009-11-25 2013-04-11 クアンタライフ, インコーポレイテッド Methods and compositions for detecting genetic material
EP2510126B1 (en) 2009-12-07 2017-08-09 Illumina, Inc. Multi-sample indexing for multiplex genotyping
US8501122B2 (en) 2009-12-08 2013-08-06 Affymetrix, Inc. Manufacturing and processing polymer arrays
MX365946B (en) 2009-12-10 2019-06-19 Turnstone Lp Oncolytic rhabdovirus.
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
US8394589B2 (en) 2009-12-21 2013-03-12 Northwestern University Methods for diagnosing scapuloperoneal spinal muscular atrophy or Charcot-Marie-Tooth disease type 2C by detecting mutations in TRPV4
WO2011087707A1 (en) 2009-12-22 2011-07-21 Elitech Holding B.V. Hypertheromostable endonuclease iv substrate probe
EP2515899B1 (en) 2009-12-23 2016-05-25 ARCA biopharma, Inc. Methods and compositions for cardiovascular diseases and conditions
WO2011082325A2 (en) 2009-12-31 2011-07-07 Life Technologies Corporation Sequences of e.coli 055:h7 genome
WO2011094577A2 (en) 2010-01-29 2011-08-04 Micronics, Inc. Sample-to-answer microfluidic cartridge
US8623603B2 (en) 2010-03-08 2014-01-07 Dana-Farber Cancer Institute, Inc. Full cold-PCR enrichment with reference blocking sequence
LT2558577T (en) 2010-04-16 2019-03-12 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
WO2011128096A1 (en) 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
CN103079567A (en) 2010-04-17 2013-05-01 拜尔健康护理有限责任公司 Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions
KR20200047642A (en) 2010-04-23 2020-05-07 유니버시티 오브 플로리다 리서치 파운데이션, 인크. Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
JP5454338B2 (en) 2010-04-28 2014-03-26 株式会社島津製作所 Real-time nucleic acid amplification by droplet manipulation
US10232374B2 (en) 2010-05-05 2019-03-19 Miroculus Inc. Method of processing dried samples using digital microfluidic device
KR101176139B1 (en) 2010-05-20 2012-08-22 광주과학기술원 Transgenic Mice Overexpressing HIF-2α as an Animal Model of Arthritis and Uses Thereof
KR101223660B1 (en) 2010-05-20 2013-01-17 광주과학기술원 Pharmaceutical Compositions for Preventing or Treating Arthritis Comprising HIF-2α Inhibitor as an Active Ingredient
US20130143214A1 (en) 2010-06-04 2013-06-06 Chronix Biomedical Prostate cancer associated circulating nucleic acid biomarkers
ES2655500T3 (en) 2010-07-16 2018-02-20 Tocagen Inc. Retrovirus detection
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US11031095B2 (en) 2010-08-06 2021-06-08 Ariosa Diagnostics, Inc. Assay systems for determination of fetal copy number variation
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US11203786B2 (en) 2010-08-06 2021-12-21 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
US10533223B2 (en) 2010-08-06 2020-01-14 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
US20130261003A1 (en) 2010-08-06 2013-10-03 Ariosa Diagnostics, In. Ligation-based detection of genetic variants
US20140342940A1 (en) 2011-01-25 2014-11-20 Ariosa Diagnostics, Inc. Detection of Target Nucleic Acids using Hybridization
US10167508B2 (en) 2010-08-06 2019-01-01 Ariosa Diagnostics, Inc. Detection of genetic abnormalities
US20130040375A1 (en) 2011-08-08 2013-02-14 Tandem Diagnotics, Inc. Assay systems for genetic analysis
US20120034603A1 (en) 2010-08-06 2012-02-09 Tandem Diagnostics, Inc. Ligation-based detection of genetic variants
US8700338B2 (en) 2011-01-25 2014-04-15 Ariosa Diagnosis, Inc. Risk calculation for evaluation of fetal aneuploidy
CA2812135A1 (en) 2010-09-07 2012-03-15 Novartis Ag Generic assays for detection of mammalian reovirus
WO2012040619A2 (en) 2010-09-24 2012-03-29 Massachusetts Eye And Ear Infirmary Methods and compositions for prognosing and/or detecting age-related macular degeneration
EP4108671A1 (en) 2010-10-01 2022-12-28 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US20150225792A1 (en) 2014-01-17 2015-08-13 Northwestern University Compositions and methods for identifying depressive disorders
US10093981B2 (en) 2010-10-19 2018-10-09 Northwestern University Compositions and methods for identifying depressive disorders
US20150218639A1 (en) 2014-01-17 2015-08-06 Northwestern University Biomarkers predictive of predisposition to depression and response to treatment
US10233501B2 (en) 2010-10-19 2019-03-19 Northwestern University Biomarkers predictive of predisposition to depression and response to treatment
WO2012086243A1 (en) 2010-12-21 2012-06-28 株式会社 島津製作所 Device and method for processing target component in tube
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
JP6121910B2 (en) 2011-01-04 2017-04-26 シラジェン バイオセラピューティクス インコーポレイテッド Generation of antibodies against tumor antigens and tumor-specific complement-dependent cytotoxicity by administration of oncolytic vaccinia virus
US9994897B2 (en) 2013-03-08 2018-06-12 Ariosa Diagnostics, Inc. Non-invasive fetal sex determination
US11270781B2 (en) 2011-01-25 2022-03-08 Ariosa Diagnostics, Inc. Statistical analysis for non-invasive sex chromosome aneuploidy determination
US10131947B2 (en) 2011-01-25 2018-11-20 Ariosa Diagnostics, Inc. Noninvasive detection of fetal aneuploidy in egg donor pregnancies
US8756020B2 (en) 2011-01-25 2014-06-17 Ariosa Diagnostics, Inc. Enhanced risk probabilities using biomolecule estimations
US20120190020A1 (en) 2011-01-25 2012-07-26 Aria Diagnostics, Inc. Detection of genetic abnormalities
ES2686309T3 (en) 2011-02-02 2018-10-17 Exact Sciences Development Company, Llc Digital sequence analysis of DNA methylation
EP2673299B1 (en) 2011-02-07 2017-05-10 Research Development Foundation Engineered immunoglobulin fc polypeptides
CA2826748C (en) 2011-02-09 2020-08-04 Bio-Rad Laboratories, Inc. Method of detecting variations in copy number of a target nucleic acid
EP3062108B1 (en) 2011-02-24 2019-06-19 Hill's Pet Nutrition, Inc. Methods for diagnosing kidney disorders in a feline
WO2012114312A2 (en) 2011-02-25 2012-08-30 Novartis Ag Exogenous internal positive control
WO2012158238A2 (en) 2011-02-28 2012-11-22 University Of Iowa Research Foundation Anti-müllerian hormone changes in pregnancy and prediction ofadverse pregnancy outcomes and gender
WO2012118745A1 (en) 2011-02-28 2012-09-07 Arnold Oliphant Assay systems for detection of aneuploidy and sex determination
EP2683835B1 (en) 2011-03-08 2017-01-11 King Abdullah University Of Science And Technology Molecular biomarker set for early detection of ovarian cancer
US11130992B2 (en) 2011-03-31 2021-09-28 Dana-Farber Cancer Institute, Inc. Methods and compositions to enable multiplex COLD-PCR
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20120252682A1 (en) 2011-04-01 2012-10-04 Maples Corporate Services Limited Methods and systems for sequencing nucleic acids
WO2012138783A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
KR101291668B1 (en) 2011-04-21 2013-08-01 서울대학교산학협력단 Shuttle Vectors for Mycobacteria-Escherichia coli and Uses Thereof
CA2834288A1 (en) 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
ES2773692T3 (en) 2011-05-12 2020-07-14 Exact Sciences Corp Nucleic acid isolation
US8993341B2 (en) 2011-05-12 2015-03-31 Exact Sciences Corporation Removal of PCR inhibitors
US8808990B2 (en) 2011-05-12 2014-08-19 Exact Sciences Corporation Serial isolation of multiple DNA targets from stool
US9364532B2 (en) 2011-06-08 2016-06-14 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
AU2012271528B2 (en) 2011-06-15 2015-06-25 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and monitoring hyperthyroidism in a feline
EP2721170A2 (en) 2011-06-17 2014-04-23 Life Technologies Corporation Compositions and methods for detection of cronobacter spp. and cronobacter species and strains
US20140275211A1 (en) 2011-06-21 2014-09-18 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
WO2013024175A2 (en) 2011-08-17 2013-02-21 Technische Universität München Diagnostic means and methods for type 2 diabetes
EP2748332B1 (en) 2011-08-24 2018-06-13 Oxoid Limited Compositions and methods for the detection of multiple microorganisms
MX2014002307A (en) 2011-08-31 2014-08-26 Hoffmann La Roche Method for predicting risk of hypertension associated with anti-angiogenesis therapy.
AU2012300985A1 (en) 2011-08-31 2014-02-13 F. Hoffmann-La Roche Ag Responsiveness to angiogenesis inhibitors
US8712697B2 (en) 2011-09-07 2014-04-29 Ariosa Diagnostics, Inc. Determination of copy number variations using binomial probability calculations
WO2013036799A2 (en) 2011-09-09 2013-03-14 Fred Hutchinson Cancer Research Center Methods and compositions involving nkg2d inhibitors and cancer
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2014114617A (en) 2011-09-19 2015-10-27 Дженентек, Инк. COMBINED TREATMENTS CONTAINING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
CN103974724B (en) 2011-10-03 2019-08-30 现代泰克斯公司 Nucleosides, nucleotide and nucleic acid of modification and application thereof
FR2981088B1 (en) 2011-10-06 2013-11-29 Biomerieux Sa RNA POLYMERASES MUTEES
EP2769007B1 (en) 2011-10-19 2016-12-07 Nugen Technologies, Inc. Compositions and methods for directional nucleic acid amplification and sequencing
PL2768985T3 (en) 2011-10-21 2019-10-31 Chronix Biomedical Colorectal cancer associated circulating nucleic acid biomarkers
WO2013071233A1 (en) 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detecting infectious agents and a novel virus detected thereby
JP6285865B2 (en) 2011-11-14 2018-02-28 アルファシグマ ソシエタ ペル アチオニ Assays and methods for selecting treatment regimens for subjects with depression
JP2014533956A (en) 2011-11-23 2014-12-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Responsiveness to angiogenesis inhibitors
US8748097B1 (en) 2011-12-02 2014-06-10 President And Fellows Of Harvard College Identification of agents for treating calcium disorders and uses thereof
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
JP6189857B2 (en) 2011-12-19 2017-08-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Compositions and methods for diagnosing and treating hyperthyroidism in companion animals
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
US9115394B2 (en) 2011-12-22 2015-08-25 Roche Molecular Systems, Inc. Methods and reagents for reducing non-specific amplification
EP3269820A1 (en) 2011-12-22 2018-01-17 Ibis Biosciences, Inc. Kit for the amplification of a sequence from a ribonucleic acid
JP5807542B2 (en) 2011-12-22 2015-11-10 株式会社島津製作所 Chip device for manipulating target components and method using the same
JP2015511116A (en) 2011-12-23 2015-04-16 ビオメリューBiomerieux Detection of methicillin-resistant Staphylococcus aureus mutant mecA strain
EP2798089B1 (en) 2011-12-30 2018-05-23 Bio-rad Laboratories, Inc. Methods and compositions for performing nucleic acid amplification reactions
WO2013112923A1 (en) 2012-01-26 2013-08-01 Nugen Technologies, Inc. Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation
US9701959B2 (en) 2012-02-02 2017-07-11 Invenra Inc. High throughput screen for biologically active polypeptides
US10265388B2 (en) 2012-02-21 2019-04-23 Cytonics Corporation Systems, compositions, and methods for transplantation
ES2663234T3 (en) 2012-02-27 2018-04-11 Cellular Research, Inc Compositions and kits for molecular counting
EP2820174B1 (en) 2012-02-27 2019-12-25 The University of North Carolina at Chapel Hill Methods and uses for molecular tags
CA2866127A1 (en) 2012-03-29 2013-10-03 Novartis Ag Pharmaceutical diagnostic
EP2834369B1 (en) 2012-04-02 2018-05-30 Life Technologies Corporation Compositions and methods for detection of mycobacterium avium paratuberculosis
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2839026B1 (en) 2012-04-19 2016-08-10 Life Technologies Corporation Nucleic acid amplification
CN116064734A (en) 2012-04-19 2023-05-05 生命技术公司 Nucleic acid amplification
US9133490B2 (en) 2012-05-16 2015-09-15 Transgenomic, Inc. Step-up method for COLD-PCR enrichment
EP2852687A4 (en) 2012-05-21 2016-10-05 Scripps Research Inst Methods of sample preparation
US10289800B2 (en) 2012-05-21 2019-05-14 Ariosa Diagnostics, Inc. Processes for calculating phased fetal genomic sequences
AU2013205064B2 (en) 2012-06-04 2015-07-30 Gen-Probe Incorporated Compositions and Methods for Amplifying and Characterizing HCV Nucleic Acid
CA2877094A1 (en) 2012-06-18 2013-12-27 Nugen Technologies, Inc. Compositions and methods for negative selection of non-desired nucleic acid sequences
US20140005061A1 (en) 2012-06-29 2014-01-02 Life Technologies Corporation Compositions and methods for detection of multiple microorganisms
US20150011396A1 (en) 2012-07-09 2015-01-08 Benjamin G. Schroeder Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
WO2014015217A1 (en) 2012-07-19 2014-01-23 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
CA2878280A1 (en) 2012-07-19 2014-01-23 Ariosa Diagnostics, Inc. Multiplexed sequential ligation-based detection of genetic variants
WO2014043143A1 (en) 2012-09-11 2014-03-20 Life Technologies Corporation Nucleic acid amplification
EP2895620B1 (en) 2012-09-11 2017-08-02 Life Technologies Corporation Nucleic acid amplification
US9212392B2 (en) 2012-09-25 2015-12-15 Exact Sciences Corporation Normalization of polymerase activity
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドModernaTX,Inc. Chemically modified mRNA
ES2730690T3 (en) 2012-12-07 2019-11-12 Suppremol Gmbh Stratification and treatment of patients suffering from idiopathic thrombocytopenic purpura
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
KR20150096788A (en) 2012-12-21 2015-08-25 마이크로닉스 인코포레이티드. Low elasticity films for microfluidic use
JP2016509206A (en) 2012-12-21 2016-03-24 マイクロニクス, インコーポレイテッド Portable fluorescence detection system and microassay cartridge
WO2014100732A1 (en) 2012-12-21 2014-06-26 Micronics, Inc. Fluidic circuits and related manufacturing methods
WO2014116721A1 (en) 2013-01-22 2014-07-31 The Arizona Board Of Regents For And On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
RU2684211C2 (en) 2013-02-21 2019-04-04 Тёрнстоун Лимитед Партнершип Vaccine composition
AU2013202805B2 (en) 2013-03-14 2015-07-16 Gen-Probe Incorporated System and method for extending the capabilities of a diagnostic analyzer
ES2712798T3 (en) 2013-03-14 2019-05-14 Exact Sciences Dev Co Llc Detection of neoplasms
WO2014144092A1 (en) 2013-03-15 2014-09-18 Nugen Technologies, Inc. Sequential sequencing
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9255265B2 (en) 2013-03-15 2016-02-09 Illumina, Inc. Methods for producing stranded cDNA libraries
KR101403507B1 (en) 2013-03-21 2014-06-09 주식회사 현일바이오 Methods for Selectively Detecting Mycobacterium tuberculosis complex and Nontuberculous mycobacteria and Kits Using the Same
KR101507505B1 (en) 2013-04-18 2015-04-07 사회복지법인 삼성생명공익재단 A Method for Diagnosing Myotonic Dystrophy Type 1
US10386377B2 (en) 2013-05-07 2019-08-20 Micronics, Inc. Microfluidic devices and methods for performing serum separation and blood cross-matching
WO2014182847A1 (en) 2013-05-07 2014-11-13 Micronics, Inc. Device for preparation and analysis of nucleic acids
US10190153B2 (en) 2013-05-07 2019-01-29 Micronics, Inc. Methods for preparation of nucleic acid-containing samples using clay minerals and alkaline solutions
US20160186263A1 (en) 2013-05-09 2016-06-30 Trustees Of Boston University Using plexin-a4 as a biomarker and therapeutic target for alzheimer's disease
GB201308313D0 (en) 2013-05-09 2013-06-19 Medical Res Council Assay Method
WO2014194113A2 (en) 2013-05-29 2014-12-04 Chronix Biomedical Detection and quantification of donor cell-free dna in the circulation of organ transplant recipients
WO2014200579A1 (en) 2013-06-13 2014-12-18 Ariosa Diagnostics, Inc. Statistical analysis for non-invasive sex chromosome aneuploidy determination
US10392670B2 (en) 2013-07-25 2019-08-27 Dch Molecular Diagnostics, Inc. Methods and compositions for detecting bacterial contamination
US9547006B2 (en) 2013-08-08 2017-01-17 Institut Pasteur Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus
WO2015031654A2 (en) 2013-08-28 2015-03-05 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
EP3039158B1 (en) 2013-08-28 2018-11-14 Cellular Research, Inc. Massively parallel single cell analysis
US20150232931A1 (en) 2013-09-20 2015-08-20 The Regents Of The University Of Michigan Compositions and methods for the analysis of radiosensitivity
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
BR112016007391A2 (en) 2013-10-03 2017-08-01 Oklahoma Med Res Found biomarkers of activity, intensity and acute phase of systemic lupus erythematosus disease
US10253358B2 (en) 2013-11-04 2019-04-09 Exact Sciences Development Company, Llc Multiple-control calibrators for DNA quantitation
EP3068883B1 (en) 2013-11-13 2020-04-29 Nugen Technologies, Inc. Compositions and methods for identification of a duplicate sequencing read
BR112016011046A2 (en) 2013-11-15 2019-01-29 Centre Nat Rech Scient method for genotyping, method for detecting an infection, kit for detecting an infection and method for detecting in a biological sample.
US9909181B2 (en) 2013-12-13 2018-03-06 Northwestern University Biomarkers for post-traumatic stress states
US10138524B2 (en) 2013-12-19 2018-11-27 Exact Sciences Development Company, Llc Synthetic nucleic acid control molecules
US11293929B2 (en) 2014-01-07 2022-04-05 Bioatla, Inc. Proteins targeting orthologs
WO2015112767A2 (en) 2014-01-22 2015-07-30 Life Technologies Corporation Novel reverse transcriptases for use in high temperature nucleic acid synthesis
WO2015113725A1 (en) 2014-02-03 2015-08-06 Thermo Fisher Scientific Baltics Uab Method for controlled dna fragmentation
WO2015131107A1 (en) 2014-02-28 2015-09-03 Nugen Technologies, Inc. Reduced representation bisulfite sequencing with diversity adaptors
EP3125936B1 (en) 2014-03-31 2019-05-08 Debiopharm International SA Fgfr fusions
EP4234722A3 (en) 2014-03-31 2023-09-20 Mayo Foundation for Medical Education and Research Detecting colorectal neoplasm
WO2015191632A1 (en) 2014-06-10 2015-12-17 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
EP3154693B1 (en) 2014-06-11 2021-11-03 PerkinElmer Health Sciences, Inc. Method for performing a sample assay with a microfluidic cartridges with integrated assay controls
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
CN106661600B (en) 2014-07-16 2021-04-06 唐恩生物科技股份有限公司 Isothermal method for amplifying nucleic acid samples
SG11201700891SA (en) 2014-08-06 2017-03-30 Nugen Technologies Inc Digital measurements from targeted sequencing
WO2016040524A1 (en) 2014-09-09 2016-03-17 Igenomx International Genomics Corporation Methods and compositions for rapid nucleic acid library preparation
CN107208012B (en) 2014-11-03 2021-06-29 唐恩生物科学公司 Device and method for cell, spore or virus capture and disruption
EP3218515B1 (en) 2014-11-10 2023-04-26 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for il-33-mediated disorders
WO2016086227A2 (en) 2014-11-26 2016-06-02 The Regents Of The University Of California Therapeutic compositions comprising transcription factors and methods of making and using the same
EP4242329A3 (en) 2014-12-08 2023-10-25 Berg LLC Use of markers including filamin a in the diagnosis and treatment of prostate cancer
EP3230476B1 (en) 2014-12-12 2020-02-05 Exact Sciences Development Company, LLC Zdhhc1 for normalizing methylation detection assays
CA3183545A1 (en) 2014-12-12 2016-06-16 Exact Sciences Corporation Compositions and methods for performing methylation detection assays
KR101718800B1 (en) 2015-01-21 2017-03-24 주식회사 디알나노 Nanocomplexs for Co-delivering a Drug and siRNA and Uses Thereof
AU2016219511B2 (en) 2015-02-09 2020-11-12 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation
US9708647B2 (en) 2015-03-23 2017-07-18 Insilixa, Inc. Multiplexed analysis of nucleic acid hybridization thermodynamics using integrated arrays
WO2016160454A1 (en) 2015-03-27 2016-10-06 Exact Sciences Corporation Detecting esophageal disorders
CA2983819A1 (en) 2015-04-24 2016-10-27 Atila Biosystems Incorporated Amplification with primers of limited nucleotide composition
US10988737B2 (en) 2015-04-28 2021-04-27 Universite De Strasbourg Clinical gene signature-based human cell culture model and uses thereof
WO2016197106A1 (en) 2015-06-05 2016-12-08 Miroculus Inc. Evaporation management in digital microfluidic devices
CN108026494A (en) 2015-06-05 2018-05-11 米罗库鲁斯公司 Limitation evaporation and the digital microcurrent-controlled apparatus and method of air matrix of surface scale
CN107849600A (en) 2015-06-09 2018-03-27 生命技术公司 For the method for molecular labeling, system, composition, kit, device and computer-readable media
US10894980B2 (en) 2015-07-17 2021-01-19 President And Fellows Of Harvard College Methods of amplifying nucleic acid sequences mediated by transposase/transposon DNA complexes
US9789087B2 (en) 2015-08-03 2017-10-17 Thomas Jefferson University PAR4 inhibitor therapy for patients with PAR4 polymorphism
KR20210048600A (en) 2015-08-17 2021-05-03 쿠라 온콜로지, 인크. Methods of treating cancer patients with farnesyl transferase inhibitors
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
US9499861B1 (en) 2015-09-10 2016-11-22 Insilixa, Inc. Methods and systems for multiplex quantitative nucleic acid amplification
US20180305748A1 (en) 2015-10-18 2018-10-25 Affymetrix, Inc. Multiallelic Genotyping of Single Nucleotide Polymorphisms and Indels
KR101651817B1 (en) 2015-10-28 2016-08-29 대한민국 Primer set for Preparation of NGS library and Method and Kit for making NGS library using the same
EP3998353A1 (en) 2015-10-30 2022-05-18 Exact Sciences Corporation Multiplex amplification detection assay and isolation and detection of dna from plasma
WO2017100212A1 (en) 2015-12-08 2017-06-15 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate
US20180363037A1 (en) 2015-12-09 2018-12-20 Life Technologies Corporation Detection and quantification of nucleic acid molecules associated with a surface
US10626383B2 (en) 2016-01-15 2020-04-21 Thermo Fisher Scientific Baltics Uab Thermophilic DNA polymerase mutants
KR101845957B1 (en) 2016-02-23 2018-04-05 전남대학교기술지주회사(주) Kit for diagnosis of leukemia and diagnostic method targeting prohibitin gene
WO2017155858A1 (en) 2016-03-07 2017-09-14 Insilixa, Inc. Nucleic acid sequence identification using solid-phase cyclic single base extension
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
US20170321286A1 (en) 2016-05-05 2017-11-09 Exact Sciences Corporation Detection of lung neoplasia by amplification of rna sequences
KR102436270B1 (en) 2016-05-05 2022-08-25 이그젝트 싸이언스 디블롭먼트 컴패니, 엘엘씨 Detection of lung tumors by methylated DNA analysis
JP7042755B2 (en) 2016-06-05 2022-03-28 バーグ エルエルシー Systems and methods for patient stratification and potential biomarker identification
CA2932910A1 (en) 2016-06-14 2017-12-14 Entos Pharmaceuticals Inc. Methods for diagnosing and treating metastatic cancer
WO2018005559A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
EP3978624A1 (en) 2016-07-19 2022-04-06 Exact Sciences Corporation Methylated control dna
ES2963227T3 (en) 2016-07-19 2024-03-26 Exact Sciences Corp Nucleic acid control molecules of non-human organisms
CA3033016A1 (en) 2016-08-10 2018-02-15 Institut Pasteur Methods and reagents for detecting piperaquine-resistant plasmodium falciparum malaria
JP2020501107A (en) 2016-08-22 2020-01-16 ミロキュラス インコーポレイテッド Feedback system for parallel droplet control in digital microfluidic devices
EP3507298B1 (en) 2016-09-02 2023-08-30 Mayo Foundation for Medical Education and Research Detecting hepatocellular carcinoma
WO2018071522A1 (en) 2016-10-11 2018-04-19 Life Technologies Corporation Rapid amplification of nucleic acids
BR112019009000A2 (en) 2016-11-03 2019-07-16 Kura Oncology Inc method for treating refractory carcinoma, scchn treatment method, squamous cell carcinoma treatment method, scc treatment method
US11371090B2 (en) 2016-12-12 2022-06-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for molecular barcoding of DNA molecules prior to mutation enrichment and/or mutation detection
WO2018126082A1 (en) 2016-12-28 2018-07-05 Miroculis Inc. Digital microfluidic devices and methods
JP7229923B2 (en) 2017-01-06 2023-02-28 エディタス・メディシン、インコーポレイテッド Methods for assessing nuclease cleavage
KR101936799B1 (en) 2017-01-09 2019-01-11 주식회사 엠이티라이프사이언스 Pharmaceutical Composition for Treating Oral Precancer and Method for Predicting or Detecting of Oral Precancer or Oral Cancer
EP3574114B1 (en) 2017-01-26 2022-06-29 Oklahoma Medical Research Foundation Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
US11118228B2 (en) 2017-01-27 2021-09-14 Exact Sciences Development Company, Llc Detection of colon neoplasia by analysis of methylated DNA
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
BR112019017375A2 (en) 2017-02-21 2020-03-31 Kura Oncology, Inc. METHOD FOR TREATING A CANCER EXPRESSING CXCL12 AND T-CELL ANGIOIMMUNOBLASTIC LYMPHOMA (AITL) IN AN INDIVIDUAL
AU2018240553B2 (en) 2017-03-24 2023-03-02 Gen-Probe Incorporated Cover assembly and related methods of use
US11623219B2 (en) 2017-04-04 2023-04-11 Miroculus Inc. Digital microfluidics apparatuses and methods for manipulating and processing encapsulated droplets
US10914729B2 (en) 2017-05-22 2021-02-09 The Trustees Of Princeton University Methods for detecting protein binding sequences and tagging nucleic acids
US10995104B2 (en) 2017-05-30 2021-05-04 Roche Molecular System, Inc. Catalysts for reversing formaldehyde adducts and crosslinks
CN110914448A (en) 2017-06-02 2020-03-24 昂飞股份有限公司 Array-based method for analyzing mixed samples using differentially labeled allele-specific probes
US11441174B2 (en) 2017-06-02 2022-09-13 Affymetrix, Inc. Array-based methods for analysing mixed samples using differently labelled allele-specific probes
US11542540B2 (en) 2017-06-16 2023-01-03 Life Technologies Corporation Control nucleic acids, and compositions, kits, and uses thereof
WO2019002178A1 (en) 2017-06-26 2019-01-03 Thermo Fisher Scientific Baltics Uab Thermophilic dna polymerase mutants
EP4286055A3 (en) 2017-07-10 2024-02-28 Gen-Probe Incorporated Analytical systems and methods for nucleic acid amplification using sample assigning parameters
KR101956315B1 (en) 2017-07-19 2019-03-08 국민대학교 산학협력단 miR494 as a biomarker for parkinson’s disease and diagnostic kit using thereof
WO2019017680A2 (en) 2017-07-19 2019-01-24 국민대학교 산학협력단 miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME
CN110892258A (en) 2017-07-24 2020-03-17 米罗库鲁斯公司 Digital microfluidic system and method with integrated plasma collection device
US11174511B2 (en) 2017-07-24 2021-11-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for selecting and amplifying DNA targets in a single reaction mixture
EP3664804A4 (en) 2017-08-07 2021-04-14 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CN115582155A (en) 2017-09-01 2023-01-10 米罗库鲁斯公司 Digital microfluidic device and method of use thereof
US11099202B2 (en) 2017-10-20 2021-08-24 Tecan Genomics, Inc. Reagent delivery system
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
EP3707278A1 (en) 2017-11-09 2020-09-16 Alnylam Pharmaceuticals Inc. Assays and methods for determining expression of the lect2 gene
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
WO2019130347A1 (en) 2017-12-26 2019-07-04 Sree Chitra Tirunal Institute For Medical Sciences And Technology Primers for isothermal amplification of mpt64 gene of mycobacterium tuberculosis and the process thereof
EP3746225A1 (en) 2018-01-29 2020-12-09 Gen-Probe Incorporated Analytical systems and methods
MA51741A (en) 2018-02-09 2021-05-19 Hoffmann La Roche THERAPEUTIC AND DIAGNOSIS PROCEDURES FOR INFLAMMATORY DISEASES MEDIATED BY MASTOCYTES
AU2019247652A1 (en) 2018-04-02 2020-10-15 Enumera Molecular, Inc. Methods, systems, and compositions for counting nucleic acid molecules
CN116585308A (en) 2018-05-25 2023-08-15 Arca生物制药有限公司 Methods and compositions relating to bucindolol treatment of atrial fibrillation
CA3105684A1 (en) 2018-07-10 2020-01-16 Gen-Probe Incorporated Methods and systems for detecting and quantifying nucleic acids
US11408030B2 (en) 2018-09-10 2022-08-09 Andy Madrid Test for detecting Alzheimer's disease
JP2022509018A (en) 2018-10-31 2022-01-20 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ Biomarkers and usage for radiation-induced lung injury
TW202031259A (en) 2018-11-01 2020-09-01 美商庫拉腫瘤技術股份有限公司 Methods of treating cancer with farnesyltransferase inhibitors
AU2019390691A1 (en) 2018-11-28 2021-05-13 Keygene N.V. Targeted enrichment by endonuclease protection
AU2019389175A1 (en) 2018-11-30 2021-06-10 Caris Mpi, Inc. Next-generation molecular profiling
WO2020142347A2 (en) 2018-12-31 2020-07-09 Gen-Probe Incorporated Systems and methods for filling multi-well cartridges with solid reagents
AU2020225760A1 (en) 2019-02-21 2021-08-19 Keygene N.V. Genotyping of polyploids
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CN113924041A (en) 2019-03-14 2022-01-11 因斯利克萨公司 Method and system for fluorescence detection based on time gating
TW202043487A (en) 2019-03-29 2020-12-01 美商庫拉腫瘤技術股份有限公司 Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
TW202102218A (en) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 Methods of treating cancer with farnesyltransferase inhibitors
WO2020206170A1 (en) 2019-04-02 2020-10-08 Progenity, Inc. Methods, systems, and compositions for counting nucleic acid molecules
CA3133124A1 (en) 2019-04-08 2020-10-15 Miroculus Inc. Multi-cartridge digital microfluidics apparatuses and methods of use
EP3956476A1 (en) 2019-04-17 2022-02-23 Igenomix S.L. Improved methods for the early diagnosis of uterine leiomyomas and leiomyosarcomas
AU2020265250A1 (en) 2019-04-30 2021-11-18 Larimar Therapeutics, Inc. Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CA3137749C (en) 2019-05-03 2023-12-05 Gen-Probe Incorporated Receptacle transport system for an analytical system
US11524298B2 (en) 2019-07-25 2022-12-13 Miroculus Inc. Digital microfluidics devices and methods of use thereof
US11702704B2 (en) 2019-10-31 2023-07-18 Mayo Foundation For Medical Education And Research Detecting ovarian cancer
EP4069865A4 (en) 2019-12-02 2023-12-20 Caris MPI, Inc. Pan-cancer platinum response predictor
EP4073245A1 (en) 2019-12-12 2022-10-19 Keygene N.V. Semi-solid state nucleic acid manipulation
JP2023506631A (en) 2019-12-20 2023-02-17 キージーン ナムローゼ フェンノートシャップ NGS library preparation using covalently closed nucleic acid molecule ends
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
CN113736858A (en) 2020-05-28 2021-12-03 香港科技大学 Real-time monitoring method of nucleic acid amplicon mediated by circular oligonucleotide probe
EP4163397A1 (en) 2020-06-05 2023-04-12 Seegene, Inc. Specimen transport kit for detecting respiratory pathogens and methods for detecting respiratory pathogens using same
KR20230049122A (en) 2020-08-19 2023-04-12 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Detection of non-Hodgkin's lymphoma
WO2022047359A1 (en) 2020-08-31 2022-03-03 Berg Llc Protein biomarkers for pancreatic cancer
EP4214243A1 (en) 2020-09-21 2023-07-26 Progenity, Inc. Compositions and methods for isolation of cell-free dna
WO2022074058A1 (en) 2020-10-06 2022-04-14 Keygene N.V. Targeted sequence addition
CA3177256A1 (en) 2020-10-21 2022-04-28 Gen-Probe Incorporated Fluid container management system
WO2022112316A1 (en) 2020-11-24 2022-06-02 Keygene N.V. Targeted enrichment using nanopore selective sequencing
WO2022112394A1 (en) 2020-11-25 2022-06-02 Koninklijke Nederlandse Akademie Van Wetenschappen Ribosomal profiling in single cells
EP4320443A1 (en) 2021-04-06 2024-02-14 BPGbio, Inc. Protein markers for the prognosis of breast cancer progression
WO2022216841A1 (en) 2021-04-06 2022-10-13 Berg Llc Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
CA3214821A1 (en) 2021-04-06 2022-10-13 Guisong WANG Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
WO2022265965A1 (en) 2021-06-14 2022-12-22 10X Genomics, Inc. Reverse transcriptase variants for improved performance
WO2023011660A1 (en) 2021-08-06 2023-02-09 Sansure Biotech Inc. Compositions for liquefying a viscous biological sample, combination products, liquefying agents, and kits thereof, and methods and application thereof
US11857961B2 (en) 2022-01-12 2024-01-02 Miroculus Inc. Sequencing by synthesis using mechanical compression
US20230357851A1 (en) 2022-04-06 2023-11-09 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring frataxin-replacement therapy
WO2023230531A1 (en) 2022-05-24 2023-11-30 Lunglife Ai, Inc. Methods for detecting circulating genetically abnormal cells
WO2023240201A1 (en) 2022-06-08 2023-12-14 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
WO2023239940A1 (en) 2022-06-10 2023-12-14 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
WO2024015331A1 (en) 2022-07-12 2024-01-18 Genentech, Inc. Therapeutic and diagnostic methods for multiple sclerosis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6349084A (en) * 1986-08-19 1988-03-01 Ikuo Yamashina Gene
EP0272098A2 (en) * 1986-12-15 1988-06-22 City Of Hope National Medical Center Method for amplification and detection of RNA sequences
WO1988010315A1 (en) * 1987-06-19 1988-12-29 Siska Diagnostics, Inc. Transcription-based nucleic acid amplification/detection systems
EP0303155A2 (en) * 1987-08-13 1989-02-15 MERCK PATENT GmbH Method to identify nucleic-acid sequences
EP0310229A1 (en) * 1987-07-31 1989-04-05 The Board Of Trustees Of The Leland Stanford Junior University Selective amplification of target polynucleotide sequences
EP0329822B1 (en) * 1988-02-24 1994-06-08 Cangene Corporation Nucleic acid amplification process

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8706823A1 (en) * 1985-03-28 1987-06-16 Cetus Corp Process for amplifying, detecting, and/or cloning nucleic acid sequences.
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
WO1989006700A1 (en) * 1988-01-21 1989-07-27 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA2005589C (en) * 1988-12-16 2001-02-06 Thomas Raymond Gingeras Self-sustained, sequence replication system

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6349084A (en) * 1986-08-19 1988-03-01 Ikuo Yamashina Gene
EP0272098A2 (en) * 1986-12-15 1988-06-22 City Of Hope National Medical Center Method for amplification and detection of RNA sequences
WO1988010315A1 (en) * 1987-06-19 1988-12-29 Siska Diagnostics, Inc. Transcription-based nucleic acid amplification/detection systems
EP0310229A1 (en) * 1987-07-31 1989-04-05 The Board Of Trustees Of The Leland Stanford Junior University Selective amplification of target polynucleotide sequences
EP0303155A2 (en) * 1987-08-13 1989-02-15 MERCK PATENT GmbH Method to identify nucleic-acid sequences
EP0329822B1 (en) * 1988-02-24 1994-06-08 Cangene Corporation Nucleic acid amplification process

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dialog Information Services, File 351, World Patent Index 81-90, Dialog accession no. 88-096821/14, Yamashina I: "Gene, for supplying thrombin-like batroxobin enzyme - used for coding polypeptide contg. batroxobin amino acid sequence", & JP,A,63 049 084 (01.03.88) 8814 (Basic). *
Dialog Information Services, File 5, BIOSIS 1969-90,BIOSIS number 69022711, Cathala G et al: "Isolation and characterization of 2 types of rnase H in krebs II ascites cells", & J Biol Chem, 254 (15) 1979, 7353- 7359. *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487628A1 (en) * 1989-08-23 1992-06-03 Cangene Corp Enhanced nucleic acid amplification process.
WO1991002818A1 (en) * 1989-08-23 1991-03-07 Cangene Corporation Enhanced nucleic acid amplification process
WO1996002668A1 (en) * 1994-07-15 1996-02-01 Azco Nobel N.V. Use of rna polymerase to improve nucleic acid amplification process
AU711115B2 (en) * 1994-07-15 1999-10-07 Akzo Nobel N.V. Use of RNA polymerase to improve nucleic acid amplification process
US6025134A (en) * 1994-07-15 2000-02-15 Akzo Nobel N.V. Use of RNA polymerase to improve nucleic acid amplification process
KR100392551B1 (en) * 1994-07-15 2003-10-30 아크조 노벨 엔브이 Use of RNA Polymerase to Improve Nucleic Acid Amplification Methods
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
US6503720B2 (en) 1999-03-30 2003-01-07 Roche Diagnostics Gmbh Method for quantification of an analyte
US7354742B2 (en) 2002-02-22 2008-04-08 Ortho-Mcneil Pharmaceutical, Inc. Method for generating amplified RNA
EP1485501A2 (en) * 2002-02-22 2004-12-15 Ortho-McNeil Pharmaceutical, Inc. Method for generating amplified rna
EP1485501A4 (en) * 2002-02-22 2005-12-28 Ortho Mcneil Pharm Inc Method for generating amplified rna
WO2007016275A2 (en) 2005-08-02 2007-02-08 Focus Diagnostics, Inc. Methods and compositions for detecting bk virus
EP2662456A1 (en) 2005-08-02 2013-11-13 Focus Diagnostics, Inc. Methods and compositions for detecting BK virus
EP2442109A1 (en) 2006-07-14 2012-04-18 The Regents of the University of California Cancer biomarkers and methods of use thereof
EP2442108A1 (en) 2006-07-14 2012-04-18 The Regents of the University of California Cancer biomarkers and methods of use thereof
EP2450710A2 (en) 2006-07-14 2012-05-09 The Regents of the University of California Cancer biomarkers and methods of use thereof
EP3796002A1 (en) 2006-07-14 2021-03-24 The Regents of The University of California Cancer biomarkers and methods of use thereof
WO2011139721A1 (en) 2010-04-27 2011-11-10 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
EP3508854A1 (en) 2010-04-27 2019-07-10 The Regents of The University of California Cancer biomarkers and methods of use thereof
US11543411B2 (en) 2014-12-05 2023-01-03 Prelude Corporation DCIS recurrence and invasive breast cancer
US11821900B2 (en) 2018-09-14 2023-11-21 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer

Also Published As

Publication number Publication date
KR920702866A (en) 1992-10-28
EP0329822B1 (en) 1994-06-08
ATE106948T1 (en) 1994-06-15
EP0329822A3 (en) 1990-08-01
ES2053648T3 (en) 1994-08-01
EP0329822A2 (en) 1989-08-30
DE3850093D1 (en) 1994-07-14
US5409818A (en) 1995-04-25
DE3850093T2 (en) 1994-11-03
KR960015744B1 (en) 1996-11-20
KR890013184A (en) 1989-09-21
CA1340807C (en) 1999-11-02

Similar Documents

Publication Publication Date Title
CA1340807C (en) Nucleic acid amplification process
US5554517A (en) Nucleic acid amplification process
US5130238A (en) Enhanced nucleic acid amplification process
US5466586A (en) Method for the synthesis of ribonucleic acid (RNA)
AU711589B2 (en) Terminal repeat amplification method
EP0368906B1 (en) Transcription-based nucleic acid amplification/detection systems
JP3514630B2 (en) Amplification and detection of nucleic acid sequences
KR100242252B1 (en) Nucleic acid sequence amplification methods
US5314809A (en) Methods for nucleic acid amplification
FI99143C (en) Self-sustaining sequence replication system
US5869251A (en) Use of primers containing nucleotides having altered base pairing characteristics in the amplification of nucleic acid molecules
AU2015270545B2 (en) Strand-invasion based DNA amplification method
IE892698A1 (en) Nucleic acid amplification process
Saunders et al. DNA amplification: general concepts and methods
CA2223527A1 (en) Linked linear amplification of nucleic acids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP KR

WWE Wipo information: entry into national phase

Ref document number: 911877

Country of ref document: FI